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Since its characterization, the definitive shortcoming of the bacterial 
luciferase (lux) bioluminescent reporter system has been its inability to express at 
a functional level in the eukaryotic cellular background.  While recent 
developments have allowed for lux function in the lower eukaryote 
Saccharomyces cerevisiae, they have not provided for autonomous function in 
higher eukaryotes capable of serving as human biomedical proxies.  Here it is 
reported for the first time that, through a process of poly-bicistronic expression of 
human codon-optimized lux genes, it is possible to autonomously produce a 
bioluminescent signal directly from mammalian cells.  The low background of the 
bioluminescent signal, along with its characteristic lack of substrate amendment 
required for bioluminescent production, makes a mammalian-based lux reporter 
system ideal for real-time monitoring of cell culture or murine model systems.  
The delectability of a lux-based system provides for a functionally equivalent 
process to monitoring firefly luciferase-expressing cells under cell culture or 
subcutaneous imaging conditions without the well-documented uncertainties 
stemming from additional substrate introduction.  However, the relatively blue-
shifted emission wavelength of the lux reporter system, along with its low 
quantum yield, has been shown to reduce its effectiveness for use during deep 
tissue imaging of animal subjects.  Despite these disadvantages, it has been 
demonstrated that a human cell line expressing the human codon-optimized lux 
 
 v 
genes can function as a biosensor for determination of human bioavailability of 
toxic compounds and that, by regulating the production of the luxC and luxE 
genes, the lux system can be employed as the first mammalian, real-time, fully 
autonomous bioreporter.  These cell lines provide unique and efficient models for 
the detection and monitoring of human-relevant compounds of interest.  The 
limiting reagent for bioluminescent production in the mammalian cellular 
background has been determined to be the cytosolic availability of the FMNH2 
co-substrate and, in light of this evidence, directions for future optimization have 
been characterized and evaluated in respect to their ability to increase 
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Background And Research Objectives 
 Biosensors, with their small size, relative simplicity, rapidity of operation, and 
continuous, real-time to near real-time monitoring capabilities, possess unique 
characteristics conducive to the high throughput and remote-based monitoring 
needs relevant to agricultural, environmental, pharmacological, and clinical 
sensing.  While the most popular biosensors have traditionally incorporated 
enzymes or antibodies as their biorecognition elements, the development and 
use of whole-cell biosensors (those housed entirely within a bacterial or 
eukaryotic cell) has increased greatly in recent history because they possess 
some interesting advantages over their enzymatic and immuno-dependent 
counterparts.  Primary among these advantages is the indication of bioavailability 
— the effect and interactions the analyte has on a living system.  As opposed to 
analytical instruments that measure only the total concentration of a target 
analyte in a sample, whole-cell biosensors that measure bioavailability indicate 
that the analyte can be assimilated by or directly affect a living organism, thereby 
exposing possible toxic interactions.  Another advantage of whole-cell 
bioreporters is that they can be designed to produce signal in a constitutive 
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manner, regardless of the presence of a target analyte.  This makes them 
valuable tools for localization and monitoring of cellular activities under in vivo, in 
vitro, or in situ conditions in ways not possible with traditional analytical 
equipment. 
 One important consequence of bioreporter-based interrogation has been the 
recent rise of whole animal bioluminescent imaging (BLI).  This technique is 
progressively becoming more widely applied by investigators from diverse 
backgrounds because of its low cost, high throughput, and relative ease of 
operation in visualizing a wide variety of in vivo cellular events (Baker 2010).  
The ability to visualize cellular processes or other biological interactions without 
the requirement for animal subject sacrifice allows for repeated imaging and 
releases investigators from the constraints of considering their process of interest 
on a “frame-by-frame” basis using labeled slides.  In addition, the ability to 
continually monitor a single individual reduces the amount of measured variation 
and can reduce error, leading to higher resolution and less data loss.  With 
continuing advances in the hardware and software required for performing these 
experiments, it is also becoming easier for researchers with little background in 
molecular imaging to obtain useful and detailed publication-ready images. 
 The mainstays of BLI are the light generating luciferase enzymes such as 
firefly luciferase, Renilla luciferase, Gaussia luciferase, Metridia luciferase, 
Vargula luciferase, or bacterial luciferase (Thompson, Nagata et al. 1989; Wood, 
Lam et al. 1989; Lorenz, McCann et al. 1991; Meighen 1991; Verhaegen and 
Christopoulos 2002; Markova, Golz et al. 2004).  These bioluminescent proteins 
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are preferred over their fluorescent counterparts because the lack of endogenous 
bioluminescent reactions in mammalian tissue allows for near background-free 
imaging conditions whereas the prevalence of fluorescently active compounds in 
these tissues can interfere with target resolution upon exposure to the 
fluorescent excitation wavelengths required for the generation of signal output.  
Of these luciferase-based reporters, only those based on the bacterial luciferase 
gene cassette have the potential for development into a fully autonomous 
reporter system, negating the need for addition of a potentially influential 
substrate that could create undo error during the data acquisition process.  The 
development of the bacterial luciferase gene cassette into a functional 
mammalian-based bioreporter has been the focus of this work and has been 
performed under the following experimental hypotheses: 
 
• Hypothesis 1:  Through a process of poly-bicistronic expression of 
Photorhabdus luminescence genes codon-optimized for expression in 
mammalian cells it will be possible to autonomously produce a 
bioluminescent signal in the human HEK293 cell line. 
 
• Hypothesis 2:  Bioluminescent expression driven by codon-optimized 
bacterial luciferase genes will allow improved temporal detection of signal 
compared to bioluminescent signal from firefly luciferase and fluorescent 





• Hypothesis 3:  By regulating the expression of the luxC and luxE genes 
from the bacterial luciferase gene cassette it will be possible to construct a 
bioluminescent reporter capable of responding to changes in target 
analyte presence autonomously and in a near real-time manner. 
 
• Hypothesis 4:  HEK293 cells constitutively expressing bioluminescence 
through expression of the codon-optimized bacterial luciferase genes will 
be capable of acting as real-time biosensors to determine the mammalian 




Bioluminescent bacteria are the most abundant and widely distributed of the 
light emitting organisms on Earth and can be found in both aquatic (freshwater 
and marine) and terrestrial environments. Despite the diverse nature of bacterial 
bioluminescence, the majority of these organisms are classified into three 
genera: Vibrio, Photobacterium, and Photorhabdus (Xenorhabdus). These 
bacteria often exist as symbiotes of other organisms, although some can be free-
living in aquatic environments as well.  Of the known genera of bioluminescent 
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bacteria, only those from the genus Photorhabdus have been discovered in 
terrestrial habitats (Meighen 1991).  
Today it is well known that the bacterial bioluminescence reaction is the result 
of two proteins, LuxA and LuxB, that work together to produce light from the 
oxidation of a long chain fatty aldehyde in the presence of reduced riboflavin 
phosphate (FMNH2) and oxygen, while the remaining proteins in the lux operon, 
LuxC, LuxD, and LuxE, function to regenerate the aldehyde substrate required 
for this reaction (Figure 1A). However, this was not always so evident. The study 
of bacterial bioluminescence is rooted in the lessons of general bioluminescence. 
The idea that oxygen was a required substrate for bioluminescent reactions 
stems from Robert Boyle’s early experiments in the mid 1600’s showing that 
removal of oxygen caused the cessation of light from what was either luminescent 
bacteria or fungi (Boyle 1666). In the late 1880’s when it was discovered from 
work in beetles that bioluminescence required a luciferase and a luciferin for 
function, this knowledge was applied to the bacterial system as well (McElroy 
and Strehler 1954).  
In 1942 Doudoroff was one of the first to observe and report on the 
metabolism of bioluminescent bacteria and found that all were able to tolerate 
oxygen, aiding in the confirmation that oxygen was required for light production 
(Doudoroff 1942). Although the first published report of a bioluminescent reaction 
occurring outside of a bacterium occurred in 1920, it could not be reproduced 






Figure 1.  Bioluminescent reaction catalyzed by the bacterial luciferase genes. 
A) The luciferase is formed from a heterodimer of the luxA and luxB gene products. The aliphatic 
aldehyde is supplied and regenerated by the products of the luxC, luxD, and luxE genes. The required 
oxygen and reduced riboflavin phosphate substrates are scavenged from endogenous metabolic 
processes, however, the flavin reductase gene (frp) aids in reduced flavin turnover rates in some 
species. B) The production of light, catalyzed by the products of the luxA and luxB genes, results from 
the decay of a high energy intermediate (R1 = C13H27).  Originally published in (Close, Ripp et al. 
2009), reprinted with permission. 
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were able to consistently produce light from autolysates of Achromobacter 
fischeri cultures upon addition of FMN. At this time they also reported the 
requirement for a luciferin compound of unknown structure. This was the first 
indication that FMN was required for bacterial bioluminescence. It was not until 
the next year that the structure of the luciferin was confirmed to be a long chain 
fatty aldehyde (Strehler, Harvey et al. 1954). 
This completed the list of required substrates, and an understanding was 
established that bacterial luciferase catalyzes the production of light through 
oxidation of a long chain fatty aldehyde in the presence of oxygen and reduced 
riboflavin phosphate. The genes encoding the bacterial luciferase were first 
cloned and expressed in E. coli in 1982 (Belas, Mileham et al. 1982), while the 
full bacterial luciferase cassette was cloned and expressed the next year 
(Engebrecht, Nealson et al. 1983). In the mid 1990’s the first crystal structure of 
the bacterial luciferase heterodimer was determined (Fisher, Raushel et al. 
1995), providing the first glimpse at the proteins that had captured researchers 
imaginations for hundreds of years. 
When the bacterial luciferase enzyme is supplied with oxygen, FMNH2, and a 
long chain aliphatic aldehyde, it is able to produce light primarily at a wavelength 
of 490 nm. There is a secondary emission peak at 590 nm, however, this is only 
detectable using highly sensitive Raman scattering (Thouand, Daniel et al. 2003). 
The natural aldehyde for this reaction is believed to be tetradecanal, however, 
the enzyme is capable of functioning with alternative aldehydes as substrates 
(Meighen 1991). The first step in the generation of light from these substrates is 
 
 8 
the binding of FMNH2 by the luciferase enzyme, and until recently its active site 
on the enzyme was not known. It has recently been confirmed, however, that 
FMNH2 binds on the α subunit in a large valley on the C-terminal end of the β-
barrel structure (Campbell, Weichsel et al. 2009).  
In order for the reaction to proceed, the luciferase must undergo a 
conformational change following FMNH2 attachment. This movement is primarily 
expressed in a short section of residues known as the protease labile region—a 
section of 29 amino acids residing on a disordered region of the α subunit joining 
α-helix α7a to β-strand β7a. The majority of residues in this sequence are unique 
to the α subunit and have long been implicated in the bioluminescent mechanism 
(Baldwin, Christopher et al. 1995). Following attachment of FMNH2, this region 
becomes more ordered and is stabilized by an intersubunit interaction between 
Phe272 of the α subunit and Tyr115 of the β subunit. This conformational change 
has been theorized to stabilize the α subunit in a conformation favorable for the 
luminescent reaction to occur (Campbell, Weichsel et al. 2009). 
NMR studies have suggested that FMNH2 binds to the enzyme in its anionic 
state (FMNH-) (Vervoort, Muller et al. 1986). With the flavin bound to the enzyme, 
molecular oxygen then binds to the C4 atom to form an intermediate 4α-
hydroperoxy-5-hydroflavin (Nemtseva and Kudryasheva 2007). It is important to 
note that this critical C4 atom was determined to be in close proximity to a reactive 
thiol from the side chain of Cys106 on the α subunit (Campbell, Weichsel et al. 
2009), a residue that has long been hypothesized to play a role in the 
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bioluminescent reaction, but recently has been proven to be non-reactive through 
mutational analysis (Baldwin, Chen et al. 1987).  
It has been shown, however, that C4 is the central atom for the luciferase 
reaction and, following establishment of the hydroperoxide there, it is capable of 
interaction with the aldehyde substrate via its oxygen molecule to form a 
peroxyhemiacetal group. This complex then undergoes a transformation (through 
an unknown intermediate or series of intermediates) to an excited state generally 
accepted to be a luciferase-bound 4α-hydroxy-5-hydroflavin mononucleotide. As 
this complex decays, it yields oxidized FMN, a corresponding aliphatic acid, and 
light (Figure 1B) (Nemtseva and Kudryasheva 2007). There have classically 
been many theories proposed to explain the exact process required for light 
emission (Hastings and Nealson 1977), and these continue to expand today as 
technology for detecting the intermediate complexes has improved. For a review 
of the proposed mechanism and their strengths and weaknesses, the reader is 
directed to Nemtseva and Kudryasheva (Nemtseva and Kudryasheva 2007). 
While the bacterial luciferase protein is all that is required to generate light in 
the presence of its required substrates, it is often beneficial for investigators to 
express other genes from the operon in order to supply the luciferase with the 
substrates required for its autonomous function. To accomplish this, it is 
necessary to co-express the luxC, luxD, and luxE genes. The products of these 
genes assemble into a multi-enzyme complex and are responsible for 
biosynthesis of myristyl aldehyde using components already present in the cell, 
thus negating the requirement to supply an aldehyde substrate exogenously. 
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The luxD gene encodes a transferase protein and is the first to act in the 
aldehyde biosynthesis pathway. It is responsible for the transfer of an activated 
fatty acyl group to water, forming a fatty acid. During the course of this reaction 
the enzyme itself becomes acylated. The newly formed fatty acid is next passed 
off to the luxC gene product, which activates the acid by attaching AMP from a 
molecule of ATP, thereby creating a fatty acyl-AMP that remains tightly bound to 
the enzyme. The fatty acyl-AMP is then transferred to the luxE gene product via 
transfer of the acyl group. This protein acts as a reductase and catalyzes the 
reduction of the fatty acyl-AMP to aldehyde using NADPH to supply the required 
reducing power (Meighen 1991). This allows for the in vivo generation of the 
aldehyde substrate. Because the organism naturally supplies the remaining 
FMNH2 and oxygen substrates, the co-expression of these genes represents the 
minimum requirement for allowing the lux system to operate in a fully 
autonomous fashion.  
lux biosensors and applications 
Prior to the demonstration of autonomous lux function in the mammalian 
cellular environment detailed here, the use of lux as a reporter has been limited 
solely to use in prokaryotic organisms and the lower eukaryote Saccharomyces 
cerevisiae.  However, the experimental designs that have been employed are 
similar to those used when the system is expressed in a mammalian cellular 
host. The most basic bacterial luciferase associated reporter assays are those 
based on determining the presence or level of bioavailability of toxic compounds. 
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Taking advantage of the autonomous nature of the lux operon, bioreporters have 
been engineered to constitutively express light under environmental conditions. 
Upon exposure of the bioluminescent reporter to a toxic compound, it undergoes 
a metabolic slowdown or death, causing a decrease in the total bioluminescent 
signal (Kelly, Lajoie et al. 1999). These assays, such as the commonly used 
Microtox assay (Johnson 2005), can be used to indicate that a toxic compound is 
present but they do not necessarily identify what that compound is. To permit 
identification of the toxicant, multiple bioreporter types are engineered to 
specifically respond only to certain target compounds or analytes of interest. The 
ability of cells to regulate transcription in response to specific compounds is 
taken advantage of in these sensing strategies to create fusions of target specific 
gene sequences with the bioluminescent lux genes. Thus, when exposed to a 
target compound, these bioreporter cells will emit bioluminescent light signals 
that are either dependent on the addition of a decanal substrate (if only the luxAB 
genes are used) or fully autonomously (if the luxCDABE genes are used 
together) (Ripp, DiClaudio et al. 2009). A distinct advantage of the fully 
autonomous luxCDABE-based bioreporters is the ability to report target analyte 
presence continuously and in a real-time or near real-time format. Historically, 
one problem associated with real-time monitoring has been the slow turnover 
time of the bioluminescent reaction. Coupled with the long life of the luciferase 
heterodimer, this has made it difficult to resolve reporter function over short 
periods of time. In order to compensate for this, it has been demonstrated that 
inclusion of a protease tag can shorten the lifespan of the luciferase proteins and 
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increase the temporal resolution of lux-based reporters (Allen, Wilgus et al. 
2007). In addition to the traditional chemical targets, lux-based reporter systems 
have also been designed to detect biological targets such as food and 
waterborne pathogens. In these systems, a bacteriophage, or bacterial virus, is 
used as a carrier of the lux genes and its ability to infect only certain bacterial 
hosts is exploited as a means towards delivering bioluminescence to a target 
bacterium (Ripp 2009). 
An important advantage stemming from the autonomous nature of the 
bacterial luminescence cassette is that, since it does not require substrate 
addition for expression, it can be used remotely if coupled to a proper detection 
device. This allows for the monitoring of compounds of interest that may be 
inaccessible to the researcher under normal conditions because of logistical or 
safety concerns (Nivens, McKnight et al. 2004).  
As a truly autonomous expression system, lux interfaces extremely well with 
signal transducers and has seen widespread use in biosensor applications. Fiber 
optic cables represent one of the easiest interfaces, with the bioreporters 
immobilized at one end of the cable and the other end terminating at a 
photomultiplier tube (PMT) or other luminometer-type device. The cable can then 
be inserted into liquid, solid, or gaseous samples to remotely monitor for target 
analytes such as heavy metals, polycyclic aromatic hydrocarbons (PAHs), or for a 
general assessment of sample toxicity (Heitzer, Malachowsky et al. 1994; Polyak, 
Bassis et al. 2001; Leth, Maltoni et al. 2002; Chang, Lee et al. 2004; Ivask, Green et 
al. 2007). Multi-fiber optical devices immobilized with differently target sensitive 
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bioreporters have also been developed and field tested for multiplexed 
monitoring (Hakkila, Green et al. 2004). In this same vein, but perhaps more user 
friendly, is the Lumisens 2 instrument developed by Horry (Horry, Charrier et al. 
2007), a device where bacteria acting as lux-based reporters are immobilized on 
a disposable card rather than the fiber optic cable itself. A fiber optic cable then 
scans each individually immobilized bioreporter to monitor for bioluminescence 
output in a flow-through format. Similar flow-through samplers have been 
constructed using bioreactors containing growing cultures of the bioreporter into 
which bare fiber optic cables are inserted. Upon exposure to a target analyte or 
toxic intermediate, the bioreporter culture yields increased (or diminished) 
bioluminescence that is detectable via the integrated fiber optics. Continuous, on-
line water toxicity monitoring has been demonstrated using small-scale (1–2 mL) 
bioreactors and larger commercially available systems such as the TOXcontrol 
sensor that can be plumbed into pre-existing water lines (Lee and Gu 2005). 
Fiber optics have also been used to monitor lux-expressing bacteria in their 
natural environment to non-invasively assess metabolic and physiological 
responses to ecosystem perturbations, for example, the addition of a 
contaminant (Dorn, Mahal et al. 2004). 
Although functional, the requisite linkage of the fiber optic cable to a PMT or 
other light gathering device necessitates size and power constraints that are not 
conducive to miniaturization. To address this, several groups have developed 
different variations of chip-based microluminometers that can directly interface 
with the bioreporter organisms. This negates the need for a fiber optic cable to 
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channel the signal to a transducer and instead forms an all-inclusive bioreporter-
on-a-chip biosensor. This technology was first demonstrated with the 
bioluminescent bioreporter integrated circuit (BBIC) that consisted of a small (1.5 
× 1.5 mm), low-power (3 mW) CMOS microluminometer for light gathering and a 
transmitter for remote data transmission (Vijayaraghavan, Islam et al. 2007). 
Polymer encapsulants attach the bioreporters directly on to the BBIC surface or 
the BBIC can be interfaced with bioreporter inoculated flow-cells or bioreactors. 
For field monitoring, the BBIC has been incorporated into a handheld wand that 
operates off of an internal lithium watch battery (Figure 2) (Ripp, Daumer et al. 
2003). 
As a photodetector add on, MOEMS (Micro-Opto-Electro-Mechanical-System) 
can increase detection limits by minimizing system noise using an integrated 
heterodyne optical system (IHOS) technique that modulates bioreporter 
bioluminescence prior to photoconversion (Elman, Ben-Yoav et al. 2008). A 
MOEMS modulator/solid state photodetector interface has been tested with a lux 
bioreporter and a minimum detectable signal of 109 photons/sec/cm2 was 
demonstrated. To accommodate multiplexed, multi-analyte sensing on a single 
chip, Eltoukhy et al. (Eltoukhy, Salama et al. 2006) designed a 128 channel array 
CMOS microluminometer capable of holding and individually sensing multiple 
bioreporters simultaneously, thus enabling high density fingerprinting of sample 






Figure 2.  Example of a CMOS microluminometer 
transducer in a hand-held biosensor format. 
Bioreporter cells engineered to emit bioluminescent 
light signals are directly interfaced to the transducer 
element to form a compact and remotely operable 
biosensor.  Originally published in (Close, Ripp et al. 




available, all within a single lab-on-a-chip platform. Avalanche photodiodes 
(APDs) may also be of utility to bioreporter sensing as they can be designed for 
photon counting, much like a photomultiplier tube, but in a miniaturized 
standalone design (Yotter and Wilson 2003). APDs currently represent the most 
sensitive solid-state devices available and can achieve quantum efficiencies 
greater than 90%. However, they require higher operating voltages, generate 
excessive background noise that may mask low level signals generated from 
bioreporter cells, and their complex circuitry translates into high cost. Despite 
these disadvantages, Daniel et al. (Daniel, Almog et al. 2008) have preliminarily 
tested an APD in conjunction with a stress responsive lux bioluminescent 
bioreporter within a 10 µL sample chamber and demonstrated sufficient 
sensitivity at low part-per-million concentrations of a nalidixic acid inducer. This 
group has also recently developed an integrating sphere device capable of 
measuring absolute photon numbers emanating from bioluminescent cells, 
which, although too complex and fragile to serve as a biosensor, should find 
important utility in shaping factors fundamental to biosensor engineering such as 
quantum yield and minimum signal detection parameters (Daniel, Almog et al. 
2009). 
While many of these examples have utilized bacteria as the host for the lux 
system, they provide valuable insights into how human cells expressing 
mammalian-adapted lux genes can be employed to serve as biosensors under 
real-world conditions. There are, of course, logistical concerns surrounding the 
growth and maintenance of human cell lines as compared to bacterial cells, but 
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advances in cell culture techniques and cell encapsulation technology will one 
day allow for duplication of many of these experimental designs using human 
cells as the reporter organism.  This would allow the determination of human 
bioavailability under environmental conditions and provide valuable information 
on metabolism and uptake of the above mentioned targets in way that has not 
previously been possible. 
Firefly luciferase 
Firefly luciferase (Luc) is the best studied of a large number of luminescent 
proteins to be discovered in insects. The insects represent a large related group 
of bioluminescent organisms, with over 2,500 species reported to be capable of 
generating light (Viviani 2002). While the vast majority of these luminescent 
reactions remain unstudied, the exception is in the order Coleoptera (beetles) 
where systems have been characterized for the chick beetles, railroad worms, 
and fireflies (predominantly Photinus pyralis) (Fraga 2008). Fireflies produce light 
in an organ called a lantern, using the rapid introduction of oxygen as a trigger for 
luminescence in order to attract mates as well as deter potential predators (Lewis 
and Cratsley 2008). 
The first studies of the mechanism behind insect luminescence were carried 
out in the late 1800’s by Raphael Dubois using ground up abdomens from the 
Elanteridae beetle. It was from these experiments that Dubois first proposed the 
existence of a system employing a luciferase and a luciferin for the production of 
light. The next advance came from Newton Harvey, who reported on the 
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specificity of luciferase/luciferin interactions and confirmed the requirement for 
molecular oxygen (Fraga 2008). In the mid 1900’s William McElroy began what 
was to be a long and successful career working with firefly luciferase by 
discovering the requirement that ATP be involved in the luminescent reaction 
(McElroy 1947). Based in part on these findings, his group soon proposed that 
the bioluminescent reaction occurred via a two step process (Hastings, McElroy 
et al. 1953) and was the first to determine the structure of the firefly luciferin as 2-
(4-hydroxybenzothiazol-2-yl)-2-thiazoline acid (White, Field et al. 1961) —
commonly abbreviated as D-luciferin in the literature. In the late 1960’s and 
1970’s the mechanism underlying the luminescent reaction was reported (White, 
Rapaport et al. 1969; McCapra 1976), as was the confirmation of the 
intermediate products of this proposed reaction (Fraga 2008). The mechanism 
was finally secured in 1980 when oxyluciferin was isolated as a purified product 
of the D-luciferin luminescence reaction (White, Steinmetz et al. 1980). The latest 
advance in the understanding of firefly luciferase came in 1996 when Conti 
(Conti, Franks et al. 1996) published the crystal structure of the luciferase at a 
resolution of 2.0 Å. This opened the door for targeted mutagenesis investigations 
and gave researchers the first look at the structure of this reporter protein. 
The Luc protein catalyzes the oxidation of the reduced luciferin (D-luciferin) in 
the presence of ATP-Mg2+ and oxygen to generate CO2, AMP, PPi, oxyluciferin, 
and yellow-green light at a wavelength of 562 nm (Figure 3). It is important to 
note that D-luciferin is a chiral molecule, and while both the D and L forms can 




Figure 3.  Bioluminescent reaction catalyzed by firefly luciferase. 
The luciferase protein holds the reduced luciferin to allow for adenylation (a). This process is 
followed by a deprotonation reaction that leads to the formation of a carbanion (b) and attack by 
oxygen (c), driving the formation of a cyclic intermediate (d). As this intermediate decays, carbon 
dioxide is released, forming the excited state luciferin in either the keto (e) or enolate (f) form. 
Originally published in (Branchini, Magyar et al. 1998), reprinted with permission. 
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continuing on in the reaction to generate light (Fraga 2008). This reaction was 
originally reported to occur with a quantum yield of 0.88 (Seliger and McElroy 
1960), but has since been shown to actually achieve a quantum yield closer to 
only 0.41 (Ando, Niwa et al. 2007). Because of the high quantum yield, the 
reaction is well suited to use as a reporter with as few as 10−19 mol of luciferase 
(2.4 × 105 molecules) able to produce a light signal capable of being detected 
(Gould and Subramani 1988). 
It has been known since the early 1950’s that the chemical reaction underlying 
firefly luminescence is a two-step process that first requires adenylation of D-
luciferin followed by oxidation and the production of light (Hastings, McElroy et al. 
1953). Prior to the initiation of the reaction, the Luc protein must first bind to D-
luciferin. However, at this time it is not yet capable of undergoing oxidation or 
producing light. The first step in the generation of light is the adenylation of the 
bound D-luciferin with the release of pyrophosphate (Ugarova 1989). The 
function of this adenylation is to increase the acidity of the C4 proton of the 
thiazoline ring on D-luciferin. This allows for removal of a proton from C4 causing 
formation of a carbanion (McCapra, Chang et al. 1968). This carbanion is then 
attacked by oxygen, displacing AMP and driving the formation of a cyclic 
peroxide with an associated carbonyl group (a dioxetanone ring). As the bonds 
supporting this structure collapse, it becomes decarboxylated, releasing CO2 and 
forming an electronically excited state of oxyluciferin in either the enol or keto 
form (Ugarova 1989). 
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The kinetics of this reaction can be altered by varying the concentration of the 
substrates, with low concentrations (in the nM range) showing steady light 
production and high concentrations (µM range) producing a bright flash followed 
by decay to 5 – 10% of the maximum (DeLuca, Wannlund et al. 1979). There are 
multiple possible inhibitory compounds that could be responsible for the kinetic 
profile generated under high substrate concentrations. It has previously been 
shown that, even though oxyluciferin is a natural product of the luciferase 
reaction, it is capable of remaining bound as an inhibitor to enzymatic turnover 
(Denburg, Lee et al. 1969). The same was found to be true of another potential 
byproduct, L-AMP, which can account for up to 16% of the product formed during 
the luminescent reaction (Fontes, Ortiz et al. 1998). This may, in part, explain 
how the addition of CoA to the luminescent reaction can result in improved 
performance. When CoA is added during the initial steps of the reaction, it 
prevents the fast signal decay normally observed, and when it is added following 
this decay it can promote re-initiation of the flash kinetics. This can be attributed 
to CoA’s interaction with L-AMP to form L-CoA, resulting in turnover of the Luc 
enzyme and reoccurrence of the luminescent reaction (Airth, Rhodes et al. 
1958). 
Insects, and specifically beetles, that produce luminescence are quite diverse 
in the colors they are capable of producing. It was originally believed that the 
colors were the result of divergent luciferase structures, however, the sequences 
of four luciferase genes from Pyrophorus plagiophthalamus with four different 
emission spectra were sequenced and it was found that they shared up to 99% 
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amino acid identity (Wood, Lam et al. 1989). There are currently three 
mechanisms that have been proposed to explain the multiple bioluminescent 
colorations: the active site polarity hypothesis (DeLuca 1969), the 
tautomerization hypothesis (White and Branchini 1975), and the geometry 
hypothesis (McCapra, Gilfoyle et al. 1994). 
The active site polarity hypothesis is based on the idea that the wavelength of 
light produced is related to the microenvironment surrounding the luminescent 
protein during the reaction. In non-polar solvents the spectrum is shifted towards 
blue and in polar solvents it is more red-shifted. It is questionable, however, if 
polarity fluctuations can account for large scale changes like those that have 
been observed in P. plagiophthalamus. The tautomerization hypothesis states 
that the wavelength of light produced is dependent on whether either the enol or 
keto form of the luciferin is formed during the course of the reaction. A recent 
study has reported that by altering the substrate of the reaction the keto form of 
the luciferin can produce either red or green light, making this hypothesis unlikely 
as well (Branchini, Murtiashaw et al. 2002). Finally, the geometry hypothesis 
suggests that the geometry of the excited state oxyluciferin is responsible for 
determining the emission wavelength. In a 90° conformation it would achieve its 
lowest energy state and red light would be produced, whereas in the planar 
conformation it would be in its highest energy state and green light would be 
produced. Intermediate colors would be the result of geometries between these 
two extremes (Viviani 2002). 
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Luc biosensors and applications 
Firefly luciferase makes an excellent reporter for the reasons previously 
discussed, however, its major hurdle for use has always been the inability for 
detection in real-time due to the requirement for addition of a separate luciferin.  
Despite this drawback, Luc has become the most popular reporter protein for 
bioluminescent imaging because its bright signal allows for detection even at low 
reporter population sizes. For example, Kim and colleagues have demonstrated 
this advantage with the newest generation of these reporters designed for tumor 
detection.  The investigators were able to inject codon-optimized Luc containing 
4T1 mouse mammary tumor cells subcutaneously and then image single 
bioluminescent cells at a background ratio of 6:1 (Kim, Urban et al. 2010).  This 
experiment effectively demonstrates how a Luc-based reporter can be used to 
continuously monitor cancer development from a single cell all the way to 
complete tumor formation. 
Some researchers have also managed to take advantage of the dependence 
of the Luc system on the presence of its D-luciferin substrate to produce a 
detectable signal.  Through bioluminescence resonance energy transfer (BRET) 
Angers et. al. was able to demonstrate the presence of G-protein coupled 
receptor dimers on the surface of living cells.  By tagging a subset of β2-
adrenergic receptor proteins with Luc and a subset with the red-shifted variant of 
green fluorescent protein, YFP, it was possible to detect both a luminescent and 
fluorescent signal in cells expressing both variants, but no fluorescent signal in 
cells expressing only YFP since no fluorescent excitation signal was used 
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(Angers, Salahpour et al. 2000).  This was made possible because the 
bioluminescent signal from Luc required to stimulate the fluorescent signal of 
YFP was not constantly produced, allowing the researchers to detect YFP 
independently from the Luc signal, and then subsequently visualizing where Luc 
was expressed either in tandem or independently of the associated YFP protein. 
Due to its persistence as the most widely used bioluminescent protein in the 
optical imaging field, there have been myriad other uses of the Luc protein in 
both cell culture and small animal imaging applications.  Multiple reviews have 
been published detailing the standard and novel implementations of this versatile 
protein, but suffice it to say that it is not without reason that Luc is consistently 
employed by a wide variety of researchers.  The intense bioluminescent signal 
allows for facile detection using short integration times and simultaneously allows 
for detection under conditions of heave photo-scattering and absorption.  The 
examples used here provide only brief highlights as to the functional sensitivity 
and range of use afforded by the Luc reporter system. 
Green fluorescent protein 
Green fluorescent protein (GFP) was first discovered during investigation into 
the related chemiluminescent protein aequorin from the jellyfish Aequorea 
Victoria (Shimomura, Johnson et al. 1962). Since that time it has been realized 
that the Aequorea derived GFP is just one of a larger family of homologous 
fluorescent proteins capable of producing light in a variety of colors due to 
alterations in the covalent structure of their chromophores or differences in the 
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surrounding non-covalent environment (Giepmans, Adams et al. 2006). Despite 
its early discovery, the use of GFP as a research tool did not begin until after it 
was successfully cloned almost thirty years later (Prasher, Eckenrode et al. 
1992). However, soon after the cDNA was available, its function was validated in 
both prokaryotic and eukaryotic organisms by Chalfie (Chalfie, Tu et al. 1994), 
and since that time it has been used in numerous applications including 
localization studies, protein expression monitoring, as a reporter gene, as a 
viability marker, to detect the onset of apoptosis, and many others (reviewed in 
(Zimmer 2002)). 
GFP has become a favored tool for molecular studies because it is 
autofluorescent and does not require the addition of any cofactors to properly 
function in exogenous systems (Naylor 1999), although it does require activation 
by an excitation light source before its signal can be measured. It has been 
shown to be resistant to heat, alkaline pH fluctuations, chaotropic salts, organic 
solvents, and many proteases (Ehrmann, Scheyhing et al. 2001), and its 
expression in exogenous environments is primarily non-toxic (Zimmer 2002) with 
a few proven exceptions (Hanazono, Yu et al. 1997; Liu, Jan et al. 1999) that may 
be due to production of hydrogen peroxide as a by-product of synthesis (Tsien 1998). 
However, the slow posttranslational chromophore formation and oxygen 
requirement of GFP, along with potential difficulty in distinguishing its signature 
from background fluorescence (Zimmer 2002), can be problematic, especially in 
aerobic organisms. Because of this, alternate fluorescent proteins such as those 
based on flavin mononucleotide are often used when developing reporters for 
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anaerobic organisms (Drepper, Eggert et al. 2007). Time, though, has proven 
that the benefits outweigh the challenges for most investigators, and GFP has 
taken its place as one of the most popular tools currently available for cellular 
and molecular signaling research. 
Wild-type GFP protein is able to absorb light at two different wavelengths. A 
minor peak occurs at 475 nm with the major peak at 397 nm (Figure 4). 
Regardless of which excitation wavelength is used, emission occurs only at 504 
nm (Patterson, Knobel et al. 1997). The different absorption peaks have been 
attributed to varying protonation states of the fluorophore, with the neutral state 
corresponding to the major absorption peak at 397 nm and the anionic form 
contributing to the minor peak at 475 nm (Niwa, Inouye et al. 1996). The large 
shift between the major absorption peak at 397 nm and the emission at 504 nm 
can be attributed to an excited state proton transfer from the side chain of the 
Tyr66 residue of the fluorophore (Chattoraj, King et al. 1996) to the carboxylate 
oxygen of Glu222 (Zimmer 2002). 
Based on this interconversion of the fluorophore, a three state model of 
photoisomerization has been put forward to explain the chemical basis for shifts 
in absorption. This model states that excitation of the neutral state fluorophore can 
cause conversion to the anionic form via an intermediate (Chattoraj, King et al. 
1996). The intermediate is structurally similar to the neutral form of the 
fluorophore, but has become deprotonated at the phenol group of Tyr66 (Zimmer 




Figure 4.  The dual absorption peaks in the GFP spectra are the result of different 
charge states in the GFP chromophore. 
The neutral state (left) is responsible for the major peak at 397 nm while the anionic form 
(right) is responsible for the minor peak at 475 nm. Regardless of the chromophore charge 




while the neutral state must necessarily convert into an excited form of this 
intermediate prior to emission (Jung, Wiehler et al. 2005). While it is possible for 
the neutral form to convert to the anionic form following excitation, this is not the 
most favorable reaction. The majority of excited, neutral fluorophores will convert 
briefly to the intermediate state, where fluorescence will occur, followed by 
reversion back to the neutral state (Chattoraj, King et al. 1996). Interconversion 
between the neutral and anionic states is possible, but requires both proton 
transfer and conformational change to occur (Zimmer 2002). Similarly, the 
majority of anionic fluorophores will revert to the ground state following 
fluorescent emission, but could instead undergo a conformational change to the 
intermediate state and then continue on to adopt a neutral charge state 
(Chattoraj, King et al. 1996). 
In a wild-type population, GFP contains a 6:1 ratio of neutral to anionic 
fluorophores (Tsien 1998), explaining why the major absorption peak is found at 
397 nm. However, upon extended ultraviolet (UV) illumination this peak will begin 
to decrease and the minor peak will increase (Cubitt, Heim et al. 1995). This 
behavior corresponds to the photoisomerization of the neutral fluorophore form 
responsible for the major absorption peak being converted into the anionic form 
as discussed above. While the photoisomerization characteristics of GFP can 
prove problematic for quantification, they do allow for the study of protein 
movement by excitation with intense UV light at 397 nm followed by excitation at 
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475 nm in order to track the movement of the photoisomerized fluorophores 
(Yokoe and Meyer 1996). 
Following the discovery of GFP, it was quickly proven that amino acid 
substitutions were capable of altering its fluorescent characteristics. Since that 
time, versions of GFP have been developed that fold more efficiently at higher 
temperatures (Crameri, Whitehorn et al. 1996), avoid dimerization at high 
concentration (Zacharias, Violin et al. 2002), or fluoresce in the blue (Heim, 
Prasher et al. 1994), cyan (Heim and Tsien 1996), or yellow (Ormo, Cubitt et al. 
1996) wavelengths. Homologs have since been discovered that fluoresce in the 
red range as well (Matz, Fradkov et al. 1999). The history and development of 
these variants is outside the scope of this review, but an excellent classification 
has been made by Tsien (Tsien 1998) and abridged by Zimmer (Zimmer 2002) 
dividing the known variants into seven classes based on spectral characteristics. 
When applied in concert, these variants of the GFP protein have given 
researchers the ability to use multiple GFP-based reporters in the same 
environment at the same time, improving the usefulness and range of this 
already dynamic protein. 
GFP biosensors and applications 
Since it was first demonstrated that GFP could be expressed in E. coli 
(Chalfie, Tu et al. 1994), it has been used in countless experiments in organisms 
ranging from bacteria to cultured human cells and even commercialized for sale 
in designer pets. Aside from basic localization assays, the two main uses of GFP 
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as a reporter focus on either the induction or suppression of GFP expression to 
indicate interaction with an analyte of interest. One of the more popular assays 
focusing on the suppressed expression of GFP is the determination of cell 
viability. In these assays, cells expressing GFP are exposed to compounds of 
interest and the severity of toxicity is determined by monitoring the decrease in 
fluorescent expression (Choi, Deng et al. 2008). This allows researchers to 
process a large number of samples very quickly in an automated fashion. As the 
cells are killed or their metabolism is slowed by interaction with toxic substances, 
the overall amount of fluorescence will decrease. This type of assay has the 
added advantage of determining the amount of a given compound that will be 
bioavailable to the organism being tested. 
The inverse of this type of experiment is to induce the expression of GFP as a 
positive result. In this case the gene encoding for GFP is placed under the 
control of a genetic promoter that responds specifically to the analyte of interest. 
This allows for visual detection when the cell is exposed to the target analyte. An 
advantage of this type of experimental design is that the amount of fluorescence 
produced can be correlated to the concentration of analyte, allowing for an 
approximate quantification (Gvakharia, Bottomley et al. 2009). It is also possible 
to use the fluorescence of GFP as a marker to isolate those members of the 
community showing a response by using fluorescence activated cell sorting 
(FACS) (Bumann and Valdivia 2007). Using GFP to confirm interaction with a 
compound of interest, quantify the amount of exposure, and isolating exposed 
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cells simultaneously illustrates its dynamic functionality in modern bioreporter 
research. 
Biosensor integration of GFP-based bioreporters, however, remains fairly 
limited due to signal output by GFP being contingent upon an excitation light 
source. Thus, these set-ups require one energy source to excite GFP and 
another to measure GFP, and the associated complexity and bulkiness are often 
not suitable for biosensor applications. There has been some application success 
using fiber optic cables where one cable is used for excitation and another for 
emission measurement. Shetty (Shetty, Ramanathan et al. 1999), for example, 
constructed a GFP-based bioreporter sensitive to the monosaccharide L-
arabinose and entrapped it within a dialysis membrane tied to the tip of a fiber 
optic bundle. Fibers terminating at a tungsten lamp served as the excitation 
source while separate fibers terminating at a PMT served as the detector. 
Immersing the reporter-entrapped sensor end of the fiber bundle in liquid was 
then shown capable of detecting L-arabinose at varying concentrations. To 
improve sensitivity, Knight (Knight, Goddard et al. 1999) bypassed fiber optics by 
interfacing a PMT directly with a flow-cell containing a eukaryotic-based GFP 
bioreporter sensitive to DNA damaging genotoxic compounds using an argon 
laser to provide the excitation source. Realizing the necessity for miniaturization 
and less complexity, new fluorescence detection techniques based on small 
footprint biosensor compliant platforms are becoming somewhat available. 
Complementary–metal–oxide–semiconductor (CMOS) photodetectors better 
tuned to the green light signature provide enhanced detection (Yotter, Warren et 
 
 32 
al. 2004), as do avalanche photodiodes, while tightly focused laser beams 
provide excitation down to the single cell level (Wells 2006). However, 
incorporating all necessary components into a true biosensor format remains 
challenging. Recently a 12 cm diameter microfluidics-based lab-on-a-compact 
disk (CD) device that microcentrifugally moved and mixed microliter volumes of 
water test samples with a GFP bioreporter sensitive to arsenic have been 
created (Rothert, Deo et al. 2005) (Figure 5). Although sensing was 
accomplished with a fiber optic probe positioned above the CD, the device could 
likely be easily reconfigured to accommodate a chip-based sensor to promote further 
miniaturization. 
in vivo bioluminescent imaging (BLI) 
 Whole animal bioluminescent imaging (BLI) is progressively becoming more 
widely applied by investigators from diverse backgrounds because of its low cost, 
high throughput, and relative ease of operation in visualizing a wide variety of in 
vivo cellular events (Baker 2010).  The ability to visualize cellular processes or 
other biological interactions without the requirement for animal subject sacrifice 
allows for repeated imaging and releases investigators from the constraints of 
considering their process of interest on a “frame-by-frame” basis using labeled 
slides.  In addition, the ability to continually monitor a single individual reduces 
the amount of inter-animal variation and can reduce error, leading to higher 
resolution and less data loss.  With continuing advances in the hardware and 




Figure 5.  Miniaturization of detection technologies allows for increased ease of use. 
A) A lab-on-a-CD microfluidic device used in conjunction with GFP bioreporters sensitive towards 
arsenic. B) A close-up view of the microfluidic channeling that permits sample and bioreporter 
mixing. Originally published in (Rothert, Deo et al. 2005), reprinted with permission. 
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researchers with little background in molecular imaging to obtain useful and 
detailed publication-ready images. 
 The mainstays of BLI are the light generating luciferase enzymes such as 
firefly luciferase, Renilla luciferase, Gaussia luciferase, Metridia luciferase, 
Vargula luciferase, or bacterial luciferase (Thompson, Nagata et al. 1989; Wood, 
Lam et al. 1989; Lorenz, McCann et al. 1991; Meighen 1991; Verhaegen and 
Christopoulos 2002; Markova, Golz et al. 2004).  Of these however, the firefly 
and Renilla luciferases are the most popular for optical imaging.  These 
bioluminescent proteins are preferred over their fluorescent counterparts 
because the lack of endogenous bioluminescent reactions in mammalian tissue 
allows for near background-free imaging conditions whereas the prevalence of 
fluorescently active compounds in these tissues can interfere with target 
resolution upon exposure to the fluorescent excitation wavelengths required for 
the generation of signal output. 
 Firefly luciferase (Luc), Renilla luciferase (RLuc), and bacterial luciferase (lux) 
all exhibit distinct imaging characteristics ranging for the substrate required (if 
any) to the wavelength at which their bioluminescent signal is produced.  It is this 
diversity that has lead to their popularity for in vitro BLI.  While none of them 
individually is suited to every experimental design, they can be interchanged and 
sometimes used in combination to function in a wide variety of imaging 
applications. The advantages and disadvantages of these reporter proteins as 




Table 1.  Comparison of BLI reporter proteins. 
Reporter Advantages Disadvantages 





• High sensitivity and low 
signal-to-noise ratio 
• Quantitative correlation 
between signal strength and 
cell numbers 
•  Low background in animal 
tissues 
•  Variations of firefly 
luciferase (stabilized and 
red-shifted) and click beetle 
luciferases (red and green) 
are available 
•  Different colors allow multi-
component monitoring 
• Requires exogenous 
luciferin addition 
• Fast consumption of 
luciferin can lead to 
unstable signal 
• ATP and oxygen 
dependent  
• Currently not practical for 







• High sensitivity 
• Quantitative correlation 
between signal strength and 
cell numbers 
• Stabilized and red-shifted 
Renilla luciferase are 
available 
• Secretion of Gaussia 





• Requires exogenous 
coelenterazine addition 
• Low anatomic resolution 
• Increased background due 
to oxidation of 
coelenterazine by serum 
•  Oxygen dependent 
• Fast consumption of 
coelenterazine can lead to 
unstable signal 
• Currently not practical for 
large animal models 
Bacterial 
luciferase 
• High sensitivity and low 
signal-to-noise ratio 
• Quantitative correlation 
between signal strength and 
cell numbers 
• Fully autonomous system, 
no requirement for addition 
of exogenous substrate 
• Noninvasive 
• Stable signal 
• Rapid detection permitting 
real-time monitoring 
• Bioluminescence at 490 nm 
prone absorption in animal 
tissues 
• Low anatomic resolution 
• NADPH and oxygen 
dependent 
• Not as bright as other 
luciferases 
• Currently not practical for 
large animal models 
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Optical properties of biological tissues 
 The unique constraints of performing data collection from within a living 
medium must be considered in relation to any choice of reporter system.  The 
detection of a luminescent signal from within a tissue sample is dependent on 
several factors, including the flux of photons from the reporter, the total number 
of functional reporter cells in the sample, and the location of the reporter cells 
within the tissue sample itself (Troy, Jekic-McMullen et al. 2004).  In addition, the 
visualization of the bioluminescent signal is dependent on the absorption and 
scattering of that signal prior to detection.  The scattering of a bioluminescent 
signal cannot be controlled, however, changing its wavelength can alter the 
absorption characteristics of the signal significantly.  This is due to the fact that 
the majority of luminescent absorption is the result of interaction of the signal with 
endogenous chromophoric material.  By moving to a more red-shifted emission 
wavelength, where the levels of absorption within tissue are lower, it becomes 
possible to measure a greater amount of signal intensity than would be possible 
from an identical reporter with a lower, more blue-shifted emission wavelength 
(Chance, Cope et al. 1998).  For this reason, it is important to consider the 
emission wavelength of a given reporter system, along with the other desired 
attributes of that reporter, prior to its introduction into any experimental design.  
For example, the bioluminescent signal from the lux reaction is produced at 490 
nm.  This is relatively blue-shifted as compared to the Luc-based bioluminescent 
probes that display their peak luminescent signal at 560 nm.  The shorter 
wavelength of the lux-based signal has a greater chance of becoming attenuated 
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within the tissue and therefore may not be as easily detected if it is used in 
deeper tissue applications (such as intraperitoneal or intraorganeller injections), 
and may require longer integration times to achieve the same level of detection 
as a longer wavelength reporter would when injected subcutaneously.  
Therefore, if short measurement times and low population level cell detections 
are the goals of a particular experiment, a Luc-based reporter would be beneficial 
compared to a lux-based reporter despite potential problems introduced through 
substrate administration in the Luc system.  However, if a near surface detection 
of large cell populations (such as a subcutaneous tumor) was the end goal, the 
effects of absorption and scattering could be overcome by the depth and position 
of the reporter, thus allowing for selection of the more blue-shifted lux reporter 
system. 
Imaging equipment 
The challenge of detecting and locating bioluminescent light emissions from 
within living subjects has been met by several commercial suppliers of in vivo 
imaging equipment (Table 2).  A basic imaging system consists of a light-tight 
imaging chamber into which the subject is placed and a high quantum efficiency 
charged coupled device (CCD) camera, usually supercooled to less than -80°C 
to reduce thermal noise, that collects emitted light.  The camera typically first 
takes a photographic image of the subject followed by a bioluminescent image.  




Table 2.  Commercial manufacturers of in vivo imaging systems. 
Company URL 
Caliper Life Sciences http://www.caliperls.com/tech/optical-imaging/ 




Li-Cor Biosciences http://www.licor.com/index.jsp 







subject’s anatomy for pinpoint identification of source emissions.  Acquisition 
times can range from a few seconds to several minutes depending on signal 
strength.  Software displays the image in a pseudocolored format and provides 
the tools needed to quantify, adjust, calibrate, and background correct the 
resulting image.  Integrated gas anesthesia systems, heated stages, and 
isolation chambers are typically available to accommodate animal handling. 
 The technology incorporated into in vivo imaging systems is rapidly advancing 
to meet user needs in a greater diversity of application backgrounds.  CCD 
cameras are being replaced by more sensitive intensified CCD (ICCD) and 
electron multiplying CCD (EMCCD) cameras that can manage acquisition times 
of millisecond durations.  These fast processing times along with powerful 
software now permit real-time tracking of conscious, moving subjects (see, for 
example, the IVIS Kinetic system from Caliper Life Sciences).  Anesthesia can 
have dramatic, unknown, and interfering effects on animals, and the ability to 
image in its absence is a major step forward in in vivo imaging technology.  In 
addition, imaging systems are becoming better integrated with existing medical 
technologies for multi-parameter analyses.  For example, electrocardiogram 
(ECG) or X-ray procedures can operate in parallel with imaging acquisition.  The 
ability of software to overlay and map these data to the bioluminescent image, 
often as a 3D representation, offers unique opportunities to visualize 
physiological status and kinetics. 
 The major drawback of in vivo imaging systems is their inability to detect 
signal at tissue depths beyond a few centimeters.  Without major advances in 
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imaging sensitivity, either with the camera systems, the internal signal, or almost 
certainly both in tandem, in vivo imaging applications may become limited solely 
to small animals and the translational leap to humans will never occur.  Rather 
than relying on a camera to visualize the signal externally, it may be feasible and 
potentially more practical to monitor the signal internally using implantable 
sensors.  Although not yet a viable technology, proof-of-concept 
microluminometer integrated circuits of only a few square millimeters in size have 
been developed and validated for bioluminescent signal acquisition 
(Vijayaraghavan, Islam et al. 2007).  These so-called bioluminescent bioreporter 
integrated circuits, or BBICs, were specifically designed for capturing the 490 nm 
bioluminescent light signal emitted by the bacterial lux system, and 
accommodated on-chip transmitters for wireless data transmission.  However, 
effectively interfacing the microluminometers with the luciferase reporter systems 
maintaining reporter viability, and implanting the chips remains challenging. 
Common in vivo bioluminescent imaging modalities 
Steady-state bioluminescent imaging 
 The classical hallmark of BLI is steady state imaging, a process whereby 
bioluminescently tagged cells are imaged over time to determine if light output is 
increasing or decreasing compared to the initial state.  In this type of imaging, 
either a gain or loss of signal can be the desired result depending on the 
experimental design.  Commonly, bioluminescent cells are injected into an 
animal model to determine the kinetics of tumorigenesis and growth.  The use of 
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BLI as a substitute for mechanical or histological measurement of tumors has 
increased rapidly in recent years as it does not entail high levels of animal 
subject sacrifice nor tedious histological analysis, and can overcome the loss of 
accuracy associated with physical analysis due to the contribution of edema and 
necrotic centers to overall tumor size (Vaupel, Kallinowski et al. 1989).  In 
addition, by monitoring tumor growth using BLI, an investigator can track 
changes within individual animals over time without requiring the subject to be 
sacrificed.  This reduces the amount of intra-animal variability and can improve 
the detection of significant results.    
 In the opposite direction, decreases in bioluminescent expression can be 
used to quickly and efficiently perform drug efficacy screening.  The same 
logistical concerns that have propelled BLI forward as the tool for choice for 
tumor monitoring are also making it the preferred choice for the screening of new 
compounds directed at tumor suppression or infection control.  In addition, the 
use of mixed culture or whole animal models can more closely mimic the target 
microenvironmental conditions that may alter the compound’s activity.  As one 
example, McMillin et al. (McMillin, Delmore et al. 2010) illustrated that high 
throughput scalable mixed cell cultures with Luc tagged cancer cells can identify 
anti-cancer drugs that are specifically effective in the tumor microenvironment 
early in the discovery pipeline, thereby aiding in their prioritization for further 
study in ways not previously possible. 
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Multi-reporter bioluminescent imaging 
 In a basic experimental design, multi-reporter BLI is performed by 
simultaneously monitoring for expression of two or more divergent luciferase 
proteins.  This is made possible because all of the characterized luciferase 
proteins have divergent bioluminescent emission wavelengths.  This type of 
experimental design is especially useful when used to monitor potentially co-
dependent, or inter-dependent protein expression such as that expressed during 
the maintenance of circadian rhythm.  Here, the expression of multiple genes can 
be monitored in real time, without the need to expose cells to potentially 
influential doses of excitation light wavelengths as would be required for imaging 
using fluorescent targets (Honma, Yoshikawa et al.).  Even when expression of 
the individual genes of interest is static, sequential imaging of multiple luciferase 
proteins provides a convenient method for localizing expression profiles of each 
gene in vivo (Heikkila, Vaha-Koskela et al. 2010). 
 The work of Audigier and colleagues (Audigier, Guiramand et al. 2008) 
demonstrates how imaging multiple bioluminescent reporters can be an 
opportune way to monitor translational dynamics using the function of the 
fibroblast growth factor two internal ribosomal entry site on neural development 
as a model.  To determine the associated ratios of cap-dependent to cap-
independent translation, they cloned the RLuc gene upstream of the site and the 
Luc gene downstream.  By doing so, they were able to quantify and compare the 
levels of expression of each reporter protein independently from the same 
sample, helping to reduce sampling error. 
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Multi-component bioluminescent imaging 
 Similar to multi-reporter BLI, multi-component BLI relies on the co-expression 
of an alternate imaging construct, however, in this case the secondary construct 
is not itself bioluminescent.  Classically, the luminescent emission signal of a 
substrate amended luciferase protein can be harnessed to act as the excitation 
signal for an associated fluorescent reporter protein, negating the requirement for 
treatment with a background stimulating exogenous light source.  This process, 
known as bioluminescence resonance energy transfer (BRET) occurs naturally in 
the sea pansy Renilla reniformis and other marine animals (Ward and Cormier 
1978), but can be used in research settings to boost the luminescent signal of a 
bioluminescent reporter, or, more popularly, to determine the interaction of two 
components of interest within a given system.  
  In some cases, the secondary component is not a fluorescent compound but 
rather a non-independently functional domain of the luciferase protein itself.  
These types of constructs are easily created using reporters such as Luc that 
have distinct N (N-Luc) and C (C-Luc) terminal domains joined by a linker region.  
These types of protein structures lend themselves nicely to separation into 
distinct components that, when brought together, can form a functional luciferase 
protein. 
 First described by Paulmurugan et al. (Paulmurugan, Umezawa et al. 2002), 
this process takes advantage of the lack of a bioluminescent signal in small 
animal tissue samples.  The individual N and C terminal components of the Luc 
protein are not capable of producing light independently of one another, however, 
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when they were independently tethered to two proteins known to interact 
strongly, the researchers were able to demonstrate that bioluminescence could 
be restored upon substrate amendment.  The complementation of a single 
luciferase protein as opposed to the adjoinment of a luciferase with a fluorescent 
partner does not require the pair matching of a luciferase/fluorescent reporter 
with overlapping emission/excitation wavelengths, and can permit co-
visualization with other reporters in a single subject to permit multi-localization of 
groups of proteins. 
Bioluminescence as a supplementary imaging technique 
 As the technology for small animal imaging continues to increase in power 
and availability, there is an increasing movement towards combining multiple 
imaging techniques to improve the amount of detail that can be obtained from a 
single subject.  While no single imaging technique can provide an investigator 
with a comprehensive picture of the system as a whole, the combination of 
multiple techniques such as computed tomography (CT), positron emission 
tomography (PET), and BLI can help to “fill in the gaps” left by each approach in 
a rapid, sequential manner.  The development of trimodal fusion proteins that are 
capable of simultaneously acting as a signal for fluorescence, bioluminescence, 
and PET, and the introduction of combined clinical PET/CT scanners has made it 
possible to obtain more information from a single animal subject than was 





Demonstration Of Autonomous Bioluminescent Production In 
The Mammalian Cellular Background 
       
Introduction 
 In vivo optical imaging is becoming increasingly utilized as a method for 
modern biomedical research.  This process, which involves the non-invasive 
interrogation of animal subjects using light emitted either naturally from a 
luciferase protein or following excitation of a fluorescent protein or dye, has been 
applied to the study of a wide range of biological processes such as gene 
function, drug discovery and development, cellular trafficking, protein-protein 
interactions, and especially tumorigenesis and cancer treatment (Contag and 
Bachmann 2002) .  While the detection limits and resolution of charge coupled 
devices (CCDs) has increased greatly in recent years (Oshiro 1998), there have 
been relatively few introductions of improved imaging compounds that function 
as light production centers within an animal subject in vivo. 
 Generally, the currently available imaging compounds can be divided into 
two classes: those containing luciferase proteins (capable of producing 
bioluminescent light without exogenous excitation) and those containing 
fluorescent compounds (dyes or proteins that require an initial excitation followed 
 
 46 
by emission at a given wavelength).  For mammalian-based whole animal 
imaging, fluorescent compounds are limited due to high levels of background 
fluorescence from endogenous biological structures upon excitation (Tsien 
1998).  Although dyes have been developed and employed that fluoresce in the 
near infrared wavelengths (Bloch, Lesage et al. 2005; Kalchenko, Shivtiel et al. 
2006) where light absorption is lowest in mammalian tissues, they can become 
increasingly diffuse during the process of cellular division, negating their 
usefulness in long term monitoring studies (Contag and Bachmann 2002) .  In 
contrast, luciferase proteins are highly amenable towards in vivo optical imaging 
(referred to as bioluminescent imaging or BLI) because they produce a 
controllable light signal in cells with little to no background bioluminescence, thus 
allowing for remarkably sensitive detection (Zhao, Doyle et al. 2005).  While 
historically the luciferase proteins used have been based on beetle luciferases 
(i.e., firefly or click beetle luciferase) or marine aequorin-like proteins (those that 
utilize coelenterazine), these each possess disadvantages when applied to whole 
animal BLI.  For example, the popular firefly luciferase protein is heat labile when 
incubated under whole animal BLI imaging conditions, and can display a half life 
as short as 3 min in its native state at 37°C (Baggett, Roy et al. 2004). 
Coelenterazine-stimulated luciferases are similarly handicapped in regards to 
long-term monitoring, as it has been reported that their rapid uptake of 
coelenterazine necessitates prompt imaging following substrate injection 
(Bhaumik and Gambhir 2002).  Applications of both these luciferase systems 
also suffer from the drawback that they require addition of an exogenous 
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substrate to produce a detectable light signal.  This current work reports for the 
first time that a modified bacterial luciferase gene cassette can be expressed in 
mammalian cells in culture or in whole animal BLI without the use of exogenous 
substrates or coincident infection with a bacterial host, thus overcoming the 
limitations imposed by currently available luciferase-based BLI assays.  
 Setting the bacterial bioluminescence system apart from other 
bioluminescent systems such as firefly luciferase and aequorin is its ability to 
self-synthesize all of the substrates required for the production of light.  While the 
luciferase component is a heterodimer formed from the products of the luxA and 
luxB genes, its only required substrates are molecular oxygen, reduced riboflavin 
phosphate (FMNH2), and a long chain aliphatic aldehyde.  Oxygen and FMNH2 
are naturally occurring products within the cell while the luxCDE gene products 
produce and regenerate the aldehyde substrate using endogenous aliphatic 
compounds initially targeted to lipid biogenesis.  To produce light, the luciferase 
protein first binds FMNH2, followed by O2, and then the synthesized aldehyde.  
This allows the lux cassette to utilize only endogenous materials to form an 
intermediate complex that then slowly oxidizes to generate light at a wavelength 
of 490 nm as a byproduct (Meighen 1991).  The overall reaction can be 
summarized as: 
 




 Realizing the distinct advantages bacterial luciferase would afford as a 
eukaryotic reporter, many groups have attempted to express the luciferase 
(luxAB) component of the lux system using either fusion proteins (Escher, Okane 
et al. 1989; Kirchner, Roberts et al. 1989; Almashanu, Musafia et al. 1990; 
Pazzagli, Devine et al. 1992) or multiple plasmids (Koncz, Olsson et al. 1987; 
Olsson, Escher et al. 1989), but with minimal success over the last twenty years.  
Although the use of lux in the study of bacterial infection of a mammalian host 
has been demonstrated using whole animal BLI (Contag, Contag et al. 1995), its 
functionality has not been demonstrated outside of a bacterial host until now.  
Recently, successful expression of a mammalian optimized luciferase dimer in an 
HEK293 cell line has provided for the limited use of lux as a mammalian 
bioluminescent reporter system, although the addition of luciferin in a manner 
similar to firefly luciferase is still required (Patterson, Dionisi et al. 2005).  To fully 
exploit the advantages of bacterial luciferase, all five genes (luxCDABE) of the 
lux operon must be expressed simultaneously.  Here it is demonstrated that 
codon-optimized, poly-bicistronic expression of the full lux cassette produces all 
of the products required for autonomous bioluminescent production in a 
mammalian background.  It is further demonstrated that cells expressing the full 
lux cassette can be applied towards whole animal BLI without the need for 
substrate addition, thus overcoming the limitations imposed by currently available 




Materials And Methods  
Strain maintenance and growth   
 Escherichia coli cells were routinely grown in Luria Bertani (LB) broth with 
continuous shaking (200 rpm) at 37°C.  When required, kanamycin or ampicillin 
was used at final concentrations of 40 and 100 µg/ml, respectfully, for selection 
of plasmid containing cells.  Mammalian cell lines were propagated in Eagle’s 
modified essential medium (EMEM) supplemented with 10% fetal bovine serum, 
0.01 mM non-essential amino acids, and 0.01 mM sodium pyruvate.  Cell growth 
was carried out at 37°C in a 5% CO2 environment and cells were passaged every 
3 - 4 d upon reaching 80% confluence.  Neomycin and/or zeocin were used for 
selection of transfected cells at concentrations of 500 µg/ml and 200 µg/ml, 
respectfully, as determined by kill curve analysis, for each antibiotic. 
Codon optimization of the bacterial bioluminescence genes  
 Codon usage patterns in the luxCDE genes for P. luminescens and the flavin 
reductase gene (frp) from V. harveyi were compared to the highest 10% of 
expressed genes as represented in GenBank.  Silent mutations at the DNA level 
that would alter native codon usage were plotted to more closely mimic the 
preferred mammalian codons while maintaining 100% amino acid identity with 
the bacterial protein sequences.  When multiple codons were preferred in equal 
or near equal frequencies by mammalian genes, the codon for the optimized 
sequence was randomly selected from the available options.  These optimized 
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sequences were submitted and synthesized de novo by GeneArt and returned as 
synthetic DNA constructs inserted into unique KpnI and SacI restriction sites in 
pPCR-Script vectors (GeneArt).  Codon-optimized versions of each gene were 
compared to their wild-type counterpart for predicted translational efficiency using 
the freely available GENSCAN software at http://genes.mit.edu.  All sequences 
were deposited to GenBank under the following accession numbers GQ850533 
(codon-optimized luxC), GQ850534 (codon-optimized luxD), GQ850535 (codon-
optimized luxE), and GQ850536 (codon-optimized frp). 
Vector construction 
 Previously described (Patterson, Dionisi et al. 2005) P. luminescens luxA and 
luxB genes partially codon-optimized for expression in human cell lines were 
obtained as a bicistronic operon in a pIRES vector (Clontech) and designated 
pLuxAB.  This vector includes an internal ribosomal entry site (IRES) for increased 
translation of downstream gene insert.  The remaining P. luminescens genes 
(luxC, luxD, luxE) and the flavin reductase gene (frp) were used in either their 
wild-type (wt) or codon optimized (co) states.  coluxC was cloned into multiple 
cloning site (MCS) A of the pIRES vector using the unique NheI and EcoRI 
restriction sites (Figure 1 A-C).  The coluxE gene was then inserted into MCS B 
using the unique SalI and NotI restriction sites.  This entire coluxC-IRES-coluxE 
sequence was then removed and ligated into pBudCE4.1 (Invitrogen) behind the 
human elongation factor 1α (EF-1α) promoter using unique XhoI and SfiI 




Figure 6.  Schematic showing construction and expression of the full lux cassette using a 
two-plasmid system. 
The two-plasmid system takes advantage of IRES-based bicistronic expression to drive 
transcription/translation of all the genes required for autonomous bioluminescent production.  (A) 
The pLuxAB plasmid contains the genes responsible for production of the luciferase protein.  
Individual luxA and luxB genes were removed from their respective vectors and ligated into the 
pIRES vector using the unique NheI (N) and EcoRI (E) or SalI (S) and NotI (Nt) restriction sites.  
(B) The pLuxCDEfrp plasmid expresses the genes required for production and regeneration of the 
aldehyde and FMNH2 substrates.  The individual luxE and luxC genes were cloned into a pIRES 
vector using the unique NotI (Nt) and SalI (S) or NheI (N) and EcoRI (E) restriction sites.  (C) A 
second pIRES vector was created that contained the luxD and frp genes inserted at the same 
sites.  The entire luxC-IRES-luxE fragment was then inserted under the control of the EF1-α 
promoter in pBudCE4.1 using the unique XhoI (X) and SfiI (Sf) restriction sites, while the luxD-
IRES-frp fragment was inserted under the control of the CMV promoter using the unique PstI (P) 
and BamHI (B) restriction sites.  Originally published in (Close, Patterson et al. 2010). 
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gene to MCS A via the unique NheI and EcoRI restriction sites and the addition 
of cofrp to MCS B using the unique SalI and NotI restriction sites.  This entire 
coluxD-IRES-cofrp sequence was then inserted behind the pBudCE4.1 human 
cytomegalovirus immediate early promoter (CMV) using the unique PstI and 
BamHI restriction sites to create pLuxCDEfrp:CO.  This process was repeated 
using wild-type codon usage versions of each of the genes to generate an 
identically oriented, but non-codon-optimized, vector referred to as 
pLuxCDEfrp:WT. 
Mammalian cell transfection 
 Transfection was carried out in six-well Falcon tissue culture plates (Thermo-
Fisher).  HEK293 cells stably expressing the pLuxAB vector were passaged into 
each well at a concentration of approximately 1 × 105 cells/well and grown to 90 – 
95% confluence in complete medium as described above.  pLuxCDEfrp:CO and 
pLuxCDEfrp:WT plasmid vectors were purified from 100 ml overnight cultures of E. 
coli using the Wizard Purefection plasmid purification system (Promega).  On the 
day of transfection, cell medium was removed and replaced and vector DNA was 
introduced using Lipofectamine 2000 (Invitrogen). 
Selection of stable bioluminescent cell lines  
 Twenty-four h post-transfection, the medium was removed and replaced with 
complete medium supplemented with the appropriate antibiotic.  Selection of 
successfully transfected clones was performed by refreshing selective medium 
every 4 – 5 d until all untransfected cells had died.  At this time, colonies of 
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transfected cells were removed by scraping, transferred to individual 25 cm2 cell 
culture flasks, and grown in complete medium supplemented with the appropriate 
antibiotics. 
Benchtop luminescent detection 
Protein extraction 
 Total protein was extracted from co-transfected pLuxCDEfrp:CO/pLuxAB and 
pLuxCDEfrp:WT/pLuxAB cell lines using a freeze/thaw procedure.  Cells were first 
grown to confluence in 75 cm2 tissue culture flasks, then mechanically detached 
and resuspended in 10 ml of PBS.  Following collection, cells were washed twice 
in 10 ml volumes of PBS, pelleted and resuspended in 1 ml PBS.  These 1 ml 
aliquots of cells were subjected to three rounds of freezing in liquid nitrogen for 
30 sec, followed by thawing in a 37°C water bath for 3 min.  The resulting cell 
debris was pelleted by centrifugation at 14,000g for 10 min and the supernatant 
containing the soluble protein fraction was retained for analysis.  
Bioluminescent detection 
 Bioluminescence was measured using an FB14 luminometer (Zylux) with a 1 
sec integration time.  To prepare the sample for in vitro bioluminescent 
measurement, 400 µl of the isolated protein extract was combined with 500 µl of 
either oxidoreductase supplemented light assay solution containing 0.1 mM 
NAD(P)H, 4 µM FMN, 0.2% (w/v) BSA and 1 U of oxidoreductase protein isolated 
from V. fischeri (Roche), or oxidoreductase deficient light assay solution (distilled 
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water substituted for the 1 U of oxidoreductase protein).  Following the initial 
bioluminescent reading, samples were amended with 0.002% (w/v) n-decanal 
and the readings were continued to determine if additional aldehyde could 
increase light output.  All bioluminescent signals were normalized to total protein 
concentration as determined by BCA protein assay (Pierce) and reported as 
relative light units (RLU)/mg total protein.  All sample runs included processing of 
cell extracts from HEK293 cells stably transfected with pLuxAB as a control for 
light expression upon amendment.  To prepare cells for in vivo bioluminescent 
measurement, the total cell contents of a 75 cm2 tissue culture flask were 
resuspended in 1 ml of Dulbecco’s Modified Eagle Medium (DMEM) without 
phenol red supplemented with 10% fetal bovine serum, 0.01 mM non-essential 
amino acids, and 0.01 mM sodium pyruvate.  A 15 µl aliquot of cells was 
removed and counted using a hemocytometer to allow all values to be 
normalized to viable cell counts.  The remainder was used directly for 
bioluminescent measurement using the FB14 luminometer with a 1 sec 
integration time. 
Growth curve analysis 
 Cells were harvested during exponential growth from a 75 cm2 tissue culture 
flask and split into four 25 cm2 tissue culture flasks at ~5 × 104 cells/cm2.  At 24 h 
intervals, the cells were detached from the flasks by mechanical agitation and 
resuspended in 3 ml phosphate buffered saline (PBS).  A 15 µl aliquot was 
removed and diluted into an equal volume of trypan blue.  Cells were counted 
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using a hemocytometer and the average of 4 counts was used to determine the 
total viable cell number. 
Bioluminescent detection from cell culture 
Determination of minimum detectable cell number in culture 
 Actively growing HEK293 cells expressing pLuxCDEfrp:CO/pLuxAB were 
trypsinized and harvested from 75 cm2 tissue culture flasks and counted using a 
hemocytometer.  Using a 24-well tissue culture plate, groups of approximately 
either 500,000, 250,000, 100,000, 50,000, 40,000, 30,000, 20,000, 10,000, 
5,000, 2,000, or 1,000 cells were plated in each of three wells in 1 ml of DMEM 
without phenol red supplemented with 10% fetal bovine serum, 0.01 mM non-
essential amino acids, and 0.01 mM sodium pyruvate.  As a negative control, 
three wells were supplemented with 1 ml of media without cells to observe 
background.  Average radiance in photons/sec/cm2/sr was determined in the IVIS 
Lumina using a 10 min integration time 15 h after plating. 
Correlation of cell population size and bioluminescent output 
 To establish the relationship of cell number to bioluminescent flux, the 
average radiance values from cells producing a visible light signal under the 




Bioluminescent detection as a target for small animal imaging 
Ethics statement  
 All animal work was performed in adherence to the institutional guidelines put 
forth by the animal care and use committee of the University of Tennessee.  All 
animal research procedures were approved by the University of Tennessee 
Animal Care and Use Committee (protocol number 1411) and were in 
accordance with National Institutes of Health guidelines. 
Cellular harvesting and preparation for injection 
Actively growing HEK293 cells expressing pLuxCDEfrp:CO/pLuxAB were 
trypsinized and harvested from 225 cm2 tissue culture flasks and counted using a 
hemocytometer.  Using the average of two counts with the hemocytometer, cells 
were resuspended at approximately 5 × 106 cells / 100 µl PBS in a 1.5 ml tube 
(Eppendorf).  Cells were maintained at 37°C in a water bath until required for 
injection. 
Whole animal bioluminescent imaging  
Five week old nu/nu (nude) mice were anesthetized via isoflurane 
inhalation until unconscious.  Subjects were then subcutaneously injected with ~5 
× 106 HEK293 cells co-transfected with pLuxCDEfrp:CO/pLuxAB in a 100 µl volume 
of PBS.  An equal number of HEK293 cells (~5 × 106) containing only pLuxAB 
were injected as a negative control in the same volume.  The subject was imaged 
immediately following the injections and average radiance was determined over 
integration times of 1 to 10 min at intervals over a 30 min period. 
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Determination of minimum detectable cell number following subcutaneous injection 
 Six week old nude mice were anesthetized via isoflurane inhalation until 
unconscious and then injected with decreasing numbers of HEK293 cells 
expressing pLuxCDEfrp:CO/pLuxAB.  In a preliminary experiment, animals were 
subcutaneously injected at 4 separate locations with 5 million, 2.5 million, 1 
million, and 500,000 cells, each in a volume of 100 µl PBS.  The subject was 
imaged for 10 min following injection of the final group of cells.  Minimum 
detectable cell numbers were further delineated in a second round of injections in 
a fresh mouse model using cell concentrations of 500,000, 250,000, 50,000, and 
25,000 cells in 100 µl PBS and identically imaged. 
 
Results 
Benchtop bioluminescent detection from stably transfected HEK293 cells 
 To determine and compare the bioluminescent output kinetics of HEK293 
cells containing the luxCDEfrp genes in either their wild-type (pLuxCDEfrp:WT) or 
codon-optimized (pLuxCDEfrp:CO) form, cells were propagated under identical 
conditions, harvested, and resuspended directly in a cuvette for measurement of 
bioluminescence against a standard photomultiplier tube interface.  Cells 
containing pLuxCDEfrp:CO/pLuxAB showed an average bioluminescent production 
12-fold greater than background in the presence of untransfected control cells 
and 9-fold greater than the bioluminescent production of their wild-type 




Table 3.  Bioluminescent production from unsupplemented HEK293 cells expressing P. 
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containing pLuxCDEfrp:CO/pLuxAB validates our dual plasmid, bicistronic, codon-
optimized expression strategy and substantiates our hypothesis that the full 
bacterial lux cassette can be designed for functional autonomous expression in a 
mammalian cell line. 
Growth curve analysis 
 To determine if the maintenance and expression of full complements of lux 
genes was detrimental to cellular growth rates in HEK293 cells, the rates of 
growth among wild-type, pLuxCDEfrp:CO, and pLuxCDEfrp:WT containing cells was 
monitored over the course of a normal passage cycle.  It was hypothesized that 
any adverse effects from production of aldehyde or increased presence of 
FMNH2 resulting from the expression of the pLuxCDEfrp plasmid would result in a 
slowed growth rate relative to the wild-type HEK293 cell line.  No significant 
difference in the rates of growth was observed among any of the cell lines tested 
(Figure 7), suggesting that any adverse effects resulting from expression of the 
luxCDEfrp genes are minimal in regards to cellular growth and metabolism. 
Bioluminescent detection from cell culture 
 For a lux-based system to function as a reporter in whole animal BLI, the 
resulting signal must be detectable using commercially available equipment 
designed for this purpose and be easily distinguishable from background light 
emissions.  To determine if this was the case in HEK293 cells expressing full lux 
cassettes, approximately equal numbers of cells containing either codon-




Figure 7.  Growth rates of lux-containing HEK293 cells. 
Growth curve analysis of cells containing no plasmids (negative control, untransfected HEK293) 
or cells containing pLuxAB co-transfected with either pLuxCDEfrp:WT or pLuxCDEfrp:CO.  Cells were 
grown over a 96 h period until 80% confluent, representing normal passage conditions.  Values 
are the average of three trials and are reported with the standard error of the mean.  Originally 
published in (Close, Patterson et al. 2010). 
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compared with untransfected cells as a negative control for background.  The 
bioluminescent signal from cells co-transfected with codon-optimized luxCDEfrp 
was differentially detectable from background using a 10 sec integration time 
(Figure 8A) and increased in magnitude with no appreciable increase in 
background up to integration times of 30 min (Figure 8 B-F).  To determine the 
maximal duration of the bioluminescent signal during constitutive expression 
under experimental conditions, approximately equal numbers of HEK293 cells in 
either their untransfected state or containing pLuxAB co-transfected with either 
pLuxCDEfrp:WT or pLuxCDEfrp:CO were continually monitored for bioluminescence 
production (Figure 8G) in an IVIS Lumina imaging system using a stage 
temperature of 37°C to mimic as closely as possible their normal growth 
conditions.  Cells containing the lux cassette genes demonstrated bioluminescent 
output over an approximate three-day period without any exogenous input.  Peak 
bioluminescent output was achieved between 12 and 13 h for both the codon-
optimized and wild-type containing cell lines, however, following peak 
bioluminescent output a slow decrease in bioluminescent production over time 
was observed.  This decrease is presumably due to a combination of the inability 
to reliably regulate the air temperature, CO2 levels, and humidity in the imaging 
system, and the continued depletion of nutrients from the media during the 
normal process of cellular growth and metabolism.  While the bioluminescent 
output of cells containing pLuxCDEfrp:WT/pLuxAB was of a lesser magnitude than 
that of their codon-optimized counterparts over this time period, their 




Figure 8.  in vitro bioluminescent imaging of lux cassette containing cells. 
pLuxCDEfrp:CO/pLuxAB containing (CO), pLuxCDEfrp:WT/pLuxAB containing (WT), and untransfected 
negative control (NEG) HEK293 cells were plated in 24-well tissue culture plates and integrated 
for (A) 10 sec, (B) 1 min, (C) 5 min, (D) 10 min, (E) 15 min, and (F) 30 min.  Bioluminescence 
from cells co-transfected with pLuxCDEfrp:CO/pLuxAB was distinguishable from background in the 
presence of untransfected cells after 10 sec and showed no increase in background detection 
even after a 30 min integration time.  Long term in vitro expression (G) demonstrates the 
temporal longevity of the signal without exogenous amendment.  The minimum detectable 
number of bioluminescent cells was determined (H) by plating a range of cell concentrations in 
equal volumes of media in triplicate (downward columns) in an opaque 24-well tissue culture 
plate.  The minimum number of cells that could be consistently detected was approximately 
20,000.  Average radiance was shown to correlate with plated cell numbers (I), yielding an R2 
value of 0.95275.  Originally published in (Close, Patterson et al. 2010). 
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suggesting that the codon-optimization process had not significantly altered the 
function of the lux proteins in vivo. 
 To be useful as an optical reporter, cells expressing bioluminescence must 
be detectable over a dynamic population range.  To determine the minimum 
detectable cell number, HEK293 cells containing pLuxCDEfrp:CO/pLuxAB at 
concentrations ranging from 1,000 to 500,000 cells were plated in triplicate in 
equal volumes of media over a constant surface area and imaged over a 10 min 
integration time.  The minimum number of cells reliably detected above 
background was approximately 20,000 although some visible signal was 
detected at approximately 10,000 cells in at least one case (Figure 8H). 
 A major advantage imparted by the use of bioluminescent or fluorescent-
tagged reporter cells is that they allow an investigator to approximately quantify 
the population size of those cells noninvasively in a living host.  For this 
approximation to be made using a lux-based system, it must be demonstrated 
that the bioluminescent flux of the cell population correlates tightly with the 
overall population size.  To determine if this is the case in HEK293 cells 
constitutively expressing codon-optimized bacterial luciferase genes, the average 
radiance of cells producing a visibly detectable bioluminescent signal was 
determined over cell concentrations ranging from 500,000 to 1,000 cells.  The 
average radiance closely correlated with the number of cells present (R2 = 
0.95275) over all visibly detectable cell numbers tested (Figure 8I). 
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Bioluminescent detection from a small animal model system 
 Although lux has been previously used in whole animal BLI (Contag, Contag 
et al. 1995), this is the first demonstration of its functionality outside of a bacterial 
host.  Bacteria-free expression of this genetic system assures that the results 
seen are directly related to the object of study, and are not artifacts of a host-
pathogen interaction stemming from the previously required bacterial infection.  
To demonstrate this functionality, 5 week old nude mice were subcutaneously 
injected with HEK293 cells co-transfected with pLuxCDEfrp:CO/pLuxAB or pLuxAB 
alone and imaged.  Cells containing only pLuxAB were injected as a negative 
control to determine if the substrates supplied by the luxCDEfrp genes in the 
pLuxCDEfrp plasmid were capable of being scavenged from endogenously 
available stocks within the host in the presence of the luciferase dimer formed by 
the products of the luxAB genes on the pLuxAB plasmid.  Bioluminescent signal 
emission from injected pLuxCDEfrp:CO/pLuxAB HEK293 cell lines was detectable 
immediately (< 10 sec) following injection (Figure 9A), mirroring the results of 
subcutaneous tumor mimic bioluminescence from firefly luciferase (FLuc)-tagged 
(Inoue, Kiryu et al. 2009) and Renilla luciferase (RLuc)-tagged (Bhaumik and 
Gambhir 2002) cells following intravenous (IV) injection of their D-luciferin or 
coelenterazine substrates, respectfully.  Following injection, the lux signal 
increased slowly in intensity over the full 60 min course of the assay (Figure 9B).  
This is in contrast to FLuc-based bioluminescent signals that exhibit a steady 
decline over the same period following IV injection of D-luciferin to a level ~20% 




Figure 9.  in vivo bioluminescent imaging using HEK293 cell expression of mammalian-
adapted lux. 
(A) HEK293 cells containing the mammalian adapted pLuxCDEfrp:CO/pLuxAB cassette (Full) were 
subcutaneously injected into nude mice and imaged.  Detection occurred nearly immediately (< 
10 sec) post-injection and remained visible up to the 60 min time point of the imaging assay.  
HEK293 cells containing only the pLuxAB plasmid (luxAB) were subcutaneously injected into the 
same mouse as a negative control.  Note that the automatic scaling of signal intensity differs 
among images, therefore creating the false appearance that image intensity is decreasing after 
the 10 min post-injection time point when in fact it continually increases as shown in panel (B).  
(C) Comparison of mammalian-adapted lux-based bioluminescence from HEK293 cells versus 
published data on the expression of FLuc (*(Inoue, Kiryu et al. 2009)) and RLuc (**(Bhaumik and 
Gambhir 2002)) tagged cells over the 60 min course of the assay.  (D) Upon termination of the 
assay 60 min post injection, the bioluminescent signal from HEK293 cells expressing the full 
complement of lux genes was detectable using an integration time as low as 30 sec.  (E)  
Subcutaneous injection of HEK293 cells containing pLuxCDEfrp:CO/pLuxAB at concentrations 
ranging from 500,000 to 25,000 cells in 100 µl volumes of PBS demonstrated a tested lower limit 
of detection of 25,000 cells using a 10 min integration time.  MPI, minutes post injection.  
Originally published in (Close, Patterson et al. 2010). 
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more temporally limited and subsides within 5 min following IV injection of 
coelenterazine (Bhaumik and Gambhir 2002)  (Figure 9C).  In contrast, the lux 
bioluminescent signal remained detectable 60 min after injection using 
integration times as low as 30 sec (Figure 9D).  Conversely, FLuc signals are 
asymptotically approaching their minimum (Inoue, Kiryu et al. 2009) and RLuc 
signals have become fully attenuated (Bhaumik and Gambhir 2002)  by 30 min, 
thus making imaging at all but the shortest post-injection incubation times 
impossible (Figure 9C).  It is important to note that the duration of the 
bioluminescent signal in FLuc containing systems can be extended by using a 
subcutaneous or intraperitoneal injection of luciferin, however, each injection 
route also produces a different bioluminescent emission profile over time (Inoue, 
Kiryu et al. 2009).  Because they forgo the addition of exogenous substrates to 
trigger bioluminescence, lux-based systems are not subject to these effects.  The 
lack of a signal after injection of cells expressing only pLuxAB at any of the time 
points sampled (Figure 9) confirms that the luciferase dimer alone is not capable 
of producing unintended bioluminescence above the background levels of light 
detection by scavenging endogenously available substrates.  These results 
demonstrate the utility of the lux system in providing bioluminescent data on 
relatively prolonged time scales without the potentially error-inducing requirement 
of disturbing the experimental environment to invasively inject additional luciferin 
substrate. 
 Having illustrated the ability to reliably detect at least 20,000 cells in a 
tissue culture setting (Figure 8H), the minimum detectable number of cells in 
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small animal models remained to be determined.  The detection of 
bioluminescent cells following subcutaneous injection is more difficult than 
detection in a culture setting due to the increased presence of chromophoric 
material leading to higher absorption of emitted photons as they must travel 
through more tissue to reach the detector.  Subcutaneous injections of 
decreasing numbers of cells into a nude mouse model revealed that the 
introduction of at least 25,000 cells was capable of producing a detectable signal 
(Figure 9E).  As predicted from the correlation of cell number to bioluminescent 
flux, injection of higher cell concentrations produced larger bioluminescent 
signals over identical integration times. 
 
Discussion 
 Development of the lux cassette into a functional and autonomous 
mammalian bioluminescent system provides researchers a unique new tool that 
allows for real-time monitoring of bioluminescence from whole animals or cell 
cultures without exogenous substrate addition or cell lysis.  The first step in the 
creation of this reporter was the functional demonstration of the luciferase 
heterodimer formed by the luxAB genes (Patterson, Dionisi et al. 2005).  This set 
the stage for the use of lux in eukaryotic cells as a non-autonomous reporter 
system via the addition of aldehyde.  Since that time, the production of aldehyde 
has been demonstrated in S. cerevisiae (Gupta, Patterson et al. 2003), leading to 
the development of the first eukaryotic lux-based autonomous reporter system.  
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Here it has been demonstrated for the first time that expression of codon-
optimized forms of the luxCDE genes from P. luminescens and the frp gene from 
V. harveyi are capable of producing sufficient levels of the aldehyde and FMNH2 
substrates required to drive light production autonomously in mammalian cells.  It 
is further demonstrated that these bioluminescent cells can be applied in whole 
animal BLI without the need for substrate addition. 
 While the addition of luxCDEfrp to cells containing luxAB demonstrates light 
emission at a level 12-fold greater than background (Table 3), it remained to be 
determined if the associated increase in aldehyde production would be cytotoxic, 
as had been demonstrated in luxAB containing S. cerevisiae and Caenorhabditis 
elegans cells (Hollis, Lagido et al. 2001).  If this scenario was determined to be 
true, the increased presence of aldehyde may therefore cause those cells 
capable of most efficiently producing aldehyde to inhibit their own growth, 
mimicking the effects of antibiotic selection and causing them to be out-competed 
in culture by cells expressing lower levels of aldehyde production.  This 
investigation revealed no significant variation among the growth rates of 
untransfected HEK293 cells or those expressing either pLuxCDEfrp:WT/pLuxAB or 
pLuxCDEfrp:CO/pLuxAB at levels capable of supporting continuous bioluminescent 
production (Figure 7).  These cells are necessarily producing the required 
aldehyde substrate as demonstrated by their constitutive bioluminescent 
production, but do not show a detectable difference in their rate of growth when 
compared to cells that are grown under identical conditions but without the 
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luxCDE genes required for the production and maintenance of the aldehyde 
substrate. 
 When these codon-optimized lux containing HEK293 cells were used in cell 
culture, concentrations of approximately 20,000 cells were reliably detected in 1 
ml of media immediately using a 10 min integration time (Figure 8H).  Increasing 
cell numbers in the same volume and area correlated with measured levels of 
bioluminescence emission, allowing one to predict the total cell number in a 
given sample from the measured average radiance (Figure 8I) and permitting 
non-invasive estimation of target size based on bioluminescent measurements. 
 When the same bioluminescent cell lines were applied in whole animal BLI, 
the low levels of detectable background signal and deficit of endogenous 
bioluminescent production associated with mammalian cells enabled lux-based 
bioluminescence to remain detectable.  This sensitivity was demonstrated both in 
cell culture and under subcutaneous whole animal BLI conditions where very little 
light is produced due to attenuation of the bioluminescent signal by absorption 
from endogenous chromophores (Vo-Dinh 2003).  It has been demonstrated here 
that cells co-transfected with the codon-optimized luxCDEfrp genes can produce 
a lasting signal that can be amplified over integration times as long as 30 min 
with little to no background to interfere with signal acquisition (Figure 8F) in a cell 
culture setting.  However, it is important to note that the bioluminescent signal 
from this reaction is produced at 490 nm.  This is relatively blue-shifted as 
compared to the Luc-based bioluminescent probes that display their peak 
luminescent signal at 560 nm.  The shorter wavelength of the lux-based signal 
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has a greater chance of becoming attenuated within the tissue and therefore may 
not be as easily detected if it is used in deeper tissue applications (such as 
intraperitoneal or intraorganeller injections), and may require longer integration 
times to achieve the same level of detection as a longer wavelength reporter 
would when injected subcutaneously.  For instance, it has been reported that a 
single cell expressing Luc can be detected following subcutaneous injection 
(Kim, Urban et al. 2010), whereas it is now demonstrated that the approximate 
lower level of detection for lux-tagged cells is closer to 25,000 cells, most likely 
due to the lower quantum efficiency of the lux bioluminescent system coupled 
with the higher rates of attenuation due to absorption at the emission wavelength 
of 490 nm.  Therefore, the goals of a particular experiment should be carefully 
weighed before applying a lux-based bioluminescent reporter.  While a lux-based 
system can produce a continuous bioluminescent signal over prolonged time 
periods without being subjected to the dynamic effects of repeated luciferin 
injections, it may not be appropriate for situations with high levels of signal 
attenuation due to its lower emission wavelength. 
 Despite such drawbacks, the use of cells expressing bacterial luciferase 
genes as a probe for whole animal BLI solves many of the problems associated 
with the currently available luciferase-based imaging systems.  Previous work 
with lux genes isolated from P. luminescens has demonstrated that the luciferase 
is thermostable at the 37°C temperature required for mammalian imaging 
experiments (Colepicolo, Cho et al. 1989).  This prevents the associated loss of 
signal associated with the short half-life of the firefly luciferase, which has been 
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shown to be thermolabile at 37°C in its native state (Baggett, Roy et al. 2004).  In 
addition, the autonomous nature of bioluminescent production associated with 
the lux system circumvents continuous re-injection of the test animal with an 
exogenous luciferin substrate.  This simultaneously reduces the amount of 
invasive injections required for imaging experiments, eliminates the detection of 
artificial results stemming from any non-specific biological reactions with the 
luciferin compound being administered, and negates the inability to compare 
otherwise similar experiments due to differential bioluminescent production 
kinetics based on dissimilar routes of substrate injection.  Thus, the bacterial 
luciferase offers a more specific, longer lasting, and more humane luciferase-
based reporter system than the currently available alternatives. 
 While mammalian-adapted bacterial luciferase gene expression has some 
notable disadvantages such as requisite introduction of multiple gene sequences 
and bioluminescent production at a wavelength that is relatively highly absorbed 
in mammalian tissues, it remains easily detectable using currently available 
imaging technology and offers several important advantages over the currently 
available reporter systems for prolonged expression without the cost or 
disturbance to the system associated with substrate administration.  It is shown 
here that expression of the luxCDEfrp genes in mammalian cells can produce the 
requisite co-substrates for bioluminescent production and that codon optimization 
of these genes improves their performance - leading to an overall increase in 
light production as compared to their wild-type counterparts.  When co-expressed 
with the luxAB genes responsible for formation of the luciferase heterodimer, 
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aldehyde production occurs at a level capable of inducing autonomous light 
production, but not of high enough concentration to be adversely cytotoxic.  
When cells containing full complements of lux genes are enlisted as probes in 
whole animal BLI, they are easily detectable when introduced at levels 
comparable to cells expressing other currently employed target luciferase genes 
and allow for facile differentiation from background over prolonged integration 
times at 37°C, making them ideal reporter systems for cell culture, subcutaneous, 






Comparison Of Mammalian-Adapted Bacterial Bioluminescence 
With Firefly Luciferase Bioluminescence And Fluorescence 
From The Green Fluorescent Protein 
 
Introduction 
 Previously it has been demonstrated that autonomous bioluminescent 
production from a mammalian cell line expressing human-optimized (ho) 
bacterial luciferase (lux) cassette genes can be used as a target for cell culture 
and small animal bioluminescent imaging (BLI) (Close, Patterson et al. 2010).  
Here the bioluminescent expression of a mammalian HEK293 cell line 
transfected with the holux genes is compared with the bioluminescent expression 
of the same cell line expressing a commercially available, ho-firefly luciferase 
gene (luc) and the fluorescent expression of a commercially available, improved 
green fluorescent protein (GFP).  The luc and gfp genes are two of the most 
widely known and used reporter genes for optical imaging (Choy, O Connor et al. 
2003) and therefore provide excellent points of comparison for determining if 
holux expression would be beneficial in a given experiment. 
 The three systems are intrinsically different, and as such, have the potential 
to fulfill alternative niches within the needs of the bioimaging community.  The 
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holux system is unique among bioluminescent systems because of its ability to 
self-synthesize and/or scavenge all required substrates from the host cell in order 
to produce bioluminescence in a fully autonomous fashion.  The system itself is 
composed of five genes with the luxA and luxB gene products forming the 
heterodimeric luciferase enzyme, and the luxD, luxC and luxE gene products 
forming a transferase, a synthase, and a reductase respectfully, that work 
together to produce and regenerate the required myristyl aldehyde co-substrate 
from endogenous myristyl groups.  A sixth gene, frp, encodes an NAD(P)H:flavin 
reductase that helps to cycle endogenous FMN into the required FMNH2 co-
substrate.  Along with molecular oxygen, these components supply the enzyme 
with all the required substrates to produce a bioluminescent signal at 490 nm 
(Meighen 1991).  
 The Luc system catalyzes the oxidation of reduced luciferin in the presence 
of ATP-Mg2+ and oxygen to generate CO2, AMP, PPi, oxyluciferin, and yellow-
green light at a wavelength of 562 nm.  This reaction was originally reported to 
occur with a quantum yield of 0.88 (Seliger and McElroy 1960), but has since 
been shown to actually achieve a quantum yield closer to only 0.41 (Ando, Niwa 
et al. 2007).  The Luc system used in these experiments utilizes a commercially 
available holuc gene from the Promega Corporation (luc2).  This gene encodes 
for an altered protein that improves translational efficiency in the mammalian 
cellular background and has also been destabilized to promote lower background 
and increased induction levels (Promega 2009).   
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 The GFP system is perhaps one of the most well characterized and longest 
studied of any reporter system available (Wang, John et al. 2008).  It differs from 
the holux and Luc systems in that it is a fluorescent reporter.  Upon excitation at 
395 or 478 nm it produces a fluorescent emission signal at 507 nm, allowing for 
detection.  These experiments use an improved gfp gene that is commercially 
available from Invitrogen.  This version of gfp has been optimized for higher 
levels of solubility and greater than 40-fold increase in fluorescent yield over the 
wild-type GFP protein (Crameri, Whitehorn et al. 1996).  Despite these 
engineered improvements, the requisite excitation signal for this, like the majority 
of GFP-variants, elicits high levels of background fluorescence under small 
animal imaging conditions (Choy, O Connor et al. 2003; Troy, Jekic-McMullen et 
al. 2004).  As such, its use in small animal imaging is becoming increasingly 
supplanted by proteins or dyes that emit light in the near infrared range where 
autofluorescence and absorption levels are lower (Hilderbrand and Weissleder 
2009), although its use in the literature is still common and its classical 
dominance in the optical imaging field makes it an excellent benchmark for 
comparison. 
 The Luc and GFP imaging targets are representative of the types of reporter 
systems commonly employed in the optical imaging community (Burdette 2008), 
and provide well known benchmarks against which to compare the 
bioluminescent expression of the new holux system.  Here the luminescent 
profile and intensity of holux expressing HEK293 cells is compared with the 
luminescent and fluorescent profiles and intensities of HEK293 cells expressing 
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the human optimized Luc and improved GFP systems in cell culture and small 
animal imaging conditions.  The shape and duration of the resulting light signals 
over time are compared, as are respective signal intensities and minimum 
detectable reporter cell numbers to establish which type of reporter system may 
be most appropriate under a given set of imaging conditions. 
 
Materials And Methods  
Strain maintenance and growth 
 Escherichia coli cells were routinely grown in Luria Bertani (LB) broth with 
continuous shaking (200 rpm) at 37°C.  When required, kanamycin or ampicillin 
was used at final concentrations of 40 and 100 µg/ml, respectfully, for selection 
of plasmid containing cells.  Mammalian cell lines were propagated in Eagle’s 
modified essential medium (EMEM) supplemented with 10% fetal bovine serum, 
0.01 mM non-essential amino acids, and 0.01 mM sodium pyruvate.  Cell growth 
was carried out at 37°C in a 5% CO2 environment and cells were passaged every 
3 - 4 d upon reaching 80% confluence.  Neomycin and/or zeocin were used for 
selection of transfected cells at concentrations of 500 µg/ml and 200 µg/ml, 
respectfully, as determined by kill curve analysis, for each antibiotic. 
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Development of constitutively active stable cell lines 
Transfection  
 Transfection was carried out in six-well Falcon tissue culture plates (Thermo-
Fisher).  HEK293 cells were passaged into each well at a concentration of ~4 × 
105 cells/well in complete medium the day before transfection.  Plasmid vectors 
were purified from 100 ml overnight cultures of E. coli using the Wizard 
Purefection plasmid purification system (Promega).  On the day of transfection, 
cell medium was removed and replaced and vector DNA was introduced using 
Lipofectamine 2000 (Invitrogen).   
Selection of stable cell lines 
Twenty-four h post-transfection, the medium was removed and replaced 
with complete medium supplemented with the appropriate antibiotic.  Selection of 
successfully transfected clones was performed by refreshing selective medium 
every 4 – 5 d until all untransfected cells had died.  At this time, colonies of 
transfected cells were removed by scraping, transferred to individual 25 cm2 cell 
culture flasks, and grown in complete medium supplemented with the appropriate 
antibiotics.  
Screening of firefly luciferase containing HEK293 cell lines  
 Following stable selection with antibiotics, cells containing the luc2 gene 
were tested to preferentially isolate lines producing the greatest luminescent 
signal following addition of D-luciferin.  Cells were passaged from individual 25 
cm2 culture flasks (Corning) to individual wells of an optically clear 24-well culture 
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plate (Costar) and grown until confluence (1 – 2 d).  Upon reaching confluence 
cells were lysed by application of 1X lysis buffer (Stratagene).  Plates were then 
transferred to a Synergy 2 microplate reader (BioTek) and luminescence was 
measured following addition of 100 µl substrate-assay buffer (Stratagene) using 
an 8 sec delay and 10 sec integration time.  The cell line producing the greatest 
luminescent output during testing was selected and maintained for experimental 
use. 
Screening of GFP containing HEK293 cell lines 
 Following stable selection with antibiotics, cells containing the gfp gene 
were tested to preferentially isolate the line producing the greatest fluorescent 
output signal upon excitation.  Cells were passaged from individual 25 cm2 
culture flasks (Corning) into black 24-well culture flasks (Costar) in a 2 ml volume 
of PBS.  Immediately following passage cells were assayed for fluorescent 
production in a Wallac 1420 Multilabel counter (Perkin Elmer) using an excitation 
wavelength of 485 nm and a 510 nm emission filter.  Cells lines producing the 
highest levels of fluorescence under these conditions were then subjected to a 
second round of testing.  In the second stage, cells stably expressing GFP were 
grown to confluence in 25 cm2 culture flasks (Corning) and harvested by 
trypination.  Cell counts were obtained as the average of two counts using a 
hemocytometer and cells were plated into black 24-well culture plates (Costar) at 
a concentration of ~1 × 106 cells/well in a 1 ml volume of PBS.  Cells were then 
assayed for fluoresce in an IVIS Lumina in vivo imaging system (Caliper Life 
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Sciences) using the GFP filter set and a 1 sec integration time.  The cell line 
displaying the highest fluorescent emission signal under these conditions was 
selected and maintained for experimental use. 
Bioluminescent measurement of bacterial luciferase expressing HEK293 
cells in culture  
Dynamics of bioluminescent production over time 
Actively growing HEK293 cells expressing pLuxCDEfrp:CO/pLuxAB (holux) 
were trypsinized and harvested from 75 cm2 tissue culture flasks (Corning) and 
viable cell counts were determined as the average of two counts using a 
hemocytometer.  Approximately 1 × 106 cells per well were plated in each of 
three wells in opaque 24-well tissue culture plates (Costar) in DMEM without 
phenol red and supplemented with 10% fetal bovine serum, 0.01 mM non-
essential amino acids, and 0.01 mM sodium pyruvate.  Along with the transfected 
cells, an equal number of untransfected HEK293 cells were plated to determine 
background luminescent detection levels.  Photon counts were recorded using an 
IVIS Lumina in vivo imaging system and analyzed with Living Image 3.0 software 
(Caliper Life Sciences).  The change in light output over time was determined in 
photons (p)/sec/cm2/steridian (sr) for each well using integration times of 10 min 
and reported as the average of three runs with the standard error of the mean. 
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Minimum detectable population size 
To determine the minimum detectable population size, serial dilutions of 
cells ranging from ~1 × 106 cells per well to ~100 cells per well were plated in 
each of three wells in opaque 24-well tissue culture plates in DMEM without 
phenol red and supplemented with 10% fetal bovine serum, 0.01 mM non-
essential amino acids, and 0.01 mM sodium pyruvate.  Along with the transfected 
cells, an equal number of untransfected HEK293 cells were plated to determine 
background luminescent detection levels.  Photon counts were recorded using an 
IVIS Lumina in vivo imaging system and analyzed with Living Image 3.0 software 
(Caliper Life Sciences).  Average radiance for all population sizes was 
determined in photons (p)/sec/cm2/steridian (sr) for each well using an integration 
time of 10 min 17 h post-plating, as this was shown to be the period of maximum 
bioluminescent production as determined by tracking the dynamics of 
bioluminescent output as described above.  Following initial analysis, a more 
specific minimum detectable population size was determined by performing a 
second assay using cell concentrations ranging between the lowest detectable 
number of the initial assay and the highest undetectable number of cells plated 
and comparing the average radiance of each population to the level of 
background light detected over cell-free medium.  For all measurements, 
statistical differences were determined by using Student’s t tests with a p value 
cutoff of p = 0.05. 
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Bioluminescent measurement of firefly luciferase expressing HEK293 cells 
in culture 
Dynamics of bioluminescent production over time 
Actively growing HEK293 cells expressing pGL4.50[luc2/CMV/Hygro] 
(Luc) were trypsinized and harvested from 75 cm2 tissue culture flasks (Corning) 
and viable cell counts were determined as the average of two counts using a 
hemocytometer.  Approximately 1 × 106 cells per well were plated in each of 
three wells in opaque 24-well tissue culture plates (Costar) in DMEM without 
phenol red and supplemented with 10% fetal bovine serum, 0.01 mM non-
essential amino acids, and 0.01 mM sodium pyruvate.  Along with the transfected 
cells, an equal number of untransfected HEK293 cells were plated to determine 
background luminescent detection levels.  Immediately prior to imaging, all wells 
were spiked with 0.07 mg D-luciferin/ml (Caliper Life Sciences).  Photon counts 
were then recorded using an IVIS Lumina in vivo imaging system and analyzed 
with Living Image 3.0 software (Caliper Life Sciences).  The change in light 
output over time was determined in photons (p)/sec/cm2/steridian (sr) for each 
well using integration times of 10 sec and reported as the average of three runs 
with the standard error of the mean. 
Minimum detectable population size 
To determine the minimum detectable population size, serial dilutions of 
cells ranging from ~1 × 106 cells per well to ~100 cells per well were plated in 
each of three wells in opaque 24-well tissue culture plates in DMEM without 
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phenol red and supplemented with 10% fetal bovine serum, 0.01 mM non-
essential amino acids, and 0.01 mM sodium pyruvate.  Along with the transfected 
cells, an equal number of untransfected HEK293 cells were plated to determine 
background luminescent detection levels.  Immediately prior to imaging, all wells 
were spiked with 0.07 mg D-luciferin/ml (Caliper Life Sciences).  Photon counts 
were then recorded using an IVIS Lumina in vivo imaging system and analyzed 
with Living Image 3.0 software (Caliper Life Sciences).  Average radiance for all 
population sizes was determined in photons (p)/sec/cm2/steridian (sr) for each 
well using an integration time of 10 sec immediately following the addition of 
luciferin, as this was shown to be the point of maximal bioluminescent output as 
determined by tracking the change in bioluminescent production dynamics as 
described above.  Following initial analysis, a more specific minimum detectable 
population size was determined by performing a second assay using cell 
concentrations ranging between the lowest detectable number of the initial assay 
and the highest undetectable number of cells plated and comparing the average 
radiance of each population to the level of background light detected over cell-
free medium.  For all measurements, statistical differences were determined by 
using Student’s t tests with a p value cutoff of p = 0.05. 
Fluorescent measurement of GFP expressing HEK293 cells in culture  
Dynamics of bioluminescent production over time 
Actively growing HEK293 cells expressing pCDNA3.1-CT-GFP (GFP) 
were trypsinized and harvested from 75 cm2 tissue culture flasks (Corning) and 
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viable cell counts were determined as the average of two counts using a 
hemocytometer.  Approximately 1 × 106 cells per well were plated in each of 
three wells in opaque 24-well tissue culture plates (Costar) in either DMEM 
without phenol red and supplemented with 10% fetal bovine serum, 0.01 mM 
non-essential amino acids, and 0.01 mM sodium pyruvate or in PBS.  Regardless 
of the assay medium, an equal number of untransfected HEK293 cells were 
plated to determine background fluorescent production levels upon addition of 
the excitation signal.   Cells were stimulated in an IVIS Lumina in vivo imaging 
system using the supplied GFP excitation filter and photon counts were recorded 
using the supplied GFP emission filter.  The resulting photon counts were 
analyzed with Living Image 3.0 software (Caliper Life Sciences).  The change in 
fluorescent output over time was determined in photons (p)/sec/cm2/steridian (sr) 
for each well using integration times of 1 sec and reported as the average of 
three runs with the standard error of the mean. 
Minimum detectable population size 
To determine the minimum detectable population size, serial dilutions of 
cells ranging from ~1 × 106 cells per well to ~100 cells per well were plated in 
each of three wells in opaque 24-well tissue culture plates in either DMEM 
without phenol red and supplemented with 10% fetal bovine serum, 0.01 mM 
non-essential amino acids, and 0.01 mM sodium pyruvate or in PBS.  Regardless 
of the assay medium, an equal number of untransfected HEK293 cells were 
plated to determine background luminescent detection levels.  Twenty-four h post 
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plating, cells were stimulated in an IVIS Lumina in vivo imaging system using the 
supplied GFP excitation filter and photon counts were recorded using a 1 sec 
integration time with the supplied GFP emission filter.  Twenty-four h post plating 
was chosen as this was determined to be the point of highest fluorescent 
radiance as determined by tracking the change in fluorescent production over 
time as described above.  The resulting photon counts were analyzed with Living 
Image 3.0 software (Caliper Life Sciences) and recorded as photons 
(p)/sec/cm2/steridian (sr) for each well.  All reported values represent the average 
of three runs with the standard error of the mean.  For all measurements, 
statistical differences were determined by using Student’s t tests with a p value 
cutoff of p = 0.05. 
Bioluminescent measurement of bacterial luciferase expressing HEK293 
cells in a small animal model system  
Ethics statement 
 All animal work was performed in adherence to the institutional guidelines put 
forth by the animal care and use committee of the University of Tennessee.  All 
animal research procedures were approved by the University of Tennessee 
Animal Care and Use Committee (protocol number 1411) and were in 
accordance with National Institutes of Health guidelines. 
Preparation of cells for injection 
Actively growing HEK293 cells expressing pLuxCDEfrp:CO/pLuxAB (lux) 
were trypsinized and harvested from 225 cm2 tissue culture flasks and counted 
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using a hemocytometer.  Using the average of two counts with the 
hemocytometer, cells were resuspended at approximately 5 × 106 cells / 100 µl 
PBS in a 1.5 ml tube (Eppendorf) for subcutaneous injection or at approximately 
1 × 107 cells / 100 µl PBS in a 1.5 ml tube (Eppendorf) for intraperitoneal 
injection.  Following resuspension, cells were maintained at 37°C in a water bath 
until required for injection. 
Subcutaneous injection 
Five week old nu/nu (nude) mice (NCRNU-M, Taconic Farms Inc.) were 
anesthetized via isoflurane inhalation until unconscious. Subcutaneous injections 
of ~5 × 106 HEK293 cells expressing pLuxCDEfrp:CO/pLuxAB (lux) in 100 µl 
volumes of PBS were performed in both the shoulder and hip of each subject (n 
= 3) for a total of n = 6 subcutaneous injections.  Due to the of the lack of 
endogenous bioluminescent processes in mammalian tissue, and to control for 
changes in overall animal size and dispersion of reporter-tagged cells following 
injection, readings were gathered as total flux values and presented in photons 
(p)/second (s). All subjects were imaged immediately following the injections 
using 1 min integration times.  Total flux from each injection site was determined 
by drawing regions of interest (ROI) of identical size over each location.  
Readings were recorded once every 10 min over a 60 min period to determine 
the change in flux over time. 
To determine the minimal detectable number of cells in vivo, a subject was 
subcutaneously injected at three locations - the scruff of the neck, the mid back, 
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and hip – with the relevant range of cells as determined by the previously 
described minimum detectable cell number assays under culture conditions.  All 
cell concentrations were injected in a 100 µl volume of PBS.  The subject was 
then imaged using integration times of up to 10 min to determine if a luminescent 
signal could be detected above background at the injected concentrations of 
cells.  For all measurements, statistical differences were determined by using 
Student’s t tests with a p value cutoff of p = 0.05. 
Intraperitoneal injection 
To measure bioluminescent flux following intraperitoneal injection of the 
lux cell line, five week old nu/nu (nude) mice (NCRNU-M, Taconic Farms Inc.) 
were anesthetized via isoflurane inhalation until unconscious and each subject (n 
= 2) then received a single injection of ~1 × 107 HEK293 cells expressing 
pLuxCDEfrp:CO/pLuxAB (lux) in a 100 µ1 volume of PBS.  All subjects were 
imaged immediately following the injections using 1 min integration times.  Total 
flux from each injection site, measured as p/s, was determined by drawing 
regions of interest (ROI) of identical size over each location.  Readings were 
recorded once every 10 min over a 60 min period in order to determine the 
change in flux over time. 
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Bioluminescent measurement of firefly luciferase expressing HEK293 cells 
in a small animal model system 
Preparation of cells for injection 
Actively growing HEK293 cells expressing luc2 (Luc) were trypsinized and 
harvested from 225 cm2 tissue culture flasks and counted using a 
hemocytometer.  Using the average of two counts with the hemocytometer, cells 
were resuspended at approximately 5 × 105 cells / 100 µl PBS in a 1.5 ml tube 
(Eppendorf) for subcutaneous injection or at approximately 1 × 106 cells / 100 µl 
PBS in a 1.5 ml tube (Eppendorf) for intraperitoneal injection.  Following 
resuspension, cells were maintained at 37°C in a water bath until required for 
injection. 
Subcutaneous injection 
Five week old nu/nu (nude) mice (NCRNU-M, Taconic Farms Inc.) were 
anesthetized via isoflurane inhalation until unconscious. Subcutaneous injections 
of ~5 × 105 HEK293 cells expressing luc2 (Luc) in 100 µl volumes of PBS were 
performed in both the shoulder and hip of each subject (n = 3) for a total of n = 6 
subcutaneous injections.  Due to the of the lack of endogenous bioluminescent 
processes in mammalian tissue, and to control for changes in overall animal size 
and dispersion of reporter-tagged cells following injection, readings were 
gathered as total flux values and presented in photons (p)/second (s).  Following 
subcutaneous injection of the reporter cells, each subject was subjected to 
intraperitoneal injection of 150 mg D-luciferin/kg and then imaged immediately 
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using 1 sec integration times.  Total flux from each injection site was determined 
by drawing regions of interest (ROI) of identical size over each location.  
Readings were recorded once every 10 min over a 60 min period to determine 
the change in flux over time. 
To determine the minimal detectable number of cells in vivo, a subject was 
subcutaneously injected at three locations - the scruff of the neck, the mid back, 
and hip – with the relevant range of cells as determined by the previously 
described minimum detectable cell number assays under culture conditions.  All 
cell concentrations were injected in a 100 µl volume of PBS.  Prior to imaging, 
the subject was intraperitoneally injected with 150 mg D-luciferin/kg.  The subject 
was then imaged using integration times of up to 10 min to determine if a 
luminescent signal could be detected above background at the injected 
concentrations of cells.  For all measurements, statistical differences were 
determined by using Student’s t tests with a p value cutoff of p = 0.05. 
Intraperitoneal injection 
To measure bioluminescent flux following intraperitoneal injection of the 
Luc cell line, five week old nu/nu (nude) mice (NCRNU-M, Taconic Farms Inc.) 
were anesthetized via isoflurane inhalation until unconscious and each subject (n 
= 2) then received a single injection of ~1 × 107 HEK293 cells expressing luc2 
(Luc) in a 100 µl volume of PBS.  Following injection of the reporter cell line, all 
subjects were injected at the same location with 150 mg D-luciferin/kg and then 
imaged immediately following the injections using 10 sec integration times.  Total 
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flux from each injection site, measured as p/s, was determined by drawing 
regions of interest (ROI) of identical size over each location.  Readings were 
recorded once every 10 min over a 60 min period in order to determine the 
change in flux over time. 
Fluorescent measurement of GFP expressing HEK293 cells in a small 
animal model system  
Preparation of cells for injection 
Actively growing HEK293 cells expressing gfp (GFP) were trypsinized and 
harvested from 225 cm2 tissue culture flasks and counted using a 
hemocytometer.  Using the average of two counts with the hemocytometer, cells 
were resuspended at approximately 5 × 106 cells / 100 µl PBS in a 1.5 ml tube 
(Eppendorf) for subcutaneous injection or at approximately 1 × 107 cells / 100 µl 
PBS in a 1.5 ml tube (Eppendorf) for intraperitoneal injection.  Following 
resuspension, cells were maintained at 37°C in a water bath until required for 
injection. 
Subcutaneous injection 
Five week old nu/nu (nude) mice (NCRNU-M, Taconic Farms Inc.) were 
anesthetized via isoflurane inhalation until unconscious. Subcutaneous injections 
of ~5 × 106 HEK293 cells expressing gfp (GFP) in 100 µl volumes of PBS were 
performed in both the shoulder and hip of each subject (n = 3) for a total of n = 6 
subcutaneous injections.  Subjects were imaged immediately following injection 
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with the reporter cell line using GFP excitation and emission filter with an 
integration time of 1 sec.  Total flux from each injection site was determined by 
drawing regions of interest (ROI) of identical size over each location.  Readings 
were recorded once every 10 min over a 60 min period to determine the change 
in flux over time. 
To determine the minimal detectable number of cells in vivo, a subject was 
subcutaneously injected at three locations - the scruff of the neck, the mid back, 
and hip – with the relevant range of cells as determined by the previously 
described minimum detectable cell number assays under culture conditions.  All 
cell concentrations were injected in a 100 µl volume of PBS.  The subject was 
then imaged using integration times ranging from 0.5 sec to 3 min to determine if 
a fluorescent signal could be detected above background at the injected 
concentrations of cells.  For all measurements, statistical differences were 
determined by using Student’s t tests with a p value cutoff of p = 0.05. 
Intraperitoneal injection 
To measure fluorescent flux following intraperitoneal injection of the Luc 
cell line, five week old nu/nu (nude) mice (NCRNU-M, Taconic Farms Inc.) were 
anesthetized via isoflurane inhalation until unconscious and each subject (n = 2) 
then received a single injection of ~1 × 107 HEK293 cells expressing gfp (GFP) in 
a 100 µl volume of PBS.  Total flux from each injection site, measured as p/s, 
was determined by drawing regions of interest (ROI) of identical size over each 
location following a 1 sec integration under GFP excitation and emission filters in 
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the IVIS Lumina in vivo imaging system (Caliper Life Sciences).  Readings were 
recorded once every 10 min over a 60 min period in order to determine the 
change in flux over time. 
 
Results 
Bioluminescent measurement of bacterial luciferase expressing HEK293 
cells in culture  
Minimum detectable population size 
Cells expressing the holux cassette genes produced a visible light signal 
over a range from approximately 1 × 106 cells/well to 1.5 × 104 cells/well using a 
10 min integration time (Figure 10A).  A detectable light signal was inconsistently 
observed at a concentration of ~1 × 104 cells/well, however this was determined 
not to be significantly distinguishable from background (p = 0.72) (Figure 11).  In 
general, detection of lower cell populations as significantly different than 
background was more feasible at time points further from the initial plating (Table 
4). 
Dynamics of bioluminescent production over time 
The luminescent profile of holux expression demonstrated a consistent 
increase in average radiance from an initial post-plating value of 1,800 p/s/cm2/sr 
to a peak of 6,400 p/s/cm2/sr 16 h post-plating (Figure 10B).  Following peak 




Figure 10.  Comparison of in vitro imaging results. 
Pseudocolor representation of the bioluminescent or fluorescent flux from cell concentrations 
ranging from 1 million (1M) to several thousand (K) to approximately single cell levels (NEG = 
negative control wells) stably transfected with (A) holux, (C) Luc, or (E) GFP.  Red lines indicate 
the combination of two separate runs, each represented by the corresponding color scale on the 
right or left side of the figure.  The yellow box in (E) indicates wells containing equal numbers of 
untransfected HEK293 cells to determine levels of background autofluorescence.  Note that 
autoscaling of the pseudocolor image assigns brighter colors and larger areas to the larger 
population sizes of low level detection experiments although their scale indicates overall lower 
levels of flux compared to larger population sizes.  Average bioluminescent or fluorescent flux 
dynamics for the (B) holux, (D) Luc, and (F) GFP containing cell populations of ~1 × 106 cells over 





Figure 11.  Detection of 10,000 lux-tagged HEK293 cells was not possible at statistically 
significant levels. 
Despite presenting an intermittently detectable pseudocolor image, a population of ~10,000 holux 
expressing cells could not be statistically differentiated from background light detection.  Boxes 





Table 4.  Detection of lux-expressing HEK293 cells over time. 
Larger population sizes of lux-expressing cells were visible sooner following plating.  Green boxes represent time points where the 
indicated cell population was significantly distinguishabe from background.  Red hatched boxes represent time points where the indicated 
cell population was not significantly distinguishable from background light detection. 
Lux 
  Time Post Plating (h) 
Cell Population 
Size 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
15K Cells/well                                                   
20K Cells/well                                                   
30K Cells/well                                                   
50K Cells/well                                                   
75K Cells/well                                                   
100K Cells/well                                                   
1M Cells/well                                                   
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the remainder of the 24 hr assay, averaging a reduction of 135 (± 16) p/s/cm2/sr 
per hr.  Expression was consistent over the course of the assay with the standard 
error of the mean averaging 58 (± 4) p/s/cm2/sr at each time point surveyed. 
Bioluminescent measurement of firefly luciferase expressing HEK293 cells 
in culture  
Dynamics of bioluminescent production over time 
The luminescent profile of the Luc expressing cells displayed a large initial 
intensity, with a peak average radiance of 8.9 (± 0.4) × 107 p/s/cm2/sr 10 min 
following addition of 0.07 mg D-luciferin/ml.  This level of radiance was not 
maintained, however, and had decreased to 3.0 (± 0.3) × 107 p/s/cm2/sr by 40 
min post addition.  The decrease in radiance occurred during the period 10 to 30 
min post substrate addition, after which the signal remained steady (± 9.3 × 105 
p/s/cm2/sr) for the remainder of the assay.  Concurrent with the higher 
bioluminescent output of the Luc expressing cells compared to holux was a 
larger standard error.  The average error over the course of the Luc 
luminescence assay was 2.9 (± 0.6) × 106 p/s/cm2/sr (Figure 10D). 
Minimum detectable population size 
Cells expressing the human-optimized luc2 gene displayed a significantly 
greater average radiance (p < 0.01) than those expressing the human-optimized 
lux genes and as a result were visible at lower concentrations.  Luc expressing 
cells produced a visible signal over a range from ~1 × 106 cells/well down to 250 
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cells/well at an integration time of 1 sec (Figure 10C and Figure 12A).  Although 
concentrations as low as 50 cells/well could be differentiated from background if 
the integration time was extended to 10 sec (Figure 12B), this concentration of 
cells was not determined to be statistically greater than background light 
detection (p = 0.65) while using the 1 sec integration time required to prevent 
saturation of the camera at the higher cell concentrations (Figure 12A).  
Detection of the Luc-tagged cell populations showed the opposite trend of those 
expressing the holux genes and was generally easier to differentiate from 
background at time points closer to luciferin addition (Table 5). 
Fluorescent measurement of GFP expressing HEK293 cells in culture  
in cell culture medium 
 When HEK293 cells expressing GFP were tested in DMEM without phenol 
red it was not possible to detect the fluorescent signal of the cells above the 
background level of fluorescent detection at any of the population sizes 
surveyed.  In order to better differentiate the target signal from background, the 
integration time was lowered down to a minimum of 0.5 sec, however this had no 
effect on the ability to distinguish signal from noise.   Based on these results it 
was concluded that the assay would be preformed in PBS, as this media did not 
contain any serum proteins or compounds to contribute to the production of non-




Figure 12.  Minimum population size detection of Luc-tagged HEK293 cells. 
Short integration times (~1 sec) are required to prevent saturation of the CCD camera when using 
a Luc-based reporter system due to its high levels of bioluminescent flux following D-luciferin 
amendment.  However, at integration times of 1 sec (A) it is not possible to differentiate Luc-
expressing cell populations below ~250 cells from background light detection.  Increasing the 
integration time to ~10 sec (B) in the absence of larger population sizes to prevent camera 
saturation allows for detection down to ~50 cells.  Boxes represent the mean values of three 
trials, reported with the standard error of the mean. 
 98 
Table 5.  Detection of Luc-expressing HEK293 cells over time. 
Larger populations of Luc-expressing cells were visible over longer periods of time following the addition of D-luciferin.  Due to the highly dynamic 
nature of Luc expression, readings are reported at 10 min intervals.  Green boxes represent time points where the indicated cell population was 
significantly distinguishable from background.  Red hatched boxes represent time points where the indicated cell population was not significantly 
distinguishable from background light detection. 
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In phosphate buffered saline  
Dynamics of bioluminescent production over time 
Average radiance of HEK293 cells stably expressing GFP in a PBS as a 
medium increased slightly but not significantly (p = 0.08) over the course of the 
assay from an initial value of 6.0 (± 0.06) × 106 p/s/cm2/sr to a peak of 6.6 (± 
0.07) × 106 p/s/cm2/sr by 22 h after the initial plating.  Over the full course of the 
assay the average radiance remained relatively steady at 6.2 (± 0.05) × 106 
p/s/cm2/sr with an average error of 7.3 (± 0.3) × 104 p/s/cm2/sr (Figure 10F).  
Minimum detectable population size 
Fluorescent detection from GFP emission presented the least sensitive 
lower limits of detection for any of the three reporter systems tested when PBS 
was used as the assay medium.  Under these conditions detection ranged from 
~1 × 106 cells/well down to 5 × 105 cells/well (Figure 10E).  Although wells of less 
than ~5 × 105 cells/well clearly show fluorescent signals, they were not 
significantly different from background following subtraction of background tissue 
autofluorescence (Figure 13).  Similar to the holux-expressing cells, detection 
ability increased for the smaller population sizes over the course of the assay 
(Table 6).  A full comparison of the pertinent expression data for all three reporter 




Figure 13.  Minimum population size detection of GFP-tagged HEK293 cells. 
Cells expressing GFP were visible down to population sizes of ~5 × 105 cells.  Boxes represent 
the mean values of three trials, reported with the standard error of the mean. 
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Table 6.  Detection of GFP-expressing HEK293 cells over time. 
GFP-expressing cells could be significantly differentiated from background fluorescence detection at all time points following plating when 
greater than ~5 × 105 cells were present.  Detection of ~5 × 105 cells became possible 9 hr after plating, while detection of less than ~5 × 
105 cells was not possible at any of the time points surveyed.  Green boxes represent time points where the indicated cell population was 
able to be significantly distinguishable from background.  Red hatched boxes represent time points where the indicated cell population 
was not significantly distinguishable from background light detection. 
GFP 
  Time Post Plating (hr) 
Cell Population Size 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
100 Cells/well                                                   
1K Cells/well                                                   
10K Cells/well                                                   
100K Cells/well                                                   
500K Cells/well                                                   
750K Cells/well                                                   




Table 7.  Summary of comparisons between the holux, Luc, and GFP reporter systems 
under in vitro and in vivo imaging conditions. 
in vitro 

















All Time Points 
holux 6.4 (± 0.1) × 103 16 4.6 × 103 58 (± 4) 1 × 105 
Luc 8.8 (± 0.4) × 107 0.17 8.9 × 107 2.9 (± 0.6) × 106 250 



















holux 1.5 (± 0.2) × 105 1.6 (± 0.3) × 104 5 × 106 60 2.5 × 104 













holux 3.6 (± 0.2) × 105 7.0 (± 2.2) × 103 1 × 107 60 




Bioluminescent measurement of bacterial luciferase expressing HEK293 
cells in a small animal model system  
Subcutaneous injection 
Average flux from subcutaneous injection of ~5 × 106 holux expressing 
cells was 1.5 (± 0.2) × 105 p/s and remained relatively constant over the full 
course of the 60 min assay, displaying a minimum flux of 1.3 (± 0.1) × 105 p/s 
and a maximum of 1.5 (± 0.2) × 105 p/s.  The standard errors of the readings 
were relatively low, averaging 1.6 (± 0.3) × 104 p/s and therefore provide 
readings with increased resolution compared to the Luc reporter system.  Over 
the full course of the assay, the bioluminescent profile remained relatively flat, 
displaying a range of 2.8 × 104 p/s between the lowest and highest recorded 
values (Figure 14A).  To obtain a representative pseudocolor image during 
acquisition, integration times of 1 min were used, however, it was previously 
demonstrated that detection following subcutaneous injection of ~5 × 106 holux-
expressing cells is possible using ~30 sec integration times (Close, Patterson et 
al. 2010).  It was also demonstrated that following subcutaneous injection the 
lower level for detection was 25,000 cells when using increased integration times 
(~10 min) (Figure 14B). 
Intraperitoneal injection 
 Intraperitoneal injections of ~1 × 107 holux expressing cells yielded a 
disparate bioluminescent profile from that of the subcutaneous injections.  The 




Figure 14.  Comparison of in vivo bioluminescence for holux and Luc cells. 
The bioluminescent signal following subcutaneous injection of holux-expressing cells (A) remains 
relatively stable following injection and is detectable (B) down to a minimum of ~25,000 cells.  
Signal dynamics are significantly altered (C), but of approximately the same strength following 
intraperitoneal injection.  Total flux from subcutaneous injection of Luc-expressing cells (D) is 
significantly higher, and as such is detectable (E) down to ~2,500 cells.  Bioluminescent output 
from intraperitoneal injected Luc-expressing cells (F) expressed peak flux immediately following 
D-luciferin injection, but then quickly diminished over the remainder of the assay. 
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3.6 (± 0.2) × 105 p/s.  Following this initial light output, the total flux continued to 
trend downward over the remainder of the assay (Figure 14C).  The greatest 
decrease, presumably from dispersion of the cells following injection, occurred 
during the first 15 min, during which the total flux decreased from the maxima to 
2.4 (± 0.2) × 105 p/s.  After this time, the rate of bioluminescent production 
remained relatively flat, decreasing ~67,000 p/s by the final time point of the 60 
min assay.  Due to the diffusion of cells within the intraperitoneal cavity following 
injection and the increased amount of scattering and absorption associated with 
intraperitoneal imaging, pseudocolor images obtained using a 60 sec integration 
time were not as well defined as those from the subcutaneous injections despite 
the injection of a higher number of cells (Figure 15 A and C).  The expression 
value differences (in p/s) that lead to these changes in pseudocolor 
representation are presented in Table 7. 
Bioluminescent measurement of firefly luciferase expressing HEK293 cells 
in a small animal model system 
Subcutaneous injection 
Subcutaneous injection of ~5 × 105 Luc containing cells produced a bell 
curve of bioluminescent production.  Immediately following intraperitoneal 
injection of 150 mg D-luciferin/kg the average total flux from each injection site 
was 1.0 (± 0.2) × 106 p/s.  Total flux then increased rapidly over the next 40 min 
to a maximum of 2.0 (± 0.5) × 108 p/s before declining for the remainder of the 60 
min assay.  Along with the increased flux values were increased error ranges at 




Figure 15.  Comparison of pseudocolor images of subcutaneously and intraperitonealy 
injected holux and Luc Cells. 
Subcutaneously injected (A) holux or (B) Luc expressing cells are capable of presenting relatively 
similar images despite the large differences in total flux from each reporter system if the 
integration time is increased from 1 sec (Luc) to 60 sec (holux).  Similar increases must be made 
to maintain uniform representative detection following intraperitoneal injection of the (C) holux 
and (D) Luc cells as well, with the holux system requiring a 60 sec integration time to achieve 
similar peudocolor patterning as a 10 sec integration of the Luc system. 
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each reading averaged 4.0 (± 0.5) × 107 p/s (Figure 14D).  Visual detection of 
signal was never problematic, with a 1 sec integration providing ample exposure 
for facile visual representation of the subcutaneous injection site (Figure 15B).  
With the system under the control of the CMV promoter, the minimum detectable 
cell number was determined to be 2,500 under subcutaneous imaging conditions 
(Figure 14E).  
Intraperitoneal injection 
 Intraperitoneal injections of ~1 × 106 Luc expressing cells produced a 
much different time dependent bioluminescent expression profile than that 
obtained following subcutaneous injections (compare Figure 14F to Figure 14D).  
The magnitude of bioluminescent flux notwithstanding, the time dependent 
bioluminescent profile following intraperitoneal injection of Luc expressing cells 
yielded a profile similar to that obtained following intraperitoneal injections of 
holux expressing cells (compare Figure 14F to Figure 14C).  The highest total 
flux occurred immediately after intraperitoneal injection of 150 mg D-luciferin/kg 
at 1.6 (± 0.3) × 109 p/s.  The bioluminescent flux then quickly decreased to 1.0 (± 
0.1) x 109 p/s by 10 min post luciferin injection.  For the remaining 50 min of the 
assay the total flux remained relatively constant, averaging 9.2 (± 0.2) × 108 p/s.  
As with the holux-expressing cells, integration time had to be extended to obtain 
a representative visual image of the intraperitoneal injection site.  Intraperitoneal 
injection of ~1 × 106 Luc-expressing cells, followed by immediate imaging post D-
luciferin injection using a 10 sec integration time, produced a pseudocolor visual 
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representation similar to the pseudocolor images obtained using a 60 sec 
integration time following injection of ~1 × 107 holux-expressing cells, but did not 
produce images that were as well defined as those following subcutaneous 
injection (Figure 15 B and D).  This is presumably due to the increases in 
absorbance and scattering associated with injection into the intraperitoneal 
cavity.  A summary of the differences between Luc expression in vivo or in vitro 
following either a subcutaneous or intraperitoneal injection can be found in Table 
7. 
Fluorescent measurement of GFP expressing HEK293 cells in a small 
animal model system  
Subcutaneous injection  
Subcutaneous injections ranging from ~1 × 104 to ~1 × 107 GFP 
expressing cells failed to produce a detectable fluorescent signal when 
expressed in a nude mouse model.  When regions of interest were drawn over 
the injection site of  ~1 × 107 cells in a 100 µl volume of PBS, these locations did 
not produce significantly more fluorescent flux then was measured over 
background from a region of identical size distal from the injection site (p = 
0.739).  The location of the injection did not have a statistically detectable effect 
on the strength of the resulting fluorescent signal, with injection into the shoulder 
or the rump resulting in similar levels of detection for equal numbers of injected 




 Similar to the results obtained following subcutaneous injection, 
intraperitoneal injection of GFP expressing cells at population sizes up to ~1 × 
107 were not able to be detected at any time point during the 60 min course of 
the assay.  Regions of interest of identical size drawn either over the injection 
site, or distal from the injection site at an area not expected to display fluorescent 
signal displayed similar levels of fluorescent flux across all surveyed time points 
(p = 0.100). 
 
Discussion 
 There have been myriad demonstrations of the bioluminescent and 
fluorescent profiles obtained in culture or small animal imaging when employing 
the Luc or GFP proteins as targets.  The variety and scope of published literature 
utilizing these, or versions of these, reporters is testament to their usefulness, as 
well as the expression strategies to which they can be adapted within the 
confines of a particular experimental design.  To aid in the comparison of the 
three different systems under conditions that are as uniform and comparable as 
could be achieved, each was expressed in the same cellular background 
(HEK293) and placed under the control of identical cytomegalovirus (CMV) 
promoters.  The use of identical promoters should encourage similar levels of 
expression when each construct is expressed in the HEK293 cell line (Qin, 
Zhang et al. 2010).  However, in the holux cell line, although luxAB is driven by 
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the CMV promoter, the luxC and luxE genes are instead under the control of the 
human elongation factor 1α (EF-1α) promoter.  Because the previously published 
demonstration of holux function was designed in this manner (Close, Patterson et 
al. 2010) it was not subjected to any modification prior to expression in order to 
allow for consistent comparison with the previously published results. 
 As expected, bioluminescence from the Luc system was detectable at lower 
cell concentrations and displayed a significantly larger total flux than holux-
containing cells in the mouse imaging experiments and its detection level was 
lower than both the lux and GFP reporters in the cell culture imaging scenarios.  
Under conditions where only small populations of Luc-expressing cells were 
assayed in cell culture as few as 50 Luc cells/well were visible (Figure 10C and 
Figure 12B) compared with a minimum of 15,000 cells/well for the holux system 
(Figure 10A) and 500,000 cells/well in the GFP system when cells were imaged 
in PBS (Figure 10E and Figure 13).  The need to use PBS as a liquid medium to 
detect lower GFP-expressing cell numbers due to the autofluorescence from the 
cell culture medium represents a crucial problem with using fluorescent systems 
for prolonged cell culture imaging.  The lack of medium components such as 
serum and nutrients required for low-level fluorescent detection does not promote 
continued cellular growth, thereby preventing potential autonomous fluorescent 
monitoring without regular medium changes. The inclusion of these compounds 
can prevent this, but increases the minimum detectable cell number beyond 1 
million cells/well, and therefore could not be detected under our imaging 
conditions.   
 
 111 
 Another approach to overcome the poor sensitivity of GFP in culture is to use 
an alternate cell line capable of more efficiently expressing the reporter.  It has 
previously been demonstrated that GFP expression under the control of the CMV 
promoter in the MCF-7 breast cancer cell line is capable of being detected at 
lower numbers of GFP expressing cells/well (Caceres, Zhu et al. 2003), however, 
these experiments were conducted in wells of significantly smaller surface area 
(0.32 cm2 as compared to 1.9 cm2) than used in these experiments. When the 
results from both experiments are normalized to media volume, this corresponds 
to a lower detection level of ~250 cells/µl using MCF-7 cells compared to ~500 
cells/µl when expressed in HEK293 cells. 
 Our results demonstrate, however, that the use of bioluminescence rather 
than fluorescence overcomes this problem completely; however, there is a large 
difference in the bioluminescent output levels and imaging strategies between 
the holux and Luc systems.  The holux system has the advantage of not requiring 
addition of a substrate to elicit bioluminescent production, therefore allowing for 
completely autonomous bioluminescent readings that should routinely correlate 
with cell number, regardless of time.  The disadvantage of the holux system is 
that it is significantly less efficient than the Luc system.  While the average 
radiance of ~1 × 106 holux cells had a peak value of 6,400 p/s/cm2/sr, this is 
comparable to the peak average radiance of only ~100 HEK-Luc cells/well 
(although this number of cells/well cannot be reliably detected following the initial 
bioluminescent burst following substrate amendment as shown in Table 5).  
Therefore, detection of small numbers of cells in culture is best suited to a Luc-
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based reporter system, especially if the production of light is only to be monitored 
over short time periods.  However, if working with larger cell populations, the use 
of a holux-based reporter system gives the benefit of continuous bioluminescent 
output, and is not dependent on the addition of luciferin to the cell culture 
medium.  Regardless of which reporter system is employed, the use of a 
bioluminescent system (either holux or Luc) has the advantage of low 
background detection when compared with the use of a fluorescent system such 
as GFP in a medium-based cell culture setting. 
 When applied to small animal imaging, the same general benefits for each 
reporter system are reiterated.  The major disadvantage of working with GFP or 
alternate fluorescent reporter systems in an animal model is the relatively high 
level of background fluorescence resulting from excitation of endogenous 
chromophoric material within the subject tissue.  The use of a bioluminescent 
reporter helps to overcome this disadvantage due to the low levels of background 
autoluminescence in mammalian tissues (Welsh and Kay 2005).  While Luc-
based systems have most often been utilized for small animal imaging, the holux 
system provides a distinct advantage for near-surface target visualization.  
Although not as bright as the Luc system (total flux averaged 1.5 (± 0.2) × 105 p/s 
for a subcutaneous injection of ~5 × 106 HEK293 holux cells vs. an overall 
average total flux of 1.4 (± 0.2) × 108 p/s for a subcutaneous injection of ~5 × 105 
Luc cells) the bioluminescent profile of the holux-containing cells was relatively 
flat over the full course of the assay, while the bioluminescent profile of the Luc-
containing cells varied greatly following substrate injection.  In addition, the act of 
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luciferin supplementation encompasses its own set of concerns.  It has been well 
documented that the bioluminescent profile can be altered depending on the 
route of substrate administration for Luc-based systems (Inoue, Kiryu et al. 
2009), with each route having different uptake rates throughout the body (Lee, 
Byun et al. 2003).  Also of concern, the process of substrate injection allows for 
the introduction of error due to differences in the efficiency of each injection 
and/or the possibility of potential injection failure (i.e. injection into the bowel 
during intraperitoneal administration) (Inoue, Kiryu et al. 2009).  Any changes in 
the quality of the luciferin over time during multiple injections (Mohler 2010) as 
well as the possible introduction of tissue damage that can prohibit further 
injections are also of concern (O'Neill, Lyons et al. 2010).  For large-scale 
experiments, the cost of luciferin must also be taken into consideration, as it is an 
expensive substrate.  Therefore, the use of a holux-based reporter is more 
simplistic and economical and may provide more reliable results if relatively large 
numbers of cells are being imaged close to the surface of the subject. 
 The inability to detect injections of GFP-expressing HEK293 cells at 
concentrations up to ~1 × 107 is in line with what has been previously reported in 
the literature.  It has been previously demonstrated that HEK293 cells expressing 
GFP were not detectable until 7 d post injection when population sizes of 1 × 106 
cells were used for injection (Choy, O Connor et al. 2003).  With the doubling 
time of HEK293 cells reported to be 34 h, these cells should have reached a 
population size of ~1 × 107 by ~5 days, two full days prior to when they were first 
reported to be detectable.  When GFP is expressed in other cell lines, however, 
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the time until detection can change.  It has been reported that injection of ~1 × 
107 GFP expressing MCF-7 cells was possible 1 d following injection (Caceres, 
Zhu et al. 2003), however, no information was given as to the detection ability 
immediately following injection.  Although it may have been possible to elicit a 
detectable fluorescent signal by injection a higher concentration of GFP 
expressing cells, injection size was limited to ~1 × 107 cells because this was the 
largest injection size commonly reported in the literature. 
 While previous reports have suggested that detection of a single cell 
expressing the luc reporter gene is possible in the 4T1 mouse mammary tumor 
line (Kim, Urban et al. 2010), it is shown here that a minimum of 2,500 cells are 
required when the Luc system is expressed in HEK293 cells under the control of 
a CMV promoter (Figure 14E).  Despite the increase in cells required for 
detection under our expression conditions, this number was still well below that 
required for detection of the holux-expressing cells (Figure 14B).  The diminished 
performance of the holux cells compared to Luc-containing cells during both 
minimal detection level testing and intraperitoneal injection demonstrates that the 
associated benefits of the holux system are of little value if they cannot be easily 
detected under experimentally relevant imaging conditions.  In cases where deep 
tissue imaging is required, the use of a Luc-based system can be advantageous 
despite the concerns associated with substrate addition, especially since its use 
in these types of experiments is widespread and well documented. Whether 
subcutaneous or intraperitoneal injection is chosen as the route of administration, 
it is important to realize that the decreased efficiency of the holux system as 
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compared to the Luc system necessitates an increase in integration time to 
obtain similar detection levels (Figure 15).  The amount of time required for signal 
detection must therefore be considered in the context of a given experiment to 
determine if detection of the holux signal at a level similar to what a researcher 
may be accustomed to using a Luc-based system is acceptable. 
 The greatest advantages of the new holux system, however, are the ability 
for researchers to integrate its use alongside other established fluorescent and 
bioluminescent systems and the ability to exploit the unique autonomous nature 
of lux bioluminescent expression with novel detection methods.  Because the 
presence of fluorescently labeled cells would not be detected under 
bioluminescent imaging conditions (i.e. in the absence of an excitation signal), 
the location and size of bioluminescent signals could be determined and then 
differentiated from any fluorescent signals detected following administration of 
the excitation signal.  In addition, the holux signal could be determined prior to 
substrate injection in conjunction with alternative bioluminescent reporter 
systems to sequentially determine the location and size of differentially labeled 
cell populations within a living host.  Alternatively, the autonomous nature of lux 
bioluminescent expression could allow it to be paired with miniaturized integrated 
circuit microluminometers (Islam, Vijayaraghavan et al. 2007) that could one day 
be implanted under the skin of an animal subject, allowing for real-time detection 
of signal without the need for external imaging equipment.  This possibility opens 
the door for development of integrated biofeedback circuits that can 
autonomously monitor and subsequently react to numerous in vivo disease 
 
 116 
conditions.  So while the introduction of a holux imaging target certainly does not 
displace the use of currently available fluorescent and bioluminescent imaging 
targets, it can overcome some of the shortcomings of these systems and 





Use Of Mammalian-Adapted Bacterial Luciferase Genes As A 




For many years researchers have been using bacteria and simple 
eukaryotes such as yeast to serve as proxies for measuring the bioavailability of 
exposed chemicals to human cells.  These simple models have distinct 
advantages of being easy to manipulate in the laboratory, inexpensive to 
maintain, and highly amenable to high throughput experimental design.  
However, as attractive as they might be, they are not completely representative 
of human derived cells.  As such, there is always some amount of caution that 
must be taken when interpreting the data obtained using these models and 
relating it to human bioavailability.  Oftentimes human derived cells cannot be 
used for bioavailability screening because of the lack of reporter systems 
allowing for real-time, autonomous reporting of the associated effects.  
Fluorescent reporter systems can be employed that do not require addition of 
potentially influential substrates for signal generation, however, these systems 
have high levels of background and can require expensive equipment to properly 
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filter their excitation and emission signals (Tsien 1998).  The use of currently 
available bioluminescent systems can overcome some of these technical hurdles 
and allow for inexpensive bench top monitoring, but does so at the cost of 
potentially error inducing substrate addition. 
The simplest solution to this problem is to work in a less complex model 
system such as Escherichia coli or various other traditional prokaryotic 
organisms.  This is most often done to partially alleviate the cost, scalability, and 
narrowed reporter availability issues that have traditionally restricted direct 
testing in mammalian cell lines.  However, these logistical considerations come 
at a cost.  Oftentimes the use of a prokaryotic or lower eukaryotic organism 
dictates that there will be significant differences in the metabolic pathways and 
extracellular receptor profiles as compared to those present when directly testing 
in mammalian cells.  This has traditionally been a problem when studying the 
effects of compounds such as estrogen, which cannot be metabolically 
processed by prokaryotic organisms, or attempting to elucidate the intricacies of 
organelle formation, which again is not feasible using a bacterium lacking in 
these cellular components (Campbell, Reece et al. 2007).   
In some cases, such as screening for estrogenic compounds, a lower 
eukaryotic host such as Saccharomyces cerevisiae is therefore employed that is 
capable of reacting to the presence of the target compound (Sanseverino, Gupta 
et al. 2005).  However, even when using another eukaryotic organism as a proxy, 
there is no way to directly relate the ensuing findings to human bioavailability.  
Ultimately, the only way to draw direct comparisons to how a given compound 
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will affect a human cell is to directly test it on the tissue of interest.  The use of 
mammalian cells that can react to the presence of a compound of interest either 
through the production or reduction of a bioluminescent signal in a near real-time 
fashion would provide a novel method for the detection and evaluation of 
biomedically relevant compounds in an efficient and high throughput manner, 
filling the niche left by the currently available mammalian-compatible reporter 
systems. 
These concerns are clearly illustrated in the toxicology field, where it is 
estimated that ~$2.7 billion is spent on toxic chemical screening alone, with much 
of that sum being directed to animal testing (Hartung 2009).  Despite this 
expenditure, the use of animal subjects has proven to be a poor substitute for 
human exposure.  In one classic example, testing using rodents was shown to be 
able to correctly identify toxic effects in humans at a rate of only 43% (Olson, 
Betton et al. 2000).  The use of a high throughput mammalian cell line that can 
be used as a screen for compound toxicity could greatly improve upon the 
current detection methods, as well as provide a low cost method to determine 
which compounds should be studied in greater detail (Ekwall, Silano et al. 1990). 
Here the use of human derived HEK293 cells stably transfected with the 
luxCDABEfrp genes of the bacterial bioluminescence cassette (lux) is 
investigated as a means of overcoming the limitations imposed by currently 
available mammalian cell based bioavailability detection methods.  To investigate 
the utility of these cells to act as biosensors for the presence of a specific target 
chemical, a version of the lux gene cassette was created that regulated the 
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expression of the luxC and luxE genes in response to doxycycline using the 
commercially available TET-On system (Clontech).  The TET-On system 
represents a common method for evaluating the effectiveness of a reporter 
system as it has previously been shown to be effective for expression of a wide 
array of reporter genes across multiple mammalian cell lines (Freundlieb 2007) 
and therefore allows for the facile comparison of reporter function with previously 
published models.   
It has previously been demonstrated that bioluminescence can be 
detected from small numbers of human cells expressing the lux genes, and that 
the bioluminescent flux can be correlated to overall cell population size (Close, 
Patterson et al. 2010).  This makes the substrate-free, real-time bioluminescent 
response of a lux-expressing cell line an excellent platform for development into 
a mammalian-based reporter system designed to signal target compound 
detection, as well as allowing for it to be developed into a first-of-its-kind 
biosentinel for toxic chemical exposure.  The latter is made possible because the 
persistence of the bioluminescent signal without excitation or addition of 
substrate makes it possible to measure changes in overall bioluminescent 
production as an indicator for changes in cellular growth and metabolism. 
These types of measurements would not be possible using other reporter 
systems due to the economic and logistical concerns related to constantly 
simulating the reporter protein in order to generate the continuous signal required 
for real-time monitoring.  The ability to autonomously produce a bioluminescent 
signal in response to a specific compound of interest without the requirement of 
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investigator intervention allows for the possibility of high throughput, on-line, 
remote detection systems that could significantly improve on the cost and 
efficiency of current detection methods.  In addition, the ability to efficiently 
screen multiple compounds in parallel in order to evaluate their potential 
cytotoxic effects directly on human cells gives the lux reporter system an 
advantage over other fluorescent or bioluminescent reporter systems in the field 
of toxicology. 
 
Materials And Methods 
Strain maintenance and growth 
Escherichia coli cells were routinely grown in Luria Bertani (LB) broth with 
continuous shaking (200 rpm) at 37°C.  When required, kanamycin or ampicillin 
was used at final concentrations of 40 and 100 µg/ml, respectfully, for selection 
of plasmid containing cells.  Mammalian cell lines were propagated in Eagle’s 
modified essential medium (EMEM) supplemented with 10% fetal bovine serum, 
0.01 mM non-essential amino acids, and 0.01 mM sodium pyruvate.  Cell growth 
was carried out at 37°C in a 5% CO2 environment and cells were passaged every 
3 - 4 d upon reaching 80% confluence.  Neomycin, hygromycin, and/or zeocin 
were used for selection of transfected cells at concentrations of 500 µg/ml, 100 




Cloning of the tetracycline response element  
PCR amplification 
 Primers were designed (TET-forward 5’-
GCTAGCAGGTGGCGTGTACGGTGGGA-3’, TET-reverse 5’-
GCGGCCGCTCCAGGCGATCTGACGGTTC-3’) to amplify a 349 bp region of 
the pTRE-Tight-BI plasmid (Clontech) containing both the tetracycline response 
element and its associated CMV promoter sequence.  The TET forward primer 
was engineered to contain an NheI restriction site, while the TET reverse primer 
was engineered with an associated NotI restriction site.  This allowed for the 
attainment of an altered PCR product that contained a 5’ NheI restriction site, 
followed by the tetracycline response element and CMV promoter, then a 3’ NotI 
restriction site.  The resulting PCR product was then immediately TOPO cloned 
into the pCR4-TOPO vector (Invitrogen) to create pCR4-TET.  This plasmid was 
used as the basis for allowing propagation and maintenance of the receptor 
fragment. 
Introduction of the tetracycline response element into pLuxCDEfrp  
The tetracycline response element and its associated CMV promoter were 
removed from pCR4-TET using the NheI and NotI restriction sites.  In parallel 
with this reaction, the EF1-α promoter was removed from pLuxCDEfrp using the 
same restriction sites.  Following restriction digest, both reactions were purified 
by gel electrophoresis.  The ~350 bp band representing the tetracycline response 
element and the CMV promoter were extracted from the lane containing the 
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pCR4-TET digestion and the ~8.9 kb band representing the pLuxCDEfrp plasmid 
with the EF1-α promoter removed was extracted from the lane containing the 
pLuxCDEfrp digestion.  Both isolated fragments were purified using QIAquick Gel 
Extraction kits (Qiagen).  The purified fragments were ligated together for 5 min 
at room temperature using T4 DNA polymerase (Promega) in LigaFast buffer 
(Promega) to create the plasmid pLuxCDEfrp-TET.  The ligated plasmid DNA was 
then used directly for transformation.  Chemically competent E. coli were 
inoculated with 2 µl of the pLuxCDEfrp-TET ligation product and selected by growth 
on LB medium containing 100 µg Ampicillin/ml.  Successful uptake the 
pLuxCDEfrp-TET plasmid was confirmed by restriction digest and the success of 
the ligation reaction was confirmed by sequencing. 
Transfection of pLuxAB and pLuxCDEfrp in HEK293 cells 
 Transfection was carried out in six-well Falcon tissue culture plates (Thermo-
Fisher).  The day prior to transfection, HEK293 cells were passaged into each 
well at a concentration of approximately 1 × 105 cells/well and grown to 90 – 95% 
confluence in complete medium.  pLuxAB and pLuxCDEfrp-TET plasmid vectors 
were purified from 100 ml overnight cultures of E. coli using the Wizard 
Purefection plasmid purification system (Promega).  On the day of transfection, 
cell medium was removed and replaced and vector DNA mixed in a 1:1 ratio was 




Screening of stably transfected reporter cell lines 
 Twenty-four h post-transfection, the medium was removed and replaced with 
complete medium supplemented with the appropriate antibiotic.  Selection of 
successfully transfected clones was performed by refreshing selective medium 
every 4 – 5 d until all untransfected cells had died.  At this time, colonies of 
transfected cells were removed by scraping, transferred to individual 25 cm2 cell 
culture flasks, and grown in complete medium supplemented with the appropriate 
antibiotics. 
 To screen the resulting cell lines for the ability to regulate luxC transcription 
in response to doxycycline, relative reverse transcription PCR (rt-PCR) was used 
to determine the level of luxC mRNA present 24 h following the addition of 0, 10, 
or 100 ng doxycycline/ml to the complete growth medium.  To this end, each 
isolated cell line was split into 4 25 cm2 cell culture flasks upon reaching 80% 
confluence.  Cells were then grown at 37°C and 5% CO2 until again reaching 
~80% confluence.  At this point, one of the flasks was routinely passaged to 
maintain a stock of cells for future use.  The remaining 3 flasks were spiked with 
0, 10, or 100 ng doxycycline/ml and returned to the incubator.  Twenty-four h 
post doxycycline addition, cells were harvested and total RNA was isolated using 
an RNeasy isolation kit (Qiagen).  Isolated RNA was used directly for rt-PCR 
analysis, and cell lines displaying the greatest range in luxC transcription 
between 0 ng Doxycycline/ml treatment and either 10 ng or 100 ng 




Bioluminescent measurement in response to doxycycline 
Cell lines displaying the greatest upregulation of luxC gene transcription 
following treatment with 10 ng and 100 ng Doxycycline/ml were passaged into 75 
cm2 tissue culture flasks (Corning) and grown at 37°C and 5% CO2 until they 
reached 90% confluence.  Cells were then harvested by trypsinization and cell 
number was determined as the average of two counts using a hemocytometer.  
Approximately 1 × 106 cells per well were plated in triplicate in opaque 24-well 
tissue culture plates (Costar) in DMEM without phenol red and supplemented 
with 10% fetal bovine serum, 0.01 mM non-essential amino acids, and 0.01 mM 
sodium pyruvate.  Immediately post plating, wells were spiked with either 0, 10, 
100, or 500 ng Doxycycline/ml.  Photon counts were then recorded using an IVIS 
Lumina in vivo imaging system and analyzed with Living Image 3.0 software 
(Caliper Life Sciences).  The change in light output over time was determined in 
photons (p)/sec (s) for each well by averaging the photon output over integration 
times of 10 min and reported with the standard error of the mean. 
Bioluminescent measurement in response to toxic chemical exposure 
To determine the ability of constitutively bioluminescent HEK293 cells to 
function as a bioreporter for toxic chemical exposure, cells stably expressing 
pLuxCDEfrp/pLuxAB were exposed to increasing concentrations of the cytotoxic 
aldehyde n-decanal. HEK293 cells previously determined to be capable of 
continuous bioluminescent output from the expression of the pLuxCDEfrp/pLuxAB 
plasmids were passaged into 75 cm2 tissue culture flasks (Corning) and grown at 
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37°C and 5% CO2 until they reached 90% confluence.  Cells were then 
harvested by trypsinization and cell number was determined as the average of 
two counts using a hemocytometer.  Approximately 1 × 106 cells per well were 
plated in all wells in opaque 24-well tissue culture plates (Costar) in DMEM 
without phenol red and supplemented with 10% fetal bovine serum, 0.01 mM 
non-essential amino acids, and 0.01 mM sodium pyruvate.  Triplicate wells were 
treated with serial dilutions of n-decanal ranging from 0.1% to 1 × 10-5%, with a 
control set receiving no n-decanal amendment to determine maximal 
bioluminescent expression.  Photon counts were then recorded using an IVIS 
Lumina in vivo imaging system and analyzed with Living Image 3.0 software 
(Caliper Life Sciences).  The change in light output over time was determined in 
photons (p)/sec/cm2/steridian (sr) for each well using integration times of 10 min 
once every hour for 24 h and reported as the average of three runs with the 
standard error of the mean. 
 
Results 
Regulation of luxC transcription in response to doxycycline dose 
Following antibiotic selection of HEK293 cells co-transfected with 
pLuxAB/pLuxCDEfrp-TET, 11 cell lines were established that were capable of 
growing efficiently under selective media conditions.  Each of these lines was 
interrogated for the ability to up regulate luxC gene transcription following 
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doxycycline amendment.  The average CT value for luxC detection in negative 
control cells containing no doxycycline was 13.6 (± 0.7) cycles.  Following 
amendment with 10 ng doxycycline/ml, the average CT value dropped to 11.9 (± 
0.7), and following amendment with 100ng doxycycline/ml the average dropped 
to 11.5 (± 0.6). Of the eleven cell lines tested, only three showed significant (p < 
0.05) reductions in CT value at both 10 and 100 ng treatment levels as compared 
to the negative control, and also between the 10 and 100 ng treatment levels 
themselves (Table 8).  The best performing cell line displayed a reduction of 3.5 
cycles to reach CT upon amendment with 10 ng doxycycline/ml, which 
corresponds to approximately 11-fold increase in luxC transcription.  Upon 
induction with 100 ng doxycycline/ml, this cell line displayed a reduction of 4.3 
cycles to reach CT, an ~20-fold increase in transcription, although this was a 
difference of less than one cycle to reach CT as compared to induction with 10 ng 
doxycycline/ml, it was determined to be a statistically significant increase in 
transcriptional level (p = 0.027).  This cell line was chosen for determination of 
bioluminescent output in response to doxycycline addition. 
Bioluminescent production in response to doxycycline dose 
Using the cell line previously determined to have the most dynamic 
response to doxycycline treatment, cells were monitored to determine the 
magnitude and dynamics of bioluminescent production over a 24 h period 
following exposure to either 10 or 100 ng doxycycline/ml.  Average background 
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Table 8.  Regulation of luxC gene transcription in response to doxycycline treatment. 
Cell lines demonstrating a significant (p < 0.05) reduction in CT value between both negative control and 10 ng/ml doxycycline treatment 
and negative control and 100 ng/ml doxycycline treatment are indicated with the * symbol.  The cell line selected for further testing is 
designated by the ** symbol. 
Time Negative Control (0 ng Doxycycline/ml) 
10 ng Doxycycline/ml 
Treatment 100 ng Doxycycline/ml Treatment 
Cell 
Line CT Value 
∆ CT From 
Negative 
p Value vs. 
Negative 
Control 
∆ CT From 
Negative 
p Value vs. 
Negative 
Control 
∆ CT From 10 
ng/ml Treatment 
p Value vs. 10 
ng/ml Treatment 
# 1** 13.8 (± 0.2) -3.5 (± 0.1) < 0.01 -4.3 (± 0.2) < 0.01 -0.8 (± 0.2) 0.03 
# 2 19.5 (± 0.1) -1.5 (± 0.4) 0.05 -3.2 (± 0.1) < 0.01 -1.7 (± 0.1) 0.04 
# 3 14.0 (± 0.8) -1.4 (± 0.2) 0.2 -1.9 (± 0.1) 0.13 -0.4 (± 0.1) 0.17 
# 4* 11.7 (± 0.1) -1.2 (± 0.2) 0.02 -2.5 (± 0.2) < 0.01 -1.2 (± 0.2) 0.02 
# 5 12.1 (± 0.1) -1.2 (± 0.3) 0.05 -1.7 (± < 0.1) < 0.01 -0.5 (± < 0.1) 0.3 
# 6 14.5 (± 0.2) -3.3 (± 0.8) 0.04 -3.2 (± 0.3) < 0.01 +0.1 (± 0.3) 0.95 
# 7 13.0 (± 0.1) -2.1 (± 0.2) < 0.01 -2.6 (± 0.1) < 0.01 -0.4 (± 0.1) 0.12 
# 8* 12.5 (± 0.2) -1.2 (± 0.1) 0.02 -2.0 (± 0.2) < 0.01 -0.9 (± 0.2) 0.04 
# 9 11.8 (± 0.2) -0.7 (± 0.1) 0.1 +0.3 (± 0.3) 0.47 +0.1 (± 0.3) 0.08 
# 10 12.6 (± 1.5) -2.6 (± 1.2) 0.25 -1.1 (± 0.2) 0.56 +1.6 (± 0.2) 0.31 
# 11 14.2 (± 0.2) -0.2 (± 0.4) 0.73 -.9 (± 0.3) 0.08 -0.7 (± 0.3) 0.23 
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bioluminescence detection from cells that did not receive doxycycline treatment 
was determined to be 11,000 (± 205) p/s.  Average total flux from cells treated 
with 10 ng doxycycline/ml was not increased significantly (p = 0.06), although it 
did trend upwards to 11,500 (± 200) p/s.  Treatment with 100 ng doxycycline/ml, 
however, further increased the total flux to 12,500 (± 200) p/s, a significant 
increase over both the negative (p = 1.1 × 10-5) and over the 10 ng/ml treatment 
(p = 9.2 × 10-4).  These values remained relatively constant over the full course of 
the assay (Figure 16), with ranges of only 2,010, 1,900, and 1,800 p/s for the 
negative control, 10 ng, and 100 ng doxycycline/ml treatments respectively 
following the initial evaluation at 1 h post treatment.  It was possible to 
significantly distinguish the 100ng/ml treatment level from background at all but 
the 5 h post treatment time point.  While it was possible to significantly 
distinguish the 10ng/ml treatment level at some of the time points, it was never 
consistently greater than that of the untreated control cells (Table 9). After it was 
discovered that bioluminescent production could be induced with treatment at 
100 ng doxycycline/ml, but not at 10 ng doxycycline/ml, cells were treated with 
500 ng doxycycline/ml to determine if higher treatment levels would be capable 
of inducing further increases in bioluminescent production.  However, it was 





Figure 16.  Bioluminescent production following treatment with varying levels of 
doxycycline.   
Cells treated with 100 ng doxycycline/ml produced significantly greater bioluminescent flux (p < 
0.05) than untreated cells at all time points except for 5 h post treatment, while cells receiving 10 
ng doxycycline/ml produced greater bioluminescent flux only intermittently. 
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Table 9.  Detection of significantly significant changes in bioluminescent production following doxycycline treatment. 
HEK293 cells containing promoter sequences capable of regulating luxC and luxE gene expression in response to doxycycline levels can 
be used to report on exposure to increased levels of doxycycline in the media.  Green boxes indicate time points where significant (p < 
0.05) up regulation of bioluminescent production was detected.  Hatched red boxes indicate that no significant (p > 0.05) increase in 
bioluminescent production was detected. 
 Time Post Doxycycline Treatment 
 1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h 9 h 10 h 11 h 12 h 13 h 14 h 15 h 16 h 17 h 
100 ng 
Treatment                                   
10 ng 
Treatment                                   
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Use of constitutively bioluminescent cells as biosensors for n-decanal 
exposure 
Constitutively bioluminescent HEK293 cells expressing pLuxAB/pLuxCDEfrp 
were exposed to increasing levels of the cytotoxic aldehyde n-decanal and the 
rate and magnitude of bioluminescent production was monitored to determine the 
bioavailability of this toxicant to a mammalian cell line.  It was observed that 
treatment with 0.1% n-decanal reduced bioluminescent output immediately 
following addition, with all of the surveyed time points displaying significantly 
down regulated production of light (Table 10).  Treatment with 0.01% n-decanal 
also had deleterious effects on bioluminescent production, however, due to the 
reduced concentration, these effects were not consistently observable until 4 h 
after addition (Table 10).  The remaining treatment levels, while not capable of 
inducing increases in bioluminescence, could not be statistically differentiated 
from cells not receiving treatment (Figure 17). 
 
Discussion 
These findings represent the first use of autonomous bioluminescent 
production from a mammalian cell line being harnessed to directly detect the 
bioavailability of compounds of interest.  The unique ability of the lux genes to 
produce a bioluminescent signal that is practically background free, without 




Figure 17.  Bioluminescent profile of constitutively bioluminescent HEK293 cells following 
decanal treatment. 
Treatment with 0.1% decanal leads to immediate reductions in bioluminescent output, while 
treatment with lower concentrations produces more subtle reductions in output.  Only treatment 
with 0.1% and 0.01% decanal adversely effected bioluminescent production, while no treatment 
levels surveyed were capable of increasing bioluminescent production. 
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Table 10.  Detection of significantly different changes in bioluminescent production following doxycycline treatment. 
Hashed red boxes indicate bioluminescent profiles similar to control (p > 0.05). Green boxes represent bioluminescent profiles lower than 
untreated control cells (p < 0.05).  At concentrations below 0.01% decanal it was not possible to differentiate the luminescent profile from 
that of the untreated control cell line.  Intermittent deviation in bioluminescent flux was detected beginning at 40 min post decanal addition 
and became constant after 4 h at a concentration of 0.01%, while treatment with 0.1% decanal was able to be differentiated from control at 
all time points surveyed. 
  Time Post Decanal Addition 
  0 min 10 min 20 min 30 min 40 min 50 min 1 h 1.5 h 2 h 2.5 h 3 h 3.5 h 4+ h 
0.00001%                           
0.00010%                           
0.00100%                           







0.10000%                           
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throughput, on-line monitoring systems.  These types of screening systems have 
not previously been possible in the mammalian cellular background because of 
the photobleaching effects related to constant stimulation of fluorescent reporters 
or the prohibitively high cost of constant substrate profusion required for 
alternative bioluminescent reporters.  With these barriers circumvented by the 
ability of the lux-expressing cells to produce light autonomously, there is now the 
potential to provide a facile method for screening large numbers of compounds 
simultaneously and directly relating the findings to human bioavailability. 
The ability of lux expression to function as a traditional bioreporter by 
modulating the expression of the luxC and luxE genes under control of a 
tetracycline responsive promoter has been demonstrated in these experiments.  
The luxC and luxE genes were chosen as the regulatable genes because 
previously published literature has suggested that regulation of the luxC and luxE 
genes would provide the most digital control over bioluminescent expression 
using mathematical models (Welham and Stekel 2009).  While this work has not 
demonstrated that this is in fact the most efficient method of regulation, it has 
validated that expression of the luxC and luxE genes can be used successfully to 
modulate bioluminescent expression at statistically significant levels (p < 0.05). 
The luxC and luxE genes play a crucial role in the production and 
regeneration of the myristyl aldehyde substrate required by the lux luciferase 
enzyme in order to produce bioluminescence.  The luxE gene encodes an acyl-
protein syntetase that activates an intermediate fatty acid compound to provide 
the energy required for its future reduction to an aldhyde.  It is the luxC gene, 
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which encodes a fatty acid reductase, that performs this reduction of the fatty 
acid precursor to form the alehyde that ultimately takes part in the bioluminescent 
reaction.  Previous work has demonstrated that constitutive expression of the 
luxA and luxB genes that form the actual luciferase enzyme is not cytotoxic 
(Patterson, Dionisi et al. 2005) and that expression of these genes alone is not 
sufficient to elicit bioluminescent production without the function of the remainder 
of the lux cassette genes (Close, Patterson et al. 2010).  It has also been shown 
that high levels of aldehyde expression can be toxic in organisms exogenously 
expressing the lux genes (Hollis, Lagido et al. 2001).  Taken together, these data 
suggest that regulation of aldehyde production within the mammalian cell will be 
the most efficient means for controlling bioluminescent expression while 
simultaneously maintaining efficient conditions for cellular growth and 
metabolism.   
While it may have been more efficient to control only a single gene (i.e. 
only luxC or luxE) rather than multiple genes to serve this purpose, it was 
necessary to simultaneously regulate two genes in order to properly mimic the 
polycistronic nature of the cassette within the mammalian host cells.  Regulation 
of only one gene would have required re-engineering of the previously validated 
lux vectors, as well as the possible introduction of a third plasmid.  This prospect 
would have been detrimental to transfection efficiency and significantly 
decreased the chances of successfully establishing a stable cell line expressing 
all three plasmid constructs. 
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Treatment of cells expressing the luxC and luxE genes under the control 
of the tetracycline responsive promoter with 100 ng doxycycline/ml was able to 
elicit a significant up regulation in bioluminescent output (p = 1.1 × 10-5) following 
a relatively short incubation period of 1 h (Figure 17).  This time period is in line 
with previously published reports that have indicated the tetracycline responsive 
promoter is strong enough to produce detectable levels of its downstream gene 
product in as little as 30 min (Yarranton 1992; Gossen and Bujard 1993).  It is not 
known why the bioluminescent levels of the control and 10 ng doxycycline/ml 
treated cells increased transiently during the 5 h time point (Figure 16).  This 
anomalous increase in flux from the control cell line represents the only surveyed 
time point where it was not possible to statistically differentiate the signal from 
cells treated with 100 ng doxycycline/ml from the negative control, however, it 
maintained the trend of non-statistically differential expression between the 
control and 10 ng doxycycline/ml treated cell lines.  The most parsimonious 
explanation is that there was a mechanical anomaly with the imaging equipment 
leading to false positive levels of photon acquisition counts over an area of the 24 
well plate that contained both the negative control and 10 ng doxycycline/ml 
treated cells, as these were spatially adjacent during imaging.  The 100 ng 
doxycycline/ml treated cells remained distal from this section of the plate, and 
therefore may not have been affected by the anomaly, explaining why there was 
not a corresponding increase in measured bioluminescent flux for all three 
treatment levels at the 5 h time point. 
 
 138 
  Levels of bioluminescent flux from cells treated with 100 ng 
doxycycline/ml were smaller than those detected from similar numbers of 
constitutively bioluminescent cells in culture.  When the luxC and luxE genes 
were continuously expressed under the control of the EF1-α promoter the 
maximum level of radiance was measured at 4.5 (± 0.16) × 105 p/s, whereas, 
with the luxC and luxE genes placed under the control of the tetracycline 
responsive promoter and induced with 100 ng doxycycline/ml, the maximum 
measured flux was 1.3 (± 0.03) × 104 p/s.  This is most likely due to a 
combination of the improved efficiency of the EF1-α promoter as compared to the 
tetracycline responsive promoter and the increases in transcriptional efficiency 
imparted during continuous expression. 
Due to the discrepancy in luminescent flux between tetracycline 
responsive cell lines and those displaying constitutive expression, increases in 
treatment levels above 100 ng doxycycline/ml were attempted, however, none 
were shown to further increase bioluminescent output.  These results indicate 
that the tetracycline responsive lux reporter cells have a relatively narrow 
detection range, and therefore would not make efficient laboratory reporter 
strains at this time.  There are, however, further avenues that could be explored 
to improve their performance.  The first steps in this direction would be the 
redesign of the plasmid vectors to regulate expression of only a single lux gene, 
or the choice of alternative lux genes as points of regulation for reporter function.  
General considerations for optimization of the lux system that could be applied as 
well will be discussed extensively in chapter V. 
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Due in part to the poor performance of lux expressing cells to act as a 
bioreporter for specific compound detection, it was further investigated whether 
or not constitutively bioluminescent mammalian cells could function as 
biosensors for toxicological screening.  These unique cells are ideal platforms for 
real-time monitoring of the mammalian bioavailability of potentially toxic 
compounds, an assay that has not been previously available.  To determine their 
effectiveness in this roll, cells were exposed to n-decanal, a cytotoxic aldehyde 
similar to the product of the bacterial bioluminescent reaction, and the minimum 
exposure level capable of reducing bioluminescent production was determined.  
Decanal was chosen for the initial assay because it can serve a three-fold 
purpose.  As a similar product to that of the reaction catalyzed by the actions of 
the luxCDE genes (Meighen 1979), there have long been concerns over the 
potential cytotoxicity of these types of compound when the lux system is 
expressed in non-native organisms (Hollis, Lagido et al. 2001).  By using 
changes in bioluminescence to monitor for the effects of n-decanal on the 
HEK293 cell line it was possible to determine 1) if small supplements of the 
compound can increase bioluminescent intensity, 2) at what level the compound 
becomes toxic to the cell, and ultimately, 3) if a constitutively bioluminescent 
mammalian cell line can function as a reporter system for toxic chemical 
exposure. 
 It was hypothesized that slight increases in n-decanal availability would 
lead to increased bioluminescent output.  Previous work had indicated that when 
additional levels of n-decanal were made available to cell extracts containing the 
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lux proteins, it was possible to increase overall bioluminescent output in vitro 
(Close, Patterson et al. 2010).  This effect was not observed during in vivo testing 
(Figure 17) however, and none of the time points surveyed produced a result 
whereby a cell population treated with any level of decanal produced significantly 
greater bioluminescent flux than the untreated control line.  The small, aliphatic 
nature of n-decanal allows it to cross the membrane of Gram negative bacteria 
(Sizemore, Geissdorfer et al. 1993), and our data supports the hypothesis that 
the saturated ten carbon tail also allows the molecule to pass through the lipid 
bilayer of mammalian cells.  Using the newly developed assay it was confirmed 
that n-decanal treatment is adversely toxic (high levels of the compound will fix 
cells in a manner similar to formaldehyde) and will become detrimental to cellular 
health at concentrations required to generate the diffusive force required to cross 
the membrane.  It is possible, however, that there are alternative explanations for 
the failure of low level n-decanal treatment to increase bioluminescent flux.  The 
cell could be reaching an equilibrium where the additional influx of aldehyde is 
boosting bioluminescent production levels, but simultaneously negatively 
effecting cellular metabolism, thereby reducing overall bioluminescent yield.  This 
situation seems unlikely, given the observation that there is no effect over three 
orders of magnitude of aldehyde concentration.  It is more parsimonious that the 
low levels of aldehyde concentration do not provide enough diffusive force to 
allow n-decanal to cross into the interior of the cell through the lipid bilayer. 
 Despite the inability of low levels of aldehyde treatment to stimulate 
bioluminescent production, it was clear that at and above concentrations of 
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0.01% the aldehyde became toxic to the HEK293 cell line (Table 10).  While 
treatment with 0.1% decanal reduced bioluminescent output at all time points 
surveyed, treatment with 0.01% was not able to consistently reduce 
bioluminescence until 4 h after addition.  These results are comparable with 
previously published reports that demonstrated the ability of aldehyde to diffuse 
into Gram negative bacteria at concentrations in the range of ~ 0.25 – 50 × 10-5 
M (Rogers and McElroy 1958).  Our 0.01% decanal treatment corresponds to a 
concentration of ~64 × 10-5 M.  While the previous experiments used the slightly 
longer dodecanal in place of decanal (C12 compared to C10), less of that 
aldehyde is required to enter the cell in order to elicit a similar bioluminescent 
response because the longer chain aldehydes have been shown to produce a 
greater bioluminescent signal upon utilization in the lux reaction despite their 
slower penetration of the cell wall (Rogers and McElroy 1958).  These data 
suggest that the concentration range of 10-5 M is the point where decanal is able 
to cross the cell wall at a rate greater then it is able to be cleared by aldehyde 
metabolizing enzymes.  
The initial production of bioluminescence within error of the positive 
control indicates that for the first 0.5 h, a sufficient concentration of aldehyde has 
not entered into the cells to elicit a change in metabolism or cellular health.  The 
fluctuations in bioluminescent production over the next 2 h indicate that aldehyde 
has entered into the cell, but is likely being processed by endogenous aldehyde 
metabolizing proteins, whereas the distinct reduction in bioluminescence 
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following the 4 h time point suggests that the concentration of aldehyde has 
become too great to be cleared and has begun causing cellular damage. 
 The clear distinction between concentrations of aldehyde that affect 
bioluminescent production, and those that do not have an affect, suggest that 
constitutively bioluminescent mammalian cells can be used as sensors for 
monitoring the bioavailability of toxic compounds in real time.  Specifically the 
treatment of cells with 0.01% decanal shows that the real-time nature of the lux 
expression system can allow researchers to determine not only the presence or 
absence of an affect from their treatment of interest, but can also do so in a time-
dependent manner.  The autonomous nature of this reaction demonstrated by 
these results will allow for the development of biosentinel devices capable of 
acting remotely to detect and report directly on the mammalian bioavailability of a 
variety of biomedically relevant compounds in a way that is not feasible using 





Initial Optimization Of The Mammalian-Adapted Bacterial 




The use of mammalian-adapted bacterial luciferase (lux) genes as a 
reporter system in human cells is still in its infancy.  While the initial results 
detailed in this work are encouraging, the future of the mammalian lux system is 
still being written.  As the newest of the mammalian-compatible reporter options, 
the lux system has not had the advantage of optimization that comes from 
widespread adoption and evaluation by multiple research groups. 
 Thus far, all of the popular genetic-based (i.e. those derived directly from 
living organisms) fluorescent and bioluminescent reporter systems currently 
being employed for small animal imaging have had the advantage of multiple 
refinements in order to increase their efficiency under standard laboratory 
conditions.  Perhaps the best example of these incremental improvements has 
been with the widely used green fluorescent protein (GFP).  Originally detailed in 
1962 (Shimomura, Johnson et al. 1962), the GFP protein has undergone 
extensive modification from its native state in the last ~50 years in order to 
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compensate for the traits that make it less attractive for use as an imaging target.  
The genetic structure of the GFP protein has been altered repeatedly in order to 
allow it to fold properly in mammalian cells at the relatively increased 
temperature of 37°C (Crameri, Whitehorn et al. 1996), to prevent dimerization 
under the high levels of constitutive expression that are preferred for facile image 
acquisition (Zacharias, Violin et al. 2002), and mutated myriad times in order to 
alter the signal emission wavelength so that it can be used in tandem with other 
reporters, or detected with greater efficiency through living tissue (Heim, Prasher 
et al. 1994; Heim and Tsien 1996; Ormo, Cubitt et al. 1996).  Each of these 
incremental changes have led to the development of a protein that, while the 
same in name, in some implementations, can not even be spectrally identified as 
its native precursor. 
 The same can be said for alternative bioluminescent proteins such as 
firefly luciferase (Luc).  Recently there have been modifications engineered into 
the luc gene, leading to is commercial replacement with luc2, a modified version 
that has been designed to improve translational efficiency in the mammalian 
cellular background and has also been destabilized to promote lower background 
and increased induction levels (Promega 2009).  As the use of optical imaging 
technologies continues to spread in the scientific community, there will continue 
to be an increasing drive for the development of new, enhanced versions of the 
Luc protein, just as there has for GFP, in order to fill the diverse requirements of 
new researcher’s specific experimental designs. 
 
 145 
 If use of the lux reporter system spreads to even moderate levels among 
those actively engaged in optical imaging, there will no doubt be great interest in 
enhancing its bioluminescent characteristics, just as there has been with other 
widely adopted reporter systems.  To this end, the groundwork for future 
development and optimization of the lux system has been laid out, with 
increasing the bioluminescent flux of the system as the primary goal.  Under its 
current implementation, the mammalian-adapted lux system cannot produce 
levels of bioluminescent flux as high as any of the commercially available 
bioluminescent proteins can, following amendment with their luciferin substrates.  
Enhancing the bioluminescent flux of the lux system to achieve levels of flux on 
par with the alternative systems would overcome this deficiency, which is viewed 
as the main hurdle to its widespread use in the optical imaging community, and 
prevent it from being used solely as a niche-based reporter for experimental 
designs that require bioluminescent production without substrate amendment. 
 To determine points for future optimization of the lux system that could 
increase bioluminescent production, the function of the lux genes within the 
HEK293 mammalian cell line was first investigated.  While the function of the 
luxA and luxB genes has previously been evaluated extensively (Patterson, 
Dionisi et al. 2005; Close, Patterson et al. 2010), the focus of these experiments 
was to evaluate the function of the remaining luxC, luxD, luxE, and frp genes that 
are responsible for establishment and regeneration of the aldehyde and FMNH2 
substrates required for bioluminescent production.  The luxC, luxD, and luxE 
genes produce protein products that work together in a complex to supply the 
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myristyl aldehyde substrate (Meighen 1991).  Their codependence allows them 
to be evaluated simultaneously, because a deficiency in any one will adversely 
effect the production of bioluminescence in vivo.  The frp gene acts 
independently, and therefore was evaluated separately in order to determine its 
function in the regeneration of cytosolically available FMNH2. 
 Because the function of these genes is in part dependent on the efficiency 
of their expression in the mammalian cellular environment, the translational 
efficiency imparted by the internal ribosomal entry site (IRES) elements that were 
included to spur translation of the lux genes while mimicking the polycistronic 
nature of the original bacterial operon was also investiagated.  The use of a 2A 
linker site as an alternative to the IRES element was investigated and the 
resulting changes in in vitro bioluminescent production levels were compared.  
The 2A element was chosen because it performs the same basic function of the 
IRES element by generating multiple protein products from a single mRNA under 
the control of a single promoter element.  However, the means by which the 
protein products are created are very different.   
IRES elements are relatively large sequences of DNA that, upon 
transcription into mRNA, form a secondary structure capable of attracting and 
binding a ribosome to initiate translation of the downstream gene (Lupez-Lastra, 
Rivas et al. 2005).  On the other hand, 2A elements are short, in-frame, linker 
regions that separate two in-frame ORF’s driven off of a single promoter.  During 
translation of the 2A sequence region the nascent amino acid sequence interacts 
with the exit tunnel of the ribosome, causing a “skipping” of the last peptide bond 
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at the C terminus of the 2A sequence.  Despite this missing bond, the ribosome 
is able to continue translation, creating a second, independent protein product.  
The short nature of the sequence (they average 10 amino acids in length) and 
highly efficient 1:1 stoichiometry of these sequences give them many advantages 
over the more bulky IRES elements (de Felipe 2004). 
By determining if increased efficiency of the aldehyde and/or FMNH2 
regulating genes increased bioluminescent output in the mammalian-adapted lux 
system, it allows future research to focus on improving the specific aspects of the 
lux system that can lead to the most beneficial improvements in the shortest 
amount of time.  Likewise, the comparison of IRES-based polycistronic 
expression with a 2A-based expression system highlights if the exchange of 
these linker regions provides tangible advantages beyond the simple reduction in 
overall system size and repetition of large sequences of DNA in the plasmid 
vectors.  It was not expected that these initial investigations would lead directly to 
the development of improved lux function in the mammalian cellular background, 
but instead, that they would provide the framework for moving forward with the 




Materials And Methods 
Replacement of IRES elements with 2A elements 
Synthesis of 2A elements 
To determine if the IRES element linking together the luxA and luxB genes 
in the original pLuxAB construct was detrimental to transcriptional/translational 
efficiency, it was replaced with a synthetic 2A element.  This sequence was 
previously characterized by Ibrahimi et. al (Ibrahimi, Velde et al. 2009), and was 
flanked by two identical sequences composed of three glycines, a serine, and 
three more glycines.  The final construct was synthetically assembled as 
GGGSGGGEGRGSLLTCGDVEENPGPGGGSGGG and placed upstream of the 
luxB gene commercially (GeneArt).  The purchased construct was cloned into 
pLuxAB using the upstream EcoNI and downstream SalI restriction sites to 
replace the IRES element, creating the pTa2AluxAB plasmid, which contained a 
CMV promoter, the luxA gene, the Ta2A linker region, and the luxB gene. 
Transfection of HEK293 cells 
 Transfection was carried out in six-well Falcon tissue culture plates 
(Thermo-Fisher).  The day prior to transfection, HEK293 cells were passaged 
into each well at a concentration of approximately 1 × 105 cells/well and grown to 
90 – 95% confluence in complete medium.  The previously described 
pLuxCDEfrp:CO/pLuxAB or pLuxCDEfrp:WT/pLuxAB vectors (Close, Patterson et al. 
2010) as well as the pTa2AluxAB plasmid were purified from a 100 ml overnight 
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culture of E. coli using the Wizard Purefection plasmid purification system 
(Promega).  On the day of transfection, cell medium was removed and replaced 
and vector DNA was introduced using Lipofectamine 2000 (Invitrogen).  Twenty-
four h post-transfection, the medium was removed and replaced with complete 
medium supplemented with the appropriate antibiotic.  Selection of successfully 
transfected clones was performed by refreshing selective medium every 4 – 5 d 
until all untransfected cells had died.  At this time, colonies of transfected cells 
were removed by scraping, transferred to individual 25 cm2 cell culture flasks, 
and grown in complete medium supplemented with the appropriate antibiotics. 
in vitro bioluminescent measurement 
Total protein was extracted from co-transfected pLuxCDEfrp:CO/pLuxAB or 
pLuxCDEfrp:WT/pLuxAB cell lines (Close, Patterson et al. 2010) or the pTa2AluxAB 
transfected cell line using a freeze/thaw procedure.  Cells were first grown to 
confluence in 75 cm2 tissue culture flasks (Corning), then mechanically detached 
and resuspended in 10 ml of PBS.  Following collection, cells were washed twice 
in 10 ml volumes of PBS, pelleted and resuspended in 1 ml PBS.  These 1 ml 
aliquots of cells were subjected to three rounds of freezing in liquid nitrogen for 
30 sec, followed by thawing in a 37°C water bath for 3 min.  The resulting cell 
debris was pelleted by centrifugation at 14,000g for 10 min and the supernatant 
containing the soluble protein fraction was retained for analysis. 
Bioluminescence was measured using an FB14 luminometer (Zylux) with 
a 1 sec integration time.  To prepare the sample for in vitro bioluminescent 
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measurement, 400 µl of the isolated protein extract was combined with 500 µl of 
either oxidoreductase supplemented light assay solution containing 0.1 mM 
NAD(P)H, 4 µM FMN, 0.2% (w/v) BSA and 1 U of oxidoreductase protein isolated 
from V. fischeri (Roche), or oxidoreductase deficient light assay solution (distilled 
water substituted for the 1 U of oxidoreductase protein).  Following the initial 
bioluminescent reading, samples were amended with 0.002% (w/v) n-decanal 
and the readings were continued to determine if additional aldehyde could 
increase light output.  All bioluminescent signals were normalized to total protein 
concentration as determined by BCA protein assay (Pierce) and reported as 
relative light units (RLU)/mg total protein.  All sample runs included processing of 
cell extracts from HEK293 cells stably transfected with pLuxAB as a control for 
light expression upon amendment. 
 
Results 
in vitro supplementation assays to determine efficiency of gene function in 
vivo 
Supplementation with NAD(P)H:flavin oxidoreductase protein 
 Previous work with the lux system in lower eukaryotes has shown the initial 
substrate, FMNH2, to be a limiting reagent in the reaction (Gupta, Patterson et al. 
2003).  To determine if this was the case in HEK293 cells, in vitro 
supplementation assays were performed with the addition of 1 U of 
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NAD(P)H:Flavin oxidoreductase protein isolated from Photobacterium fischeri.  
Protein extracts from cells containing the lux genes in either their codon-
optimized or wild-type forms were subjected to in vitro analysis to determine if the 
addition of oxidoreductase protein could improve light output.  Upon addition of 
the flavin oxidoreductase protein, the average bioluminescent output increased 
from 1,400 (± 200) RLU/mg total protein to 111,500 (± 10,500) RLU/mg total 
protein in pLuxCDEfrp:WT containing cells (Figure 18A) and from 1,600 (± 200) 
RLU/mg total protein to 245,000 (± 20,500) RLU/mg total protein in pLuxCDEfrp:CO 
containing cells (Figure 18B).  
Supplementation with aldehyde 
The synthesized co-substrate required for light production in the lux 
system is a long chain aliphatic aldehyde that binds to the luciferase and is 
oxidized (Meighen 1991). The ability, conferred by the luxCDE genes, to produce 
and recycle the aldehyde substrate endogenously makes lux a uniquely 
beneficial reporter system.  To assay for the production of aldehyde, cell extracts 
were supplemented with 0.002% (w/v) n-decanal, as this has previously been 
shown capable of functioning in place of the natural aldehyde substrate (Dunn, 
Michalis et al. 1973; Meighen, Bogacki et al. 1976; Gupta, Patterson et al. 2003; 
Szittner, Jansen et al. 2003; Patterson, Dionisi et al. 2005).  When supplied with 
aldehyde, both the pLuxCDEfrp:WT and pLuxCDEfrp:CO containing cell extracts 




Figure 18.  Supplementation assays demonstrating the functionality of the luxCDEfrp 
genes in the mammalian cell environment. 
Supplementation with 1 U oxidoreductase protein significantly increased light output in cell 
extracts from (A) wild-type and (B) codon-optimized cell lines.  Supplementation with 0.002% n-
decanal resulted in increased bioluminescent output in both the (C) wild-type and (D) codon-
optimized cell extracts as well, but at a lower magnitude than oxidoreductase supplementation.  
Values are the average of four trials, and are reported with the standard error of the mean.  
Originally published in (Close, Patterson et al. 2010). 
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containing cells showed an increase from 1,400 (± 200) RLU/mg total protein to 
22,000 (± 1,500) RLU/mg total protein (Figure 18C).  Extracts from 
codon-optimized cells increased from the baseline of 1,600 (± 200) RLU/mg total 
protein to 94,000 (± 10,800) RLU/mg total protein (Figure 18D). 
Determination of bioluminescent output from HEK293 cells containing 2A 
linked luxAB genes 
Five cell lines were recovered that stably expressed the 2A linked luxAB 
gene sequences following transfection with pTa2AluxAB.  These five lines were 
subjected to in vitro analysis to determine if they were capable of producing more 
light than approximately equal numbers of cells stably expressing the IRES 
linked luxAB gene sequences from pLuxAB.  It was determined that the average 
bioluminescent signal from cells containing 2A linked lux genes was ~5500 (± 
3700)% greater than that from cells with IRES linked lux genes.  The major 
contributing factor to the large standard error of the mean was a single cell line 
that achieved 20,500% greater bioluminescent production than the pLuxAB 
control (Table 11).  When excluded from the calculations, this reduced the 





Table 11.  Bioluminescent expression from in vitro expression of luxA and luxB genes 
linked by 2A elements is consistently higher than that of IRES linked luxA and luxB genes. 
 
Bioluminescent Output  
(RLU/mg Protein) 
% of Control 
IRES linked luxA / luxB 1,719,940  N/A  
2A linked luxA / luxB #1 21,103,893 1,227 
2A linked luxA / luxB #2 35,885,713 2,087 
2A linked luxA / luxB #3 29,711,493 1,728 
2A linked luxA / luxB #4 352,781,297 20,511 
2A linked luxA / luxB #5 38,499,816 2,238 





Although the codon-optimized lux system is functioning at a level capable 
of producing bioluminescent detection under a wide array of conditions, it is clear 
that concentrations above the available levels of either the FMNH2 (Figure 18 A 
and C) or aldehyde substrates (Figure 18 B and D) will result in increased 
bioluminescent output.  However, an increase in aldehyde production can be 
cytotoxic, as has been demonstrated in luxAB containing S. cerevisiae and 
Caenorhabditis elegans cells (Hollis, Lagido et al. 2001).  This may lead to a 
scenario where the luxCDE containing cells that most efficiently produce the 
aldehyde substrate are selected against during the initial period of growth 
following transfection with luxCDEfrp due to slowed growth and/or elevated 
cytotoxicity.  The increased presence of aldehyde may therefore cause those 
cells capable of most efficiently producing aldehyde to inhibit their own growth, 
mimicking the effects of antibiotic selection and causing them to be out-competed 
in culture by cells expressing lower levels of aldehyde production.  Mathematical 
models of the lux system have indicated that the production of light is much more 
sensitive to the aldehyde turnover rates modulated by the luxCE genes 
responsible for encoding the reductase and synthase that convert the myristyl 
acid to a myristyl aldehyde than it is to the concentration of luciferase dimer 
formed by the luxAB genes responsible for catalyzing the reaction and facilitating 
the production of light.  The model predicts that a reduction in the concentration 
of the luxC or luxE gene products will lead to a drastic reduction in light output 
(Welham and Stekel 2009).  If true, then it is hypothesized that the cytotoxicity of 
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aldehyde within the cell may be a non-issue in regards to selecting cell lines that 
can function in bioluminescent imaging assays.  Cells with cytotoxic levels of 
aldehyde production will be removed early in the selection process due to slow 
growth rates and inability to compete with faster growing cell lines during the 
antibiotic selection phase following transfection.  Similarly, cells with low levels of 
luxCDE expression will not generate high levels of bioluminescence during in 
vitro screening of luxCDEfrp containing cell lines.  This would tend to encourage 
only the selection of cell lineages capable of producing just enough aldehyde to 
drive the lux reaction, but not enough to impair cellular growth and function, as 
platforms for biosensor development.  Experiments aimed at determining if 
expression of the lux cassette genes (and, by extension, the products of their 
associated reactions) altered cellular metabolism and growth rates have 
supported these predictions. 
 As shown in Figure 18, the availability of FMNH2 appears to contribute as 
a limiting reagent for the lux reaction in a mammalian cell environment.  
Supplementation with as little as 1 U of oxidoreductase protein in vitro led to 
relatively large (up to 151-fold) increases in bioluminescent output levels, while 
supplementation with 0.002% n-decanal produced less substantial (up to 58-fold) 
increases in light production.  When supplemented with additional 
oxidoreductase protein to drive the turnover of FMN to FMNH2, the average 
production of light increased by 82-fold in wild-type cell extracts (Figure 18A) and 
by 151-fold in extracts from cells containing codon-optimized lux genes (Figure 
18B).  The increases in light production attributed to additional FMNH2 were 
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consistently of greater magnitude than those associated with aldehyde 
supplementation.  The highest increase in light output achieved through addition 
of n-decanal was 58-fold in cells containing codon-optimized genes (Figure 18D), 
compared with only a 16-fold increase in light output from cell extracts co-
transfected with the wild-type genes (Figure 18C).  These results suggest that 
codon optimization of the remaining luxCDE genes from P. luminescens allows 
for more efficient processing of the available substrates in the mammalian cell 
environment, but does not allow for production levels that rival the ideal 
conditions of in vitro substrate supplementation where the bioluminescent output 
would be limited only by the efficiency of the LuxAB luciferase dimer.  When 
supplemented with identical levels of aldehyde, cell extracts containing codon-
optimized luxCDEfrp genes were able to produce over four times as much light 
as those containing the wild-type genes (Figure 18 C and D).  A similar result 
was obtained under oxidoreductase supplementation, with extracts from the 
codon-optimized cell lines producing over twice as much light as their wild-type 
counterparts (Figure 18 A and B). 
 The data also indicate that the use of IRES elements is a contributing 
factor for inefficient bioluminescent expression in the mammalian cellular 
background.  As demonstrated in Table 11, exchanging the IRES element for a 
2A element lead to increased bioluminescent output in all cell lines that were 
stably isolated.  It is important to note that during the process of Lipofectamine-
based mammalian cell transfection, it is not possible to effectively control the 
location of gene insertion into the genome, nor is it possible to regulate the 
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number of integration events that take place.  Taken together, these factors can 
help to explain the large discrepancy in bioluminescent output between clone 
number 4 and the remaining pTa2AluxAB transfected cell lines.  It is conceivable 
that the resulting increase in bioluminescent production from cell line number 4 is 
the result of multiple luxAB gene insertions into the parental cell genome.  
Assuming all of these insertions remain under the control of the constitutively 
active CMV promoter, this will afford the cell with multiple locations for 
simultaneous production of LuxAB protein.  Because all cell lines were tested in 
vitro, each was supplied with an identical level of the remaining required 
substrates for bioluminescent production.  Under these circumstances, the cell 
line expressing the most LuxAB protein would be capable of producing the most 
light. 
 To compare and contrast the light output data, all readings are normalized 
to the total soluble protein concentration from each cell line.  This method does 
not allow for determination of the total amount of Lux protein expression or even 
the ratio of Lux protein to endogenous protein available during the assay.  As a 
result, there is no way to calculate if the increase in bioluminescent production is 
the result of multiple insertion events during the course of transfection, or if it is 
the result of increased up regulation of luxAB gene transcription due to their 
location within the genome.  An additional explanation is that the luxAB genes 
transfected into clone number 4 were inserted into a euchromatic region of the 
genome as opposed to a more heterochromatic portion, or that they inserted 
near another strong promoter, which has caused them to be expressed at even 
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higher levels then would be found under the control of the CMV promoter alone.  
This explanation is less likely, however, because recent work has demonstrated 
that the CMV promoter is one of the most active promoters known in the HEK293 
cellular environment (Qin, Zhang et al. 2010). 
 Regardless of the genetic reasons underlying the heightened 
bioluminescent production of clone number 4, it is important to note that the 
remaining 2A containing clones averaged ~1,800 (± 230)% over their IRES linked 
counterparts.  This increase was relatively consistent (± 230%), indicating that 
increases in this range should be routinely achievable when IRES elements are 
exchanged for 2A elements.  Although it is not yet known whether exchanging 
the IRES elements governing the expression of the remaining lux genes will have 
similar effects on autonomous bioluminescent expression, it is clear that the use 
of 2A elements are an attractive alternative due to their smaller size and 





Summary And Conclusions 
 
This investigation has lead to the development and documentation of the 
first published autonomously bioluminescent reporter system capable of 
functioning in the mammalian cellular environment.  This type of system can be 
employed either in tandem or in replacement of traditional bioluminescent and 
fluorescent mammalian imaging systems such as firefly luciferase (Luc) and 
green fluorescent protein (GFP) to provide investigators with an additional tool for 
the interrogation of biological function in cell culture or small animal based 
imaging experiments.  Although the mammalian-adapted bacterial luciferase (lux) 
system has not yet been subjected to enhancement and optimization, it can be 
deployed in its present state and used for the acquisition of data under protocols 
similar to those currently in place for alternative bioluminescent reporter proteins.  
The following conclusions have been drawn from this investigation in regards to 
the initial hypotheses: 
 
 Hypothesis 1:  Through a process of poly-bicistronic expression of 
Photorhabdus luminescence genes codon-optimized for expression in 
mammalian cells it will be possible to autonomously produce a 
bioluminescent signal in the human HEK293 cell line. 
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It has been shown that poly-bicistronic expression of codon-optimized P. 
luminescence lux genes is capable of inducing constitutive bioluminescent 
production in the human HEK293 cell line.  The codon optimization process was 
not shown to alter the pattern of bioluminescent expression over time as 
compared to expression of the wild-type genes, however, it has been 
demonstrated that the codon-optimization process leads to increased 
bioluminescent production.  This increase is presumably due to the enhanced 
efficiencies in transcription and translation associated with the codon optimization 
process (Kim, Oh et al. 1997; Slimko and Lester 2003; Mechold, Gilbert et al. 
2005; Barrett, Sun et al. 2006).  Despite the production and regeneration of 
potentially cytotoxic substrates required for constitutive bioluminescent 
production, the expression of codon-optimized lux genes has not been shown to 
negatively effect the growth rate of their host cells as compared to untransfected 
control cells.  The production of a stable bioluminescent signal without a 
corresponding reduction in cellular growth rate has confirmed our initial 
hypothesis that continuous bioluminescent production is possible in the HEK293 
cell line using codon-optimized lux gene sequences. 
 
Hypothesis 2:  Bioluminescent expression driven by codon-optimized 
bacterial luciferase genes will allow improved temporal detection of signal 
compared to bioluminescent signal from firefly luciferase and fluorescent 




 The bioluminescent signal resulting from expression of the mammalian-
adapted lux genes is stable over prolonged time periods as compared to that of 
substrate dependent luciferase proteins and therefore allows for detection at 
multiple time points throughout the life of the host cell.  While multiple signal 
detection is possible using repeated luciferin injections with alternative 
bioluminescent systems, the lux system allows for increased resolution by 
circumventing the requirement for luciferin clearance from the host prior to 
secondary image acquisition.  This allows investigators using the lux system to 
achieve greater resolution of their visualized process by virtue of increasing the 
total amount of images they can obtain within a given time period.  In addition, 
the substrate independent nature of the lux system provides investigators with a 
larger window for imaging small animal hosts by freeing them from the 
requirement of imaging at the same time point post substrate addition in order to 
accurately compare data obtained from multiple time point studies.  These major 
considerations are all above and beyond the alleviation of standard concerns 
related to the efficiency and consistency of substrate injection that must be 
considered for any experiment utilizing conventional, exogenous luciferin-
dependent bioluminescent systems. 
 While these concerns can also be avoided by imaging with a fluorescent 
imaging target, the lux system has the advantage of producing a bioluminescent 
signal with relatively low background in the mammalian cellular environment.  As 
such, the lux system has proven to require a lower reporter cell population in 
order to successfully differentiate the signal from background light detection in 
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both cell culture and small animal imaging conditions than its fluorescent 
counterpart GFP.  These combined advantages support our hypothesis that lux-
based bioluminescent expression provides an improved system for temporal 
detection of signal as compared to the Luc and GFP systems, however, this 
statement must be considered in light of the relatively decreased bioluminescent 
flux of the lux system in its current state.  Both the Luc and GFP systems display 
a greater photonic flux than does the lux system for an equal number of cells.  
When imaging in the mammalian cellular environment, this is especially 
important because the increased flux can overcome the negative effects of 
scattering and absorption of detection signal photons due to endogenous 
chromophoric material (Chance, Cope et al. 1998; Welsh and Kay 2005). For this 
reason, the lux system may not always be an ideal choice of reporter for 
mammalian imaging, especially if the detection signal is originating from depths 
lower than a few millimeters of tissue.  Under these conditions the advantages of 
a higher flux system such as Luc may outweigh the disadvantages imposed by 
its requirement for exogenous substrate addition.  The choice of an appropriate 
reporter system must therefore be made on a case-by-case basis at the 
discretion of the investigator. 
 
Hypothesis 3:  By regulating the expression of the luxC and luxE genes 
from the bacterial luciferase gene cassette it will be possible to construct a 
bioluminescent reporter capable of responding to changes in target analyte 
presence autonomously and in a near real-time manner. 
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This investigation has demonstrated the proof-in-principle work showing 
that regulation of the luxC and luxE genes under control of a tetracycline 
response element is capable of regulating bioluminescent production in a dose-
response fashion, concurrent with administration of the activator chemical 
doxycyline. Unfortunately, the results did not demonstrate a relatively large 
increase in bioluminescent production in response to doxycyline treatment, nor 
did they show induction of bioluminescent production across a wide range of 
doxycycline concentrations.  While the results obtained indicate that a 
tetracycline receptor-based, luxC and luxE regulated biosensor is not yet ready 
for routine laboratory use, they do show that regulating the production and 
regeneration of the myristyl aldehyde substrate within the mammalian cellular 
environment is a suitable method for controlling bioluminescent production from 
the host cell.  These results can serve as a springboard for future optimization 
and design of lux-based bioreporters capable of responding to mammalian 
bioavailable target analytes. 
 
Hypothesis 4:  HEK293 cells constitutively expressing bioluminescence 
through expression of the codon-optimized bacterial luciferase genes will 
be capable of acting as real-time biosensors to determine the mammalian 
bioavailability of toxic chemicals. 
 Exposure of constitutively bioluminescent HEK293 cells to the cytotoxic 
aldehyde n-decanal demonstrated a reduced level of bioluminescent production 
from cells exposed to concentrations at or above 0.01% of the toxicant.  This 
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level of treatment is in line with previously published reports for aldehyde toxicity 
(Rogers and McElroy 1958), supporting the hypothesis that continuously 
bioluminescent cell lines can be developed into successful screening tools for 
detection of mammalian bioavailable cytotoxic chemicals.  The most important 
finding from this line of inquiry is that fluctuations in bioluminescent production 
can be detected during periods of transition from good to poor cellular health.  
The ability to detect these transition periods is intrinsic to the autonomous nature 
of the lux reaction.  While it would be possible to visualize these fluctuations 
using other bioluminescent reporter systems such as Luc, the costs and logistical 
concerns related to the constant perfusion of luciferin would make these assays 
unfeasible for both basic and high throughput screening applications. 
 Similarly, detection of these transition periods would prove problematic 
using the commonly available fluorescent reporters, but for different reasons.  
The short time period repeated imaging necessary to obtain the resolution 
required for viewing small fluctuations in fluorescent production would entail 
repeated administration of fluorescent excitation signals.  If not provided with a 
suitable recovery period between excitation signal applications, the fluorescent 
reporter system could succumb to photobleaching, thereby rendering the results 
suspect (Widengren and Rigler 1996). 
 In addition, both the fluorescent reporter proteins and the non-lux 
bioluminescent reporter proteins derive their resulting photon production signal 
from access to an exogenously supplied signal (either an excitation light signal 
for fluorescent reporters, or a chemical luciferin addition for bioluminescent 
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reporters).  As a result, they would remain capable of producing an emission 
signal regardless of changes in cellular health and metabolism, so long as the 
reporter protein has not been degraded beyond use.  This makes it challenging 
to link changes in their resulting light expression signals to changes in cellular 
health over relatively short time scales.  Because the lux system is responsible 
for continuously producing and regenerating its substrates using endogenously 
available cellular materials it will be more adversely affected by changes in 
cellular function than the alternative reporter systems would be over the same 
time scale.  This imparts a greater level of detection resolution to the lux system 
than would be available for a similarly designed Luc or GFP-based system.  
While additional work will be required before the mammalian-adapted lux system 
can be employed for high throughput mammalian bioavailability toxicology 
screening, the results demonstrated here suggest that it has excellent potential 
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